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 CHAPTER 1
Introduction and Outline of the Thesis
            Chapter 1 8 
Cytotoxic T lymphocytes for immunotherapy of cancer 
Immunotherapy is a promising therapeutic strategy for a range of cancer types with 
the potential to raise a specific, adaptive and long-lasting anti-cancer protection1. The 
main effector cells of a successful antitumor immune response are cytotoxic T 
lymphocytes (CTL), which kill cancer cells in a cell-contact and antigen-specific 
manner2. Besides activation and expansion of tumor-specific CTL, successful tumor 
elimination requires an efficient CTL effector phase in the tumor lesion3. Induction of 
target cell apoptosis thereby relies on a sequence of multiple events, including 
migration towards and scanning the surface of target cells, antigen recognition and 
formation of an immunological synapse, and execution of effector function followed by 
detachment and resumed migration2. Consequently, interference at any step will 
ultimately compromise killing efficiency. In this thesis, in vitro and in vivo models for 
extended imaging of CTL-target cell interactions and outcome are developed, which 
facilitate monitoring of the full sequence of CTL effector function to deliver novel 
insight into rate limiting steps and interference mechanisms imposed by the 
immunosuppressive tumor microenvironment4. The acquired knowledge on the 
mechanisms of local immune response success or failure will contribute to the rational 
design of new therapy approaches to reactivate antitumor immunity for potent, long-
lasting responses.  
Interstitial migration is an integral part of CTL function 
Chapter 2 summarizes molecular and biophysical mechanisms of immune cell migration 
and guidance. Interstitial migration represents an integral part of CTL effector function, 
by facilitating the search for target cells and the scanning of receptors expressed at the 
cell surfaces encountered. Consequently, the tumor may escape immune control by 
counteracting the migration of infiltrating CTL. This may comprise exclusion from 
entering the tissue, stop signals that arrest CTL motility, barriers created by extracellular 
matrix structures or signals that misroute CTL to some tumor regions while sparing 
others, thereby creating tumor survival niches. Thus, besides “immunological” 
mechanisms such as TCR-mediated recognition and signaling, effector function in tumors 
critically depends on coordinated CTL positioning and migration within the tumor tissue.  
Multimodal intravital multiphoton microscopy to observe cellular dynamics 
within living tissues 
The three-dimensional tissue topography of the tumor microenvironment can act as 
barrier5 or provide guidance6 for immune cell infiltration of solid tumors as well as for 
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tumor cells invading healthy tissue7. While in vitro models fail to mimic the complex 
matrix architecture of tumor environments, immunohistological analyses of intact tissues 
depict tissue complexity but are restricted to fixed samples, lacking the possibility to 
observe the dynamic nature of immune cells including cell migration as well as cellular 
interactions and outcome. To integrate the time- and space-dependent complexity, 
monitoring immunotherapy of solid tumors with intravital multiphoton microscopy (IV 
MPM) in living animals enables direct observation of CTL effector function in the context 
of the reactive host stroma. When applied longitudinally over days or weeks, IV MPM 
reveals long-term dynamics and turn-over of tumor progression, infiltrating immune cells 
and therapy response8.  
In Chapter 3 multimodal intravital MPM was established which includes infrared-
excited two-photon fluorescence and second harmonic generation and, as novel 
modality in cancer research, third harmonic generation (THG) microscopy for label-free 
visualization of the structural microenvironment of melanoma growing in the mouse 
dermis. Destructive tissue invasion and distant metastasis formation are the main cause 
of fatal outcome in cancer disease and consequently, of particular importance to control 
cancer progression. Although studied extensively, the mechanisms driving initiation, 
mode and sustained progression of cancer cell dissemination from the primary tumor are 
not yet fully understood. By mapping melanoma cell invasion in relation to tissue 
organization, we identified that tumor cells preferentially navigate through connective 
tissue by taking routes of least resistance, including preexisting tissue tracks and open 
spaces along blood vessels, myofibers, nerves, between adipocytes and collagen bundles, 
without immediate anatomic tissue remodeling or destruction.  
An organotypic assay to integrate CTL dynamics in the effector phase 
To simulate the connective tissue environment in an in vitro assay we established a 3D 
collagen-based real-time imaging model of CTL function that allows the observation of 
active migration, interaction, dissociation and serial killing of single target cells over 
extended time periods (Chapter 4). CTL mediated cytotoxicity is commonly studied in 2D 
liquid cocultures of CTL and cancer cells9,10, which promote passive aggregation and likely 
result in an overestimation of CTL killing efficacy. In contrast, in vivo, immune cells face 
structurally heterogeneous tissue architectures and complex interactions with diverse 
factors and cell types of the tumor microenvironment5,11–13. This discrepancy likely 
explains the poor correlation of in vitro measured CTL killing capacities and their anti-
tumor efficacy after adoptive transfer into patients4. The here established novel 
migration-based assay promotes the natural dynamic CTL behavior and thus provides 
improved physiologically relevant information on CTL killing kinetics. 
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Cytotoxic T cell cooperation is required for serial killing of cancer cells  
In Chapter 5 the mechanisms of CTL effector function are reviewed and fluorescent 
histone-2B labeling is established as readout for CTL-mediated apoptosis induction in 
tumor cells. While the molecular mechanisms of CTL effector response are well 
defined14,15, the parameters determining CTL success or failure in established tumors 
remain less clear. In Chapter 6 we used dynamic imaging of organotypic 3D assays of 
tumor cells confronted with migratory CTL and intravital multiphoton microscopy to 
identify a cooperation mechanism dependent on sequential CTL-tumor cell interactions 
and the accumulation of sub-lethal hits to overcome melanoma cell resistance to CTL-
mediated apoptosis. Consistently, in orthotopic melanoma in vivo, tumor regions with 
high CTL density supported additive cytotoxicity and correlated with high local apoptosis 
rates. Highest CTL densities and apoptosis induction occurred at the invasive tumor 
front, where invading tumor cells and CTL both move and accumulate along the same 
anatomic trails of least resistance, suggesting invading tumor cells as target for 
immunotherapy. Thus, kinetic imaging shows CTL efficiency as function of the cumulative 
dwell time per target cell, which is dependent on local CTL density and coordinated CTL 
migration into and along niches of tumor-cell residence, both controlled by the 
topographic organization of the tumor microenvironment. 
Agonist ɲ-CD137 monoclonal antibodies focus and sustain anti-tumor CTL 
response 
The amplitude and quality of CTL effector reaction towards target cells are controlled by 
stimulatory and inhibitory signals (“immune checkpoints”)16. Under physiological 
conditions, immune checkpoints are crucial to maintain an appropriate balance between 
self-tolerance to prevent tissue damage by autoimmunity and specific activation to 
eliminate malignant cells. Tumors co-opt inhibitory mechanisms of self-tolerance to 
escape immune control17. To activate anti-cancer immunity, immunmodulatory 
monoclonal antibodies (mAbs) are used to antagonize immune-repressor molecules18 or 
stimulate immune-activating receptors19. CD137 (4-1BB) is a TNFR family costimulatory 
receptor expressed by activated T cells and other immune cells and CD137 ligation by 
agonist mAbs promotes immune cell proliferation, survival, memory formation and 
enhanced effector function20. Significant therapeutic effects of ɲ-CD137 mAb against 
transplanted tumor models have provided a rationale for ongoing clinical trials; however, 
underlying mechanisms and which immune cells mediate the effect remain unclear. In 
Chapter 7 we show a synergy of adoptive CTL transfer and ɲ-CD137 mAb against mouse 
melanoma. Intravital microscopy provides direct evidence that ɲ-CD137 mAb therapy 
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prolongs CTL contacts with target cells and sustains the efficacy of adoptively transferred 
CTL over extended time periods. 
Chapter 8 summarizes findings and emerging concepts of this thesis and discusses their 
implications for understanding cancer invasion and improving cancer immunotherapy. 
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Abstract 
The trafficking of leukocytes into and within lymphoid and peripheral tissues is central 
to immune cell development, immunosurveillance and effector function. Interstitial 
leukocyte trafficking is the result of amoeboid polarization and migration, guided by 
soluble or tissue-bound chemoattractant signals for positioning and local arrest. In 
contrast to other migration modes, amoeboid movement is particularly suited for 
scanning cellular networks and tissues. Here, we review mechanisms of leukocyte 
migration and sensing involved in diapedesis, tissue-based interstitial migration and 
egress, immune cell positioning in inflammation, and emerging therapeutic 
interference strategies. 
An efficient immune reaction requires leukocytes to be at the right place at the right 
time. Nearly all steps, from maturation to activation and effector function, depend upon 
leukocyte migration and positioning in lymphoid and non-lymphoid tissues1. Both innate 
and adaptive immune functions depend upon interstitial leukocyte migration2–5. After 
leaving the bone marrow by way of the blood, monocytes and granulocytes reach 
lymphoid or peripheral tissues, move toward their targets and execute effector 
functions. T lymphocytes emigrate from the thymus, become activated by a cascade of 
cell-cell interactions in secondary lymphoid organs and circulate to peripheral tissues for 
effector function. Similarly, B lymphocytes move within secondary lymphatic tissues to 
capture antigen, receive T cell help and recirculate and become resident in the bone 
marrow and other lymphoid organs as antibody-secreting plasma cells. Leukocyte entry 
into tissue through the vascular endothelium has been studied in detail (reviewed in 
refs.1,6), whereas the mechanisms of leukocyte diapedesis into and navigation within and 
out of tissues are less clear. The density and position of leukocytes in tissues is a steady-
state result of influx and migration, local activation, proliferation and death, and efflux 
(Supplementary Fig. 1 online), which together confers effector functions. Efficient 
pathogen elimination and resolution can be reached by either subthreshold non-
inflamed immune surveillance or nondestructive short-term inflammation7. Persisting 
antigen, however, may lead to chronic inflammation, tissue remodeling and formation of 
de novo structures, such as tertiary lymphatic tissues or granulomas. In chronic 
inflammation, stepwise tissue destruction is followed by defective healing. Because of 
their role in mediating inflammatory reactions, interstitial migration and positioning of 
leukocytes represent therapeutic targets for either suppressing unwanted inflammation 
or boosting insufficient host responses8.  
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Mechanisms of amoeboid migration in leukocytes 
Leukocytes use amoeboid cell migration mechanisms. Reminiscent of the amoeba 
Dictyostelium discoideum, polarized leukocytes develop a small leading edge consisting 
of short-lived pseudopods, followed by the cell body that contains the nucleus, and a 
posterior, near-cylindrical tail of 2 to 10 µm in length termed the uropod (Fig. 1a,b). Four 
steps mediate the amoeboid migration cycle: the leading edge protrudes one or several 
pseudopods by actin flow, protruding membrane and surface receptors interact with the 
substrate, actomyosin-mediated contraction of the cell body occurs in mid-region, and so 
the rear of the cell moves forward. These steps occur in a cyclic manner, generating 
forward movement. Amoeboid migration is very different from mesenchymal or 
collective migration modes employed by other cell types in three-dimensional models9. 
Amoeboid migration is used by leukocytes (and likely many stem cells), is fast (up to 30 
µm/min), lacks strong adhesive interactions to the tissue and commonly preserves tissue 
integrity rather than degrading it10. Mesenchymal migration used by fibroblasts, smooth 
muscle cells and cancer cells is much slower (less than 1 µm/min), generates stronger 
adhesion sites and causes proteolytic extracellular matrix (ECM) remodeling11. Collective 
cell migration is used by cells that retain their cell-cell junctions, remodel ECM, and move 
either as a two dimensional sheet, three-dimensional strand or compact cluster through 
tissue12, as during branching morphogenesis, vascular sprouting and epithelial wound 
closure13. Compared to other migration types, amoeboid movement is special because it 
supports a uniquely fast capability to sense and integrate signaling input from the 
extracellular environment (‘scanning’)14. After polarization, the leading edge contains 
rapidly forming and rebuilding networks of filamentous actin that include abundant 
membrane ruffles indicative of dynamic probing of the environment. The leading edge is 
particularly sensitive to receptor engagement, including that by Fc receptors (FcRs), T cell 
antigen receptors (TCRs), chemokine receptors15 and  ɴ2 integrins in intermediate or 
active state16, all of which serve to initiate contact with other cells, induce signal 
transduction17 and mediate phagocytosis after binding of bacteria and other particles18. 
If normalized to membrane area, the density of most surface and chemoattractant 
receptors on the leading edge is equal to that on other cell parts, at least at the light-
microscopic level19,20, but at ultrastructural resolution, other receptors, such as ɴ2 
integrins in neutrophils, show discrete relocation toward the tips of ruffles21. The mid-
region of amoeboid cells contains the nucleus and a relatively immobile cell region that 
maintains the front–rear axis. The trailing edge contains the highly glycosylated surface 
receptors CD43 and CD44, adhesion receptors including intercellular adhesion molecule 
(ICAM)-1, ICAM-3, ɴ1 integrins and ERM adaptor proteins, as well as GM-1-type 
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cholesterol-rich microdomains22. The uropod mediates cell–matrix and cell–cell 
interactions during migration and has a putative anchoring function10.  
Polarization of cytoskeletal and signaling scaffolds  
At the leading edge (Fig. 1c), pseudopod and lamellipod protrusion occurs either 
spontaneously or induced by migration-promoting factors binding to surface receptors. 
In leukocytes, polarization and migration to chemoattractant gradients, known as 
chemotaxis, are induced by various compound classes, including chemokines and 
cytokines, lipid mediators, bacterial factors and ECM degradation products including 
fragments of collagen, fibronectin and elastin23–25. Many chemoattractants transmit 
signals through heterotrimeric G-protein-coupled receptors (GPCRs). In leukocytes, most 
GPCRs transmit through the ɲ subunit of Giɲ, the subtype of G protein that can be 
inhibited by pertussis toxin. These GPCRs include the fMLP (N-formyl-Met-Leu-Phe) 
receptor and C5a receptor; chemokine receptors including CCR7, CXCR4, CXCR5 and 
CCR3; the leukotriene B4 receptor BLT1; sphingosine-1-phosphate receptors 1–4  (S1P1–
4) and lysophosphatidic acid (LPA) receptors 1–326.  All  these  GPCRs  mediate  
promigratory signals but also enhance cell activation. A key GPCR-mediated pathway is 
signaling through class Ib phosphatidylinositol-3-kinase (PI(3)K), containing the p110ɶ 
catalytic subunit). PI(3)K-ɶ is recruited to the inner leaflet of the plasma membrane by 
the G protein ɴɶ subunit, where it becomes activated, and then phosphorylates 
phosphatidylinositol phosphates (PIPs) and other effectors (reviewed in ref. 27). PIPs 
serve as docking sites for pleckstrin-homology domain–containing proteins, notably Akt 
(also known as protein kinase B), which is implicated in inducing actin polymerization 
and pseudopod protrusion by phosphorylating downstream effectors28, such as the 
actin-binding protein girdin29. A second pathway linked to PI(3)K activation is induced by 
ɺ-chain-associated receptors, including TCRs and FcRs. These receptors signal through 
tyrosine kinases Lck and Zap-70 to class Ia PI(3)Ks (consisting of p110ɷ) and activate 
downstream  Akt,  as  well  as  the  GTPases  Rac  and  Cdc4230. A third, PI(3)K-independent 
pathway induced by the fMLP receptor in neutrophils leads to the activation of p38 
mitogen-associated protein kinase and downstream Rac activation7. Lastly, the Rac 
guanine nucleotide exchange factor DOCK-2 leads to Rac activation at the leading edge31. 
Ultimately, Rac induces actin polymerization through WAVE (Scar) and Arp2/3. WAVE, a 
member of the WASP family of actin-binding proteins, mediates actin filament 
formation32; Arp2/3 causes sideward branching of actin filaments. Together, these 
activities generate interconnected, branched networks33. Thus, promigratory signals 
received at the leading edge generate local Rac activation and actin network protrusion, 
pushing the plasma membrane outward. The mechanisms of preferential receptor 
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sensitivity at the leading edge are likely diverse and may include local signal amplification 
mechanisms34 and the exclusion of counter-regulatory proteins.  
The mid-region (Fig. 1d) generates actomyosin-based stiffness and contractility, 
limits lateral protrusions and thereby maintains a stable, bipolar cortex. The cytoskeletal 
motor protein myosin II located in the central and rear regions of leukocytes promotes 
actin filament contraction and limits lateral protrusions. Myosin II cross-links actin 
filaments in parallel, forming the contractile shell required to hold the extending cell 
together and propelling the cell nucleus, the most rigid part of the cell, forward35. 
Inhibition of myosin II in neutrophils leads to ectopic lamellae on two-dimensional 
substrates36 or the loss of rear-end retraction in three-dimensional tissues37, resulting in 
impaired migration. Upstream of myosin II, by yet unclear mechanisms, PI(3)K-ɶ and 
possibly DOCK-2 suppress lateral protrusions38; deletion of either protein enhances cell 
turning such that overall cell mobility is compromised31. The phosphatase PTEN also 
contributes to lateral stability by preventing ectopic protrusion formation7. PTEN is 
excluded from the leading edge but active in lateral and rear cell parts, where it 
dephosphorylates kinases, including PI(3)K and Akt, as well as phosphatidylinositol-
(3,4,5)-tris-phosphate, and thereby counteracts protrusion formation7,39. The uropod 
(Fig. 1e) extends rearward from the nucleus and contains the microtubule-organizing 
center and rearward-polarized microtubules, the Golgi, and abundant actin-binding ERM 
proteins. In association with microtubules, mitochondria localize to the rear of the cell, 
which, presumably owing to local ATP delivery to the region of ATP-dependent 
actomyosin contraction, is required for proper polarization, uropod retraction and 
migration40. Amoeboid polarization thus generates a bipolar mechanosensory state with 
a dynamic leading edge to acquire new contacts and signals, a stiff mid-body, and a 
sticky uropod that is dragged along the substrate and stabilizes the cell position in 
complex environments10,41. 
Leukocyte migration in different environments 
Leukocytes are able to migrate along or through most, if not all, tissues of the body. Both 
two-dimensional surfaces, such as inner vessel walls, the peritoneum and the pleura, and 
three-dimensional tissues, composed of mostly cellular (lymph node) or fibrillar ECM 
components, serve as ‘substrates’ for this migration (Fig. 2). As part of the amoeboid 
migration program, leukocytes use adhesion receptor–dependent mechanisms, known 
as haptokinesis, for migration across two-dimensional surfaces. Migration across two-
dimensional ECM or an endothelial surface requires integrin-mediated attachment and 
polarized adhesion, notably through binding of integrins ɲϰɴ1 and LFA-1 to counterpart 
ligands VCAM-1 and ICAM-1 on the endothelial cell (Fig. 2a)6.  
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By contrast, in three-dimensional ECM environments, cells use weakly adhesive to 
nonadhesive interaction and traction mechanisms. Leukocyte migration within interstitial 
tissue in vitro and in vivo is integrin independent, being mediated instead by actin flow 
along the confining ECM scaffold structure, shape change, and squeezing (Fig. 2b)10,22,37. 
In contrast to two-dimensional migration, the three-dimensional tissue network confines 
and mechanically anchors cells from all sides so they intercalate alongside and 
perpendicular to tissue structures10,37,42; this differs from integrin-dependent 
mesenchymal and other migration modes9. How leukocytes distinguish substrate 
anatomy - that is, two-dimensional versus three-dimensional environments - and adjust 
their adhesion requirements is presently unknown. 
 
 
Figure 2. Principles of leukocyte–substrate interactions and guidance. (a) Haptokinetic, adhesion-dependent 
migration across a two-dimensional (2D) surface. Two-dimensional leukocyte migration requires integrin-
mediated interaction with the substrate. in vivo, haptokinetic migration is present during leukocyte crawling 
across vascular endothelium or inner body surfaces, such as the peritoneum or the bronchial tract. (b) Three-
dimensional (3D) haptokinesis and contact guidance results from shape change and the flow of anterior actin, 
but in leukocytes, lacks integrin-mediated adhesion requirements. In organized tissue, alignment of the cell 
body to nonrandom tissue structures leads to contact guidance. (c) Chemotaxis is induced by soluble, freely 
diffusing compounds that lead to preferential signaling and actin-rich protrusions at the leading edge. 
Chemotaxis adds a direction to 2D and 3D haptokinetic migration. (d) Haptotaxis is the directed migration 
toward chemoattractants that are immobilized on tissue structures, such as interstitial collagens or a stromal 
cell network. 
            Chapter 2 22
Pericellular proteolysis 
The degradation of ECM is a key mechanism supporting cell migration through physically 
constraining tissue regions43. The penetration of the very dense meshwork of basement 
membranes likely requires proteolytic activity, at least during the initial phase of 
leukocyte influx6,44,45. Whether interstitial leukocyte migration in vivo depends upon 
similar proteolytic ECM degradation is unclear, as controversial results have been 
reported10. Better dissection of the in vivo requirements for proteolytic ECM processing 
in different phases of leukocyte trafficking will require knowledge of ECM structure and 
composition before and after trafficking and consideration of other protease functions 
that may affect migration rates through diverse mechanisms, including the processing of 
surface receptors, cytokines, and growth factors46,47. In defined in vitro environments, 
such as fibrillar three-dimensional collagen matrices of known pore diameter (averaging 
3 to 6 µm), lymphocytes and myeloid cells migrate in the absence of collagen 
degradation or proteolytic track generation10. As a mechanism, nonproteolytic amoeboid 
migration results from marked shape change, propulsion and squeezing through narrow 
tissue regions (Fig. 2b), similar to leukocyte movement through interstitial tissue with 
minimum collateral damage during nondestructive inflammation10,41,48. Because the 
physical structure of interstitial human and mouse tissues in vivo is quite heterogeneous, 
ranging from loose fibrillar regions of spacing similar to that of three-dimensional 
collagen lattices to compact dense connective tissue with submicron spacing (K. Wolf 
and P.F., unpublished data), it is likely that leukocytes adapt to tissue geometry and 
follow paths of least resistance, a process known as contact guidance. 
Migration programs in different leukocytes subsets 
The basic amoeboid migration program is retained in most, if not all, leukocytes as well 
as lymphoma cells49. Whereas granulocytes and lymphocytes maintain the typical ‘hand-
mirror’ shape reminiscent of Dictyostelium, monocytes contain more cytoplasm and 
often lack a bona fide uropod, but otherwise follow amoeboid principles of shape change 
and squeezing10. In dendritic cells (DCs), the leading edge consists of multiple dendrites 
that intercalate between tissue structures, but the cell body and uropod are retained37,50. 
As perhaps the only exception, tissue-resident macrophages and macrophage-derived 
epithelioid cells adopt adhesive fibroblast-like morphology51, are poorly motile and show 
upregulated ɴ1, ɴ2 and ɴ3 integrins, together with matrix metalloproteases (MMPs)52,53. 
Whereas the principles of amoeboid movement, including basic adhesion, protease and 
signaling requirements, seem to apply to all rapidly moving leukocytes, their peak 
velocities in vitro and in vivo differ for neutrophils (up to 30 µm/min), lymphocytes (up 
to 25 µm/min),  B cells (15 µm/min),  DCs (10 µm/min) and monocytes (5 µm/min).  The 
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maximum migration velocity is likely proportional to myosin II activity and the 
deformability of the nucleus, as suggested by impaired migration rates in vitro because 
of nuclear entrapment at ECM structures after myosin II inhibition37. Further, the 
repertoire of expressed chemoattractant and adhesion receptors mediating migration 
and attachment diverge, providing cell type–specific recruitment and positioning in 
tissues1,8,26,31. 
Leukocyte trafficking into tissues and initial migration  
For immigration of circulating leukocytes into tissues (Fig. 3), transmigration through the 
vascular endothelial layer is the rate-limiting step, involving two independently regulated 
events, binding to vessel endothelium followed by diapedesis1,54. The basement 
membrane underlying all normal vessels represents the first postendothelial tissue 
structure and barrier to cells undergoing diapedesis (Fig. 3a). The known mechanistic 
steps of vascular basement membrane penetration include adhesion to the substrate via 
integrin ɲϲɴ1, the principal laminin receptor on leukocytes55. For passage through vessel 
basement membrane in interstitial tissue, locally confined cleavage of the structural 
proteins laminin-10 and type IV collagen occurs by secreted or membrane-anchored 
MMPs and serine proteases44,56. Cell body deformation is coupled to cytoplasmic 
propulsion and streaming through preexisting or newly formed pores. In acute 
inflammation in vivo, early neutrophil diapedesis occurs preferentially through basement 
membrane regions having decreased density of laminin-10, collagen IV and nidogen-2, 
suggestive of anatomic zones of least resistance between the pericytes45.  As  leukocyte  
influx and proteolytic ECM degradation proceed, these regions further lose basement 
membrane components and develop into inflammation-induced preferred entry points 
for other leukocytes6,45. In brain vessels, proteolytic basement membrane remodeling is 
essential for immune cell diapedesis57,58, but it remains unresolved whether proteolytic 
breakdown is indispensable or rather auxiliary for diapedesis through other basement 
membranes44,45,59. The deformation capability of leukocytes is considerable, reaching 
submicron constrictions in neutrophils60; thus, proteolytic and nonproteolytic 
mechanisms may synergize. In transendothelial migration models in vitro, the 
engagement of CD31 and likely of integrin ɴ2 in neutrophils and activated lymphocytes 
leads to the upregulation of integrin ɲϲɴ1 and ɲϰɴ1, thus initiating a tissue phenotype 
that supports interstitial and cell-guided crawling55,61,62. Upon leukocyte diapedesis, 
while the uropod is still engaged with the vessel wall, the leading edge reaches the 
perivascular loose connective tissue, consisting of filamentous collagen fibers and 
elongated gap-like tracks that facilitate cell alignment and migration (Fig. 3a). Such 
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perivascular tracks are present in virtually all organs and provide preferential cell 
migration routes to distal regions of the tissue41.  
With inflammation, these tracks become further widened by hydrostatic pressure 
from vascular leakage and edema, likely facilitating cell trafficking41. In inflamed tissue, 
freely diffusing chemoattractants, such as bacterial peptides, provide short-lived or 
pulsatile directional information (Fig. 2c), in addition to the longer-lived cues provided by 
constitutive or induced tissue-bound chemoattractants (Fig. 2d)26. Thus, besides 
chemotaxis, haptotaxis and contact guidance synergize to direct early steps of interstitial 
trafficking. 
 
 
 
Figure 3. Leukocyte migration in different environments in vivo.  (a) Interstitial leukocyte migration in loose 
connective tissue. Such preformed tracks of least resistance are present along most basement membranes 
(BMs), including those lining blood vessels and below epithelia that are particularly receptive to edematous 
swelling  and  enlargement  of  ECM  gaps  and  tracks41. (b) Migration along cellular networks in lymphoid 
organs, such as fibroblastic reticular cells63 (FRCs) or DC networks64 in the T cell zone in lymph nodes.  (c) 
Intraepithelial migration and positioning. After reverse transmigration through the basement membrane, 
leukocytes migrate briefly along cell–cell junctions until stable positioning is reached. In epidermis, integrin 
ɲɴ7 in lymphocytes is the counterpart receptor for epithelial E-cadherin.  (d) Intratumoral migration 
guided by cell–matrix and cell–cell contacts. CK, cytokine. 
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Migration along cell scaffolds 
In contrast to epithelial and mesenchymal cells, leukocytes are particularly prone to use 
other cell surfaces for guided migration, recognition and arrest as part of their immune 
surveillance function (Table 1). In uninflamed lymph nodes, T and B lymphocytes 
immigrate through high endothelial venules and predominantly migrate along the 
cellular network of fibroblastic reticular cells (FRCs), DCs and follicular dendritic cells, as 
shown by intravital microscopy in living lymph nodes (Fig. 3b)63,64. FRCs in particular 
provide a structural scaffold, with cell-surface ICAM-1 as a counter-ligand to leukocyte 
LFA-1 and also with decoration with chemokines63. T cell positioning is dependent on 
CCR7 and its ligands CCL21 and CCL19, expressed by and bound at the surfaces of FRCs 
and DCs63. Mice lacking CCR7 or its chemokine ligands fail to generate proper T and B cell 
regions65,66; thus, both lymphocyte positioning and the anatomy of the T and B cell zones 
largely depend upon chemokine guidance. The migration pattern up and down the FRC 
network corresponds to a persistent random walk2–4, suggesting haptokinesis and/or 
contact guidance2,63,67. Besides promoting migration, chemokine signals submit latent 
preactivation that increases T cell sensitivity to subsequent activation, such as TCR 
triggering68.  
Despite their importance for cell-cell interactions and migration across surfaces16, no 
active role for LFA-1–ICAM-1 interaction in the intranodal migration of T cells, B cells and 
DC has been detected37,69. Other mechanisms providing translocation along cell scaffolds 
may include weak adhesion by chemokine-chemokine receptor interaction or non-
adhesive shape change37,69. Given cell scaffold–mediated migration strategies in lymph 
nodes, it is likely that leukocytes in peripheral tissues move along stromal cells as part of 
their surveillance function61.  
Balancing adhesion and migration  
Trafficking leukocytes often reduce their migration speed, pause and polarize toward the 
bound cell or tissue structure to execute crucial functions, including phagocytosis, cell-
to-cell signaling and activation, and the release of cytokines or toxic factors toward a cell 
encountered. In vivo studies using histological end points cannot differentiate interstitial 
leukocyte accumulation by chemotaxis from random migration coupled to local arrest of 
migration and so provide only indirect insight into positioning mechanisms. Because of 
the current lack of data from live-cell imaging in peripheral tissues, little is known about 
the steady-state proportion of moving and sessile infiltrating cells during acute and 
chronic inflammation. Therefore, most knowledge of positioning stems from dynamic 
imaging in three-dimensional in vitro models and in lymph nodes in vivo. At least three 
basic kinetic states govern leukocyte positioning in tissues, including fast migration (5 to  
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25 µm/min), slow and often locally confined movement (2 to 5 µm), and adhesive arrest; 
and these rapidly interconvert (Fig. 4). 
Based on these kinetic states, leukocyte accumulation in tissues occurs through at 
least three distinct mechanisms. Local engagement of adhesion receptors causes 
individual leukocytes to stick and become immobilized at a specific spot. The degradation 
of promigratory ‘go’ signals causes cell populations to slow down or stop movement. And 
the loss of exit signals confines cells to a local microenvironment despite ongoing 
migration.  Complete migration arrest is mediated by activation of adhesion receptors on 
the moving cell followed by attachment to counter-receptors on other cells or ECM 
structures, leading to an immobilized cell (Table 1)70. Within seconds, adhesion overrides 
ongoing promigratory signals; this is followed by cytoskeletal polarization toward the 
bound cell or ECM structure70,71. Despite the promigratory lymph node environment, 
antigenic signaling prompts T and B cells to cease migration through LFA-1–ICAM-1 
interaction70 followed by the formation of a stable immunological synapse72. Under 
conditions of strong antigenic signaling, T cells contacting DCs undergo a rapid and 
strong adherence response to the antigen-presenting DC for signal exchange73–75. 
 
Figure 4. A balance between amoeboid migration, adhesive arrest and intermediate states. Moving 
leukocytes  are  able  to  slow  down  and  completely  cease  migration  within  seconds  to  minutes  and  vice  
versa. High-velocity movement occurs by actin flow and shape change but without integrin- mediated 
adhesion and high calcium currents. Conversely, adhesive arrest is mediated by integrin engagement, 
accompanied by calcium oscillations and loss of amoeboid polarization. Because promigratory and 
antimigratory signals are gradual, rather than discrete, intermediate states may be adopted, resulting in 
slow migration in a confined region, often on the surface of a single cell. IS, immunological synapse.  
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Activated B cells after antigen uptake attach to follicular stromal cells through LFA-1–
ICAM and integrin ɲϰɴ1–VCAM interactions and receive survival signals76. Besides cell–
cell signaling, such stable binding further supports the polarized release of cytokines into 
the cell–cell junction, as in helper T cells bound to B cells77. By contrast, local 
confinement despite ongoing motility occurs by local adhesion coupled to slow migration 
‘on the spot’72. Here, integrin-mediated arrest is coupled to polarized cytoskeletal 
dynamics and movement across the surface of the counterpart cell; this movement is 
thought to support receptor turnover and scanning of the cell surface3–5,14,74,78. In both 
cases, the immobilization response is proportional to, and probably caused by, transient 
elevation of intracellular calcium in the T cell that confines migration by enhanced 
adhesion (Fig. 4)5,74. The adhesive contact structures mediating arrest vary. In T cells, the 
immunological synapse is mediated by an adhesion plane enriched in filamentous actin, 
LFA-1, TCR and costimulatory molecules72. In monocytes and immature dendritic cells, 
adhesive arrest to ECM substrate is mediated by podosomes composed of multiple actin-
rich focal adhesion zones of 1 to 3 µm in diameter and 10 to 30 min duration, formed 
underneath cells adhering to two-dimensional ECM substrate79. Compared to migrating 
cells, both immunological synapses and podosomes are relatively stable and thus slow 
migration down or confer adhesive arrest for a limited duration, ranging from minutes to 
hours. Thus, whereas arrest mechanisms and underlying signals and adhesion structures 
vary in a cell- and context-dependent manner, migration confinement is a graded 
response proportional to proadhesive signal strength.  
Long-lived confinement and tissue residency  
Under homeostatic conditions, long-lasting tissue residency (for days and weeks) of 
leukocytes supports sentinel and surveillance function at epithelial interfaces to the 
outside world or at inner surfaces that filter blood or lymph for pathogens80. Whereas 
the tissue lifespan of neutrophils until death is estimated at a few hours and that of 
interstitial T cells until egress is estimated at 1 d, resident macrophages, DCs or ɶɷ T cells 
may survive months to years until egress or death. In the skin, intraepidermal ɶɷ T cells 
integrate between keratinocytes and use integrin ɲɴ7 for binding to epidermal E-
cadherin (Fig. 3c)81. Likewise, intraepithelial leukocytes in the gut are dependent on ɲɴ7 
binding to E-cadherin82. For other tissue-resident leukocytes, such as interstitial DCs or 
macrophages, the retention mechanisms are unknown.  
Relocation  
After immigration and migration arrest, the re-onset of migration prompts leukocyte 
relocation toward regions nearby54. The lymph node is the best-studied organ for 
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relocation; here, T and B cells change subregions in the course of their activation and 
differentiation program. After antigen capture, B cells located within the B cell follicle 
become activated, upregulate CCR7 and migrate chemotactically along a CCL21 gradient 
toward the follicle boundary, where they contact activated CD4+ helper T cells83. 
Conversely, initially activated CD8+ T cells expressing CCR5 are directed by CCL3 and CCL4 
to reach the region of ongoing interaction between CD4+ T  cells  and  DCs,  where  they  
receive T cell help84. In lymphoid organs relocation connects particular leukocyte 
functions to sequentially occur in different anatomic regions; however, repositioning 
programs in peripheral tissues remain elusive. Relocation further serves to allow 
lymphocytes to accumulate short- lived activation signals. Naive T cells migrate at high 
velocity across the surface of DCs presenting noncognate or very weak antigen and 
receive weak, homeostatic signals2,74 (J. Storim and P.F., unpublished data). If antigenic 
strength is moderate, naive T cells slow down after engaging with the DCs, detach again 
within minutes and engage with neighboring DCs, where they receive TCR triggering 
signals75. Here, serial interactions with different DCs are mediated by relocation and 
provide pulsatile cognate TCR-mediated signals until early activation is reached, 
mediating T cell arrest and commitment to a single DC4,75,85. A special type of relocation 
during stable cell–cell adhesion is the ‘carried translocation’ of T cells bound to a moving 
DC86,  a  resting  B  cell  pushed  by  a  moving  T  cell71 and  the  guidance  of  T  cells  by  an  
activated migrating B cell83. Because of their stability, these conjugates provide antigenic 
signaling and passive translocation of immobile cells to another tissue region, yet the 
function of these interactions remains unclear. Thus, both active and passive cell 
movements contribute to leukocyte relocation.  
Counter-regulation of interstitial leukocyte trafficking  
Beyond adhesive migration arrest, the local reduction of promigratory signals is achieved 
by the down-modulation of chemoattractant receptors, receptor desensitization and 
ligand competition, whereas termination of chemoattractant activity occurs through 
capture by neutralizing chemoattractant receptors and/or proteolytic degradation. After 
ligation, chemoattractant receptors become internalized and either recycled to the 
leading edge or stored in vesicles in the uropod, thus limiting the availability of both the 
chemoattractant and its receptor20. In T cells, the activation-induced downregulation of 
S1P1 is the best-studied example of how chemoattractant signaling is tuned (see 
below)87. Migration-inducing agonists can further be competed away from the receptor 
by endogenous antagonists. Resolvin E1 acts as a competitive antagonist of LTB4 by 
binding to and desensitizing BLT188. Resolvins are found in high concentrations in 
inflammatory tissue fluids, where they counteract the influx of neutrophils by limiting 
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LTB4-mediated chemotaxis and enhance the resolution of dermal inflammation, 
peritonitis and colitis in mouse disease models89. Local chemokine availability is reduced 
by binding to chemokine receptors on bystander cells (‘sink function’). Erythrocytes and 
endothelial cells express silent chemokine receptors, including DARC (Duffy antigen 
receptor for chemokines), which capture interleukin (IL)-8, CCL5 and others, thereby 
limiting their bioavailability in tissues26. Further, chemoattractants are drained by the 
lymph fluid or blood. Lastly, chemokine degradation occurs through MMP2, MMP9 and 
other MMPs released by resident and infiltrate cells46.  These  proteases  cleave  many,  if  
not all, chemokines, including CCL2, CCL7, CCL8, CCL13 and CXCL12, into either inactive 
or even antagonistic forms (reviewed in ref. 90). This function of MMPs downscales 
inflammatory infiltrates in a timely fashion and prevents tissue damage46. How these 
different mechanisms act together or synergize to limit interstitial leukocyte trafficking is 
unclear.  
Exit control from tissues  
Emigration from tissues and organs is confined to lymphocytes and DCs; it does not occur 
for granulocytes and macrophages. Exit of lymphocytes and DCs from lymph nodes 
provides peripheral tissues with activated effector cells for host defense91. In peripheral 
tissues, efflux delivers peripheral T cells and antigen-presenting cells (APCs) to the lymph 
node1. Efflux further limits and resolves an inflammatory response. In both lymph nodes 
and interstitial tissues, a monolayer of lymphatic endothelial cells (LECs) needs to be 
crossed,  likely  by  a  process  of  reverse  diapedesis.  In  peripheral  tissues,  exit  also  may  
occur through gaps and blunt ends of terminal lymph vessels92. In the lymph node, exit 
routes are the paracortical and medullary sinuses. After 12–24 h of intranodal migration, 
T cells reach the sinus epithelium, which releases S1P into predominantly the afferent 
lymphatic vessel, thus likely creating a chemotactic gradient. In the absence of activation 
signals, passenger T and B cells express S1P receptors and require the S1P signal to cross 
the epithelium for exit91.  However,  once  T  cells  receive  TCR  triggering  and  early  
activation signal by APCs leading to the upregulation of CD69, S1P1 becomes 
downregulated for 2–3 d and the cells are prevented from exiting the lymph node93. 
Thus, down-modulation of a chemoattractant receptor that does not participate in 
maintaining baseline motility limits egress and confines mobile T cells to the lymph node 
until activation is complete. In peripheral tissues, exit occurs into afferent lymph 
capillaries located parallel to blood vessels by a chemoattractant- and adhesion 
receptor–dependent process rather than by passive entry94. In T cells, experimental S1P1 
agonism causes migration arrest at the basal surface of the lymphatic endothelium 
through adhesion mediated by LFA-1–ICAM-1 and VLA4–VCAM-1 interactions95. 
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Therefore, high S1P concentrations in inflamed tissue may support tissue retention of 
effector cells95. The egress of DCs from peripheral tissues is promoted mostly by 
chemokines. In epidermal Langerhans cells, signals induced by irritants or pathogens 
downregulate E-cadherin but upregulate CCR792,96,  which  allows  Langerhans  cells  to  
leave the epidermis, follow CCL21 constitutively produced by and decorating dermal 
LECs, and diapedese into lymphatic vessels of the upper dermis96. Thus, active reverse 
diapedesis rather than passive transport of lymphocytes and DCs mediates egress into 
afferent lymphatics95. At their basal surface LECs express macrophage mannose receptor 
and CLEVER-1, which have been implicated as counter-receptors for leukocyte adhesion 
to LECs and migration to lymph nodes92,97,98. The counter-receptors on leukocytes likely 
are not integrins, because integrin-deficient dermal DCs efficiently travel through 
afferent lymph vessels into lymph nodes37. In blood vessels of the liver sinus, monocytes 
use LFA-1 binding to ICAM-1 to migrate along the intraluminal endothelium of the vessel 
wall99,100, but it remains to be shown where leukocytes use such haptokinetic 
mechanisms to move along the inner LEC walls and where passive transport occurs.  
Migration during interstitial inflammation  
Any acute or chronic inflammation in the tissue in response to damage, tumor growth or 
viral infection or in autoimmune disease and allograft rejection prompts tissue 
infiltration by effector cells, including neutrophils, monocytes, T cells and, in chronic 
states, B cells. Often, chronic inflammation causes de novo, tertiary lymphoid tissue 
formation, dependent upon a multistep developmental program of cell migration and 
positioning. Initially small and unstructured T cell infiltrates eventually segregate into a T 
cell area with DC networks, high endothelial venules and adjacent B cell follicles with 
germinal centers101. This process is initiated by lymphotoxin ɲϭɴ2 released from 
activated B and T cells, which activates stromal cells to release lymphoid homeostatic 
chemokines (CCL19, CCL21, CXCL12 and CXCL13)101,102. How the spatial separation into T 
and B cell areas occurs is unknown but, in reminiscence of secondary lymphoid organs, 
guidance and adhesion likely direct the temporary assembly of peripheral lymph follicles. 
If persistent for weeks and months, chronic inflammation may eventually trigger the 
remodeling of tissue structures within and adjacent to connective tissues. In mouse 
models of rheumatoid arthritis, a progressive influx of granulocytes followed by T cells is 
observed preceding destruction103.  Immigrated  T  cells  of  the  CD4+ memory phenotype 
reach the synovial membrane; secrete IL-2, interferon-ɶ and IL-17; and  thereby activate 
monocytes, tissue macrophages, fibroblasts and the synoviocytes to produce ECM-
degrading enzymes and fibrosis-inducing transforming growth factor-ɴ, IL-13 and 
platelet-derived growth factor104,105. In later stages, B cells may infiltrate the synovium 
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and form tertiary lymphoid tissue. Experimental arthritis in mouse models is reduced or 
abrogated by interfering with PI(3)K-ɶ106 and LTB4107 signaling, which link interstitial 
trafficking, particularly of neutrophils, to disease outcome.  
Migration in cytotoxic effector response  
Cytotoxic T lymphocytes (CTLs) infiltrate solid tumors by moving along the tumor–matrix 
interface and along junctions between target cells (Fig. 3d)108,109. LFA-1–ICAM 
interactions have been implicated in CTLs crawling along tumor cell strands in vitro110, 
but the in vivo mechanisms are unclear. In experimental tumors, activated CTLs reach 
their target site after a phase of movement through the adjacent stroma rather than 
from vessels inside the tumor108. Chemokines produced by tumor cells, tumor-associated 
macrophages111 or fibroblasts112,113, including CXCL12 (through CXCR4)114,115, CXCL10 
(CXCR3)114,115 and CCL2 (CCR4)116, are important in attracting effector T cells into the 
tumor tissue. Likewise, monocytes are recruited de novo and activated by CCL3, CCL4 
and CCL5 released by tumor-infiltrating T cells117. Effector cells migrate through 
interstitial spaces and across the surface of stromal and tumor cells and scan for 
expressed  cognate  antigen  (Fig.  3d).  This  ‘search  function’  follows  the  rules  of  a  
persistent random walk, similarly to T cells in the lymph node cortex, as shown by in vivo 
microscopy118,119. With antigenic peptide present, fast scanning by CTLs converts to 
migration arrest and prolonged engagement with individual target cells in both virally 
infected or tumor cells108,109,118,119. An effector synapse polarizes TCR and LFA-1 to the 
target cell in vitro119, which results in migration arrest until target cell apoptosis in 
vivo108,109 and  regression  of  the  lesion108,109,118,119.  Integrin  ɲɴ7  engagement  on  CTLs  
supports polarized binding to target cells and enhances exocytosis of cytolytic 
granules120, consistent with a function in adhesive costimulation. Other adhesion-
promoting and costimulatory molecules, including Mac-1, LFA-1 and VLA-4, support 
CD8+ effector T cell function in viral disease, but whether transendothelial migration, 
local positioning or both are favored remains unclear121. Tumors may also counteract the 
migration of infiltrating leukocytes. By unresolved mechanisms, stop signals can arrest 
the movement of tumor-infiltrating lymphocytes122, and they represent a potential 
escape strategy. Further, the sequence of cells encountered before the target cells 
affects effector function. If nearby regulatory T cells suppress effector functions, target 
cell killing but not migration or conjugation may be impaired by a transforming growth 
factor-ɴ–sensitive mechanism123. Thus, effector function is critically dependent on both 
efficient immigration of CTLs into the tumor and killing of it, and interference with either 
process supports target cell survival.  
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Migration during liver inflammation  
Immune surveillance in the liver is provided by both resident and blood-borne 
‘passenger’ lymphocytes and macrophages. In liver sinusoids, passenger lymphocytes 
scan endothelium and - without leaving the bloodstream, but rather through endothelial 
fenestrations - hepatocytes for antigenic peptide124–126.  Likewise,  natural  killer  (NK)  T  
cells and monocytes crawl along and patrol the lumen of liver sinusoids100 through 
binding of LFA-1 and chemokine receptor CX3CR1 to their respective ligands ICAM-1 and 
CX3CL1 (also known as fractalkine) on liver endothelium99. During liver inflammation, 
such as viral hepatitis, NK, ɶɷ T, NK T and CD8+ effector cells become further recruited to 
cross the endothelium, move between hepatocytes and diffusely infiltrate the liver127,128. 
This  recruitment  requires  CCR5  and  CXCR3  expression  on  leukocytes  and  CCL3,  CCL4,  
CCL5, CXCL9 and CXCL10 produced by hepatocytes and sinus endothelial cells128. 
Recruitment of CD8+ T cells into liver parenchyma and elimination of virally infected 
hepatocytes both depend upon CXCL9 and CXCL10129. Instead of recirculating, most 
infiltrate cells in the liver die within hours to days127; thus, little is known about exit 
mechanisms. During chronic colonization of liver cells with intracellular bacteria, 
including Mycobacterium tuberculosis, migration and positioning of infiltrate cells leads 
to granuloma formation to locally confine and eliminate the infection130. Pathogen-
infected macrophages recruit other macrophages and blood-derived monocytes to 
accumulate and form a dense cellular scaffold around the pathogen-infected region. This 
monocyte-derived convolute serves as track system for effector cells, including CD4+, 
CD8+, ɶɷ and CD1-restricted T lymphocytes, which rapidly enter the macrophage network 
and engage in dynamic as well as sustained macrophage–T lymphocyte interactions131. 
Effector CD4+ T lymphocytes secrete TH1-type cytokines, such as interferon-ɶ, which 
activate macrophages and CD8+ effector cells to eliminate intracellular pathogen and 
infected cells, respectively130. Thus, recruited macrophages form a structural barrier that 
hosts mobile T cells, conditioning the microenvironment with cytokines and effector 
molecules. Dynamic imaging data are not yet available for other inflammatory disorders, 
including glomerulonephritis, atherosclerosis, acute and chronic lung inflammation, and 
thyroiditis, which likely comprise similar recruitment and resolution mechanisms.  
Therapeutic targeting of leukocyte trafficking in tissues  
Many new anti-inflammatory drugs aim at interfering with transendothelial migration by 
antagonizing surface integrins, selectins or chemokines involved in leukocyte homing8. 
Because of its contribution in virtually every step of inflammation, interstitial leukocyte 
migration is another target function to modulate immune cell function in tissues 
(Supplementary Table 1 online). In clinical use since the early twentieth century to blunt 
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acute inflammation, colchicine prevents microtubule assembly by binding to tubulin, 
which inhibits chemotactic migration of neutrophils and monocytes into and within 
interstitial tissue132. More recently developed strategies to interfere with 
chemoattractant signaling show strong promise in reducing tissue damage in chronic 
inflammation8. Likewise, competitive inhibitors of the LTB4 receptor BLT1 reduce 
inflammation in models of rheumatoid arthritis and atherosclerosis107,133. FTY-720, an 
agonist of S1P1, leads to short-term receptor activation followed by internalization and 
degradation and, thereby, suppresses S1P signaling. The FTY-720– induced inhibition of T 
and B cell egress from lymphoid and peripheral organs causes secondary lymphopenia 
and blunts T cell–dependent tissue inflammation134. Inhibition of PI(3)K-ɶ strongly 
reduces the infiltration of neutrophils and T cells in mouse models of chronic destructive 
inflammation, including rheumatoid arthritis and lupus-like syndrome106,135. To improve 
effector function, such as in established cancers, proinflammatory strategies aim at 
enhancing tissue infiltration by CTLs and cytolytic killing. Small molecule agonists of Toll-
like receptors 7 and 8 activate cutaneous dendritic cells and macrophages. They release 
proinflammatory cytokines, including interferon-ɶ, tumor necrosis factor and the 
chemokines CCL3, CCL4 and CCL2, that attract CTLs and support CTL-mediated 
eradication of skin tumors in small-animal models and humans136,137.  
Conclusions  
With increased kinetic information on different disease models, many interference 
strategies are likely to show effects on interstitial trafficking and signal exchange 
between cells. Because of their role in navigation control, chemokines and their 
downstream signaling pathways show promise as therapeutic targets, at both the 
vascular and interstitial tissue levels. Because diseases that often are not immediately 
fatal will be targeted, issues of safety will increase. To avoid unwanted chronic 
immunosuppression, fine-tuning of dosing and meaningful combination therapy will be 
needed. Targeting interstitial migration will need to aim at particular contexts and 
specific leukocyte subsets to modulate migration and positioning; this promises to 
complement interference with cell cycle progression (cytostatic drugs) or 
transendothelial migration (for example, integrin antagonists). Interstitial leukocyte 
migration is regarded not only as means to change position from one place to another 
but as integral to immune cell surveillance and molecular recognition, including the 
search for APCs and target cells, the scanning of receptors expressed at the cell surfaces 
encountered and the accumulation of signals during migration and over time. Because of 
their amoeboid features, moving T cells act as bipolar sensory cells that integrate 
discrete signals over time until thresholds are reached and result in a cellular reaction, 
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not unlike a mobile, position-changing neural cell. Whether myeloid cells collect signals 
in a similar, migratory manner is not known. In conclusion, live-cell microscopy has 
shifted our conceptions of immune processes from an abstract, imagined appreciation of 
leukocyte trafficking into a visual and more detailed understanding of how, when, where 
and in which sequence immune cells get together, exchange information and eliminate 
pathogens and tumor cells.  
 
Note: Supplementary information is available on the Nature Immunology website. 
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Abstract 
Cancer cell invasion is an adaptive process based on cell-intrinsic properties to migrate 
individually or collectively, and their adaptation to encountered tissue structure acting 
as barrier or providing guidance. Whereas molecular and physical mechanisms of 
cancer invasion are well-studied in 3D in vitro models, their topographic relevance, 
classification and validation toward interstitial tissue organization in vivo remain 
incomplete. Using combined intravital third and second harmonic generation (THG, 
SHG), and three-channel fluorescence microscopy in live tumors, we here map B16F10 
melanoma invasion into the dermis with up to 600 ʅm penetration depth and 
reconstruct both invasion mode and tissue tracks to establish invasion routes and 
outcome. B16F10 cells preferentially develop adaptive invasion patterns along 
preformed tracks of complex, multi-interface topography, combining single-cell and 
collective migration modes, without immediate anatomic tissue remodeling or 
destruction. The data suggest that the dimensionality (1D, 2D and 3D) of tissue 
interfaces determines the microanatomy exploited by invading tumor cells, 
emphasizing non-destructive migration along microchannels coupled to contact 
guidance as key invasion mechanisms. THG imaging further detected the presence and 
interstitial dynamics of tumor-associated microparticles with submicron resolution, 
revealing tumor-imposed conditioning of the microenvironment. These topographic 
findings establish combined THG, SHG and fluorescence microscopy in intravital tumor 
biology and provide a template for rational in vitro model development and context-
dependent molecular classification of invasion modes and routes. 
Introduction 
Tumor cell invasion into adjacent tissues is a key step of cancer cell dissemination 
towards locoregional and systemic metastasis1,2. Invasive migration of individual cells 
through 3D connective tissue depends upon a sequence of physicochemical steps that 
generate polarized cell interaction with the tissue substrate and force transmission. 
Actin-driven protrusion of the leading edge is followed by focalized cell-matrix adhesion, 
proteolysis of extracellular matrix constraints and actomyosin mediated contractions of 
the cell body, which together mediate a cycle of forward protrusion and rear retraction.3 
Besides individual cell migration, collective invasion of multiple cells occurs when moving 
cells maintain functional cell-cell adhesion, leading to a “supracellular” organization of 
the actin cytoskeleton and multicellular polarity, protrusion and traction force 
generation.4 Single-cell and collective invasion are interconvertible, dependent on the 
up- or downregulation of cell-cell junctions and supracellular coordination; consequently, 
in cancer lesions invasion patterns range from broad multicellular masses with intact 
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cell-cell connections to small multicellular files and fully individualized cells.5 The cellular 
and molecular mechanisms driving different types of cancer invasion are commonly 
studied in vitro using reconstituted 2D or 3D environments with relatively uniform but 
controllable structural pattern and composition.6,7 In connective tissue in vivo, tumor 
cells however face more complex and structurally heterogeneous 3D tissue architecture 
consisting of molecular and physical interfaces of different composition, length scale and 
stiffness, that provide space and guidance or act as a physical barrier and restrict cell 
motility.8,9 Thereby, multiple cell and ECM parameters are integrated by migrating cells 
to determine type, direction, efficiency and protease-dependence of migration.5,8 
Traditionally, the guidance mechanisms of cancer cell invasion are deduced from 
histological tissue samples or defined in vitro environments, resulting in the concepts of 
barrier function of connective tissue as well as its guidance principles.5,10 In vitro models 
have allowed to establish the mechanisms of contact guidance, chemotaxis, guidance by 
gradients of adhesive substrates (haptotaxis) and substrate rigidity (durotaxis), and the 
de novo track generation by proteolytic remodeling of tissue structures.3,11,12 In vivo, 
deduced from histopathological analysis of tumor samples, cancer invasion preferentially 
occurs along tracks of least resistance such as perineural, perimuscular and perivascular 
invasion,9 however the relative contribution of molecular and biophysical guidance 
mechanisms, such as matrix guidance vs. barrier function, remain to be determined. As 
complement to histological studies which provide a static and two-dimensional view on a 
dynamic and three-dimensional biological process and further suffers from structural 
artifacts due to tissue fixation and processing, intravital microscopy provides direct 
access to the three-dimensional cell and tissue morphology and function at cellular 
resolution and over time. Thereby, multiphoton-excited second and third harmonic 
imaging allows the visualization of 3D topography of tissue structures13,14 and delivers 
comprehensive insight into cell invasion and topographic guidance by tissues.10,15-17 
Second harmonic generation (SHG) results from the near-simultaneous arrival of two 
photons at dense, non-centrosymmetric structures to be combined into one emitted 
photon of half the wavelength.14,18 In interstitial tissues, SHG is elicited by collagen fibers 
and striated muscle myosin,18 detecting tumor-associated remodeling of collagen-rich 
ECM.10,19 Third harmonic generation (THG) is sensitive to local differences in third-order 
nonlinear susceptibility, refractive index and dispersion, resulting in unification of three 
near-simultaneously arriving photons to one emitted photon of triple frequency.20 In 
tissues, third harmonic signals are particularly generated by water-lipid or water-protein 
scaffold interfaces and media of optical heterogeneity, including lipid bodies, fat cells, 
nerve fibers as well as cell membranes and intracellular vesicles.21-23 Similar to SHG, THG 
is a predominantly forward scattering signal, the optimized detection of which requires 
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excitation by a strong pulsed infrared laser and forward detection, amenable to trans-
parent samples or organisms including embryos of Zebrafish, Drosophila, C. elegans or 
mouse.24-27 As caveat of THG imaging in thick and optically challenging samples, such as 
collagen-rich connective tissue and tumors, the high laser intensities required for 
backward detection of scattered signal may introduce phototoxicity and compromise cell 
and tissue function. Consequently, examples for backward THG in interstitial tissues are 
rare, except for imaging of thin or poorly absorbing samples, such as the mouse 
cremaster muscle,22 lung surface28 and mouse spinal cord23 or brain tissue.29 Thus, the 
potential of THG imaging in thick and scattering tissues and disease states, such as 
progressing tumors, remains uncertain. Using infrared multiphoton microscopy (MPM),30 
we establish the efficacy and tolerability of backward THG compared with SHG and 
fluorescence detection in tumor-free and B16F10 melanoma-bearing tissue in live mice. 
The data establish THG as important complement to SHG and fluorescence imaging for 
the longitudinal monitoring of cancer biology in living tissue and the detection of 
migration-enhancing and -impeding tissue structures, particularly to tumor invasion 
routes, secondary tissue remodeling and microenvironment conditioning by 
microparticles.  
Results  
Model set up for backward third harmonic generation (THG) microscopy.  
A tandem near-infrared and infrared MPM set-up was used for simultaneous excitation 
of THG, SHG, and fluorophores GFP, E2-Crimson and AlexaFluor750 for both, forward 
and backward detection (Fig. 1A and B). To optimize THG efficacy, 3D collagen lattices 
containing homogeneously distributed single cells were used to detect backward and 
forward THG and SHG emission from collagen fibers and cells at increasing excitation 
power (Fig. 1B, left). THG and SHG emission were significantly stronger in forward 
compared with backward direction (SHG: ~5 times, THG: ~25 times) and showed 
respective third- and second order dependence (Fig. 1C), as described.20,22 To determine 
an optimized wavelength for simultaneous THG and SHG, excitation spectra were 
obtained by intravital imaging of mouse dermis at constant laser power (80 mW under 
the objective) and the backscatter of both signals was collected by rearward detection, 
showing peak efficacies at excitation with 1190 nm and 1130 nm wavelengths, 
respectively (Fig. 1D). The poor THG efficiency at emission wavelengths below 390 nm 
(corresponding to THG excitation wavelength of 1170 nm) is consistent with the limited 
UV transmission of barium fluoride glass components in the beam path. Because weak 
THG signals are rate-limiting in the backward direction, 1180 nm excitation for highest 
THG efficacy was used subsequently. Signal selectivity and separation were verified by  
 the narrow filter bandwidth (FF01 395/8 (THG) and FF01 593/11 (SHG) and by the type 
and topography of emitting str
Figure 1.
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Backward THG imaging in vivo: tissue penetration and phototoxicity. 
The invasion of B16F10 melanoma cells was monitored using the dorsal skin-fold 
chamber model for multiphoton-excited THG, SHG and fluorescence intensity detection 
in backward direction in established tumors.16 Because surgery is performed only prior to 
tumor implantation but not required at the day of imaging, this model allows live-tumor 
observations without surgery-imposed disturbance of tissue anatomy including 
perfusion, cell viability and motility, and thus provides sufficient tissue stability for high-
resolution time-lapse studies and particle-tracking. To establish the depth efficacy of 
backward THG compared with SHG and NIR fluorescence (AlexaFluor750) detection in 
the mouse dermis, the respective intensities retrieved with increasing imaging depth 
were estimated from a deep z-stack reaching 870 ʅm into the dermis. THG was retrieved 
for a significant tissue volume, ranging from deep to mid dermis with peak intensities 
caused by dense collagen and a fat cell layer located at 500 to 600 ʅm and sufficient THG 
signal-to-noise ratio reached to 650 ʅm in depth (Fig. 2A; Vid. S1). Likewise, SHG and NIR 
fluorescence were retrieved with similar profile and maximum depths of up to 650 ʅm 
(Fig. 2A). Thus, despite its emission in the blue range which shows higher absorption by 
tissue structures compared with red signal, the sensitive setup allowed to detect 
backward THG at depths beyond 600 ʅm. Because of the high laser power required to 
obtain THG in backward direction (100 to 150 mW under the objective), we addressed 
the risk of laser-induced tissue damage using continuous exposure and time-lapse 
monitoring of potentially sensitive tissue structures, such as highly absorbing fat cells 
and capillaries. Using a typical time-lapse setting with 60 sec time interval between 
individual z-scans, tissue integrity remained unperturbed for a 3.8 h observation period 
(230 frames), including normal morphology of fat cells, collagen fibers and striated 
myofibers, as well as regular erythrocyte flow indicating lack of heat-induced blood 
clotting with erythrocyte stasis (Fig. 2B, Vid. S2). To test the toxicity limits of time-lapse 
THG microscopy, a small scan field was exposed to continuous scanning of the same focal 
plane (130 mW laser power under the objective; frame rate 1.1/ sec). Regular 
erythrocyte flow persisted for 60 sec (60 frames), but with doubling of the frame rate 
(0.6/sec) tissue damage including swelling of fat cells (Fig. 2C, asterisk), intra-vascular 
coagulation and perturbed erythrocyte flow (Fig. 2C, arrowheads) were rapidly induced. 
Thus, with sufficient time intervals between individual imaging scans, even high infrared 
laser intensities required for generating backward THG are well tolerated by dermal 
tissues, whereas conditions requiring small imaging fields and continuous or high-speed 
exposure may be challenged by photodamage.  
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Interfaces of the tumor-free deep dermis.  
THG is an interface signal particularly suited to detect cell membranes and tissue 
discontinuities.14,22 In the deep dermis of tumor-free mice, backward THG was generated 
by interfaces of cells and ECM while SHG was confined to fibrillar collagen and 
actomyosin structures, similar to mouse cremaster tissue.22 With progressing imaging 
depth, tissue structures eliciting THG included the loose connective tissue of the deep 
dermis (Fig. 2A; Vid. S2), a muscle layer, perfused blood vessels and nerves of the mid-
dermis (Fig. 3A) and adipocytes with adjacent collagen bundles of the upper mid-dermis 
(Fig. 3B). Strongest THG was elicited by thick collagen bundles (Fig. 3C and D), peripheral 
nerves (Fig. 3D), adipocytes (Fig. 3E), striated muscle fibers (Fig. 3F) and perfused blood 
vessels (Fig. 3F). Combined with SHG and fluorescence signal, THG delivered quantitative 
information on the 3D anatomy of connective tissue, including pre-existing tissue tracks 
and barriers that may impact tumor cell invasion. Collagen networks were 
heterogeneous in organization, including randomly organized loose collagen networks 
(Fig. 3C; space diameter up to 30 ʅm) and aligned and more densely structured collagen 
bundles bordered by longitudinal, fissure-like tracks (Fig. 3D; 5–10 ʅm diameter). Spaces 
between fat cells included interspersed collagen bundles and showed heterogeneous 
widths, ranging from narrow clefts (1–2 ʅm) to wider gaps (up to 10 ʅm in cross-section) 
(Fig. 3E). Perineural tracks defined by nerve strands eliciting strong THG and adjacent 
collagen bundles generating both SHG and THG were linear in shape with 2–5 ʅm in 
diameter (Fig. 3D). Similar longitudinal interface signals were present along and between 
myofibers, revealing narrow tracks (up to 5 ʅm in cross-section) or imposing as interface 
signal without apparent track lumen (Fig. 3F, dotted lines). Thus, complementary 
THG/SHG imaging allows detailed 3D reconstructions of anatomic tissue structures and 
interfaces, suggesting a constitutive range of collapsed and non-collapsed tracks. 
Interfaces guiding invasion of B16F10 melanoma cells.  
B16F10 melanoma tumors expressing a mixture of H2B-eGFP single and H2B-eGFP/E2-
Crimson double positive cells (Fig. S1A) were implanted in the dorsal skin-fold chamber 
and growth and invasion dynamics were monitored over up to 13 d. The growth curve of 
the main tumor, after an initial lag phase of 2 to 3 d, showed exponential growth starting 
day 4–5 (Fig. 1A), as described for other tumor types.16 The onset of invasion was 
observed in most tumors 1 to 4 d after implantation, resulting by day 8 in multicellular 
elongated strands of up to 120 densely arranged cells with several hundred micrometer 
in length (Fig. 4B). Dependent on the guiding tissue structures, two types of collective 
invasion were observed, (1) linear multicellular files headed by one or two leading tip  
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cells (Fig. 4AоD),  and (2)  broad collecƟve  invasion  zones  lead  by  mulƟple  Ɵp cells  (Fig.  
4E). Linear invasion strands were composed of coherent, tightly organized cell strains of 
uniform 3–5 cells in diameter, consistent with collective invasion,16 and detachment of 
single cells or small cell files was observed at the tips of a subset of invasion strands (Fig. 
4B, inset). 
Despite their compact organization, time-lapse recording and single-cell tracking 
revealed high intra-strand dynamics of individual B16F10 cells within multicellular 
strands maintaining median velocities of 0.25 ʅm/min in forward and, occasionally, 
rearward direction (Fig. 4C; Vid. S3). Thereby, linear invasion strands recapitulated the 
orientation of confined 3D spaces present in the tissue, particularly aligned muscle 
fibers, small blood vessels, and perineural tracks detected by THG/ SHG (Fig. 4D). 
Perimuscular invasion followed the outline of myofibers precisely, often accompanied by 
tumor cell deformation to adapt to the given narrow tracks between adjacent myofibers 
or myofiber and blood vessel (Fig. 5A). Occasionally, invading tumor strands entirely 
wrapped around the complete circumference of the myofiber with the nuclei in outward 
direction and inward-oriented cell extensions, consistent with cell polarization toward 
the myofiber interface (Fig. 4F; Fig. S2B). Remarkably, melanoma-cell containing paths 
were thereby widened to a caliber of 1 to 3 cells without apparent destruction of muscle 
integrity (Fig. 4D and F). Likewise, perineural space guided linear tumor cell strands with 
tumor cells oriented between lining collagen bundles and the nerve fiber, resulting in 
thin files (Fig. 4G, dotted line). Diffuse collective invasion into the irregular spaces of fat 
tissue and collagen networks consisted of two morphological zones. First, multiple 
“leader” cells formed an invasive front infiltrating with thin lamella-like protrusions along 
the interfaces between adipocyte surfaces and adipocyte and collagen bundles (Fig. 4H, 
arrowheads). This invasion front was followed by a broad multicellular mass which  
Figure 2. Depth efficiency and phototoxicity of backward THG. (A) THG, SHG and AlexaFluor750 signal 
intensity as function of depth obtained from a 870 ʅm deep z-stack into the mouse dermis (*, level of the 
cover glass above the tissue). Images were acquired with a z-resolution of 10 ʅm, excitation wavelength of 
1,180 nm and an excitation power of 150 mW under the objective. Images were background subtracted and 
average  intensity  of  THG/SHG  or  AlexaFluor750  signals  over  the  z-profile  was  plotted.  THG  (cyan)  was  
detected up to 650 ʅm, similarly to SHG (red) and Alexa- Fluor750 (yellow). (B) Representative time points 
of  THG (cyan)  and SHG (red)  during  time-lapse  recording  of  dermal  tissue  [ʄ (excitation)  =  1,180  nm;  110  
mW excitation power under the objective]. Z-scans of 80 ʅm tissue volume were acquired with z-steps of 5 
ʅm and frame intervals of 60 sec (230 frames; 3.8 h observation period). Unperturbed tissue structures, 
including fat cells (asterisks), muscle fibers (arrow heads) and erythrocyte flow in capillaries (dotted line). (C) 
erythrocyte flow (temporal color coded) morphology of adipocytes (asterisk). (a) continuous exposure of 
small  (60  ʅm × 70  ʅm) scan  field  for  60  frames  (frame rate:  1.1/sec)  at  1,180  nm excitation  and 130  mW 
excitation intensity. (b and c) Doubling of the frame rate (0.6/sec) followed by tissue damage, detected by 
swelling of adipocytes (asterisk) and intravascular coagulation and perturbed erythrocyte flow 
(arrowheads). Scale bars, 20 ʅm.  
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surrounded adipocytes and concomitantly widened existing spaces without obvious 
adipocyte destruction, but the SHG signal of collagen bundles between adipocytes 
somewhat weakened (Fig. 4E). A similar diffuse invasion with often single-cell or loosely 
connected multicellular pattern occurred along and into collagen networks, 
characterized by a broad, loosely interconnected leading edge of multiple tip cells 
followed by a multicellular group, aligned parallel to collagen fibers (Fig. 4L; Fig. S2). 
When encountering narrow pores in the collagen network, cells deformed and adapted 
their shape to the given trail diameters (Fig. 4L). To estimate the reciprocal adaptation of 
tumor cells and tissue tracks and obtain insight into the extent of tissue remodeling 
secondary to invasion, track widths in tumor-free tissues, i.e., before invasion, were 
compared with the diameter of invading B16F10 cells, as measured for the space 
consumed between tissue boundaries (Fig. 5A). Near-identical constitutive track widths 
and diameters of infiltrating tumor cell bodies were found for collagen networks, 
perineural and adipose tissue invasion, suggesting lack of microscopic tissue deformation 
or degeneration at leading fronts of invasion (Fig. 5B). In contrast, track widening by 5–
10 ʅm was detected for perimuscular invasion, suggesting either proteolytic degradation 
of boundaries or non-proteolytic track widening by passive by outward pushing and 
space expansion. Cell diameters were largely unaltered in loose collagen tissue, besides 
occasional cell bodies squeezing through narrow matrix pores resulting in localized cell 
deformation (Fig. 4L, arrowhead; 2–5 ʅm in cross-section). 
Likewise, perimuscular, perineural, and fat tissue invasion resulted in similar 
deformation of cell bodies with diameters of cell bodies ranging from 3–10 ʅm (Fig. 5B). 
Thus, SHG/THG imaging of tissue scaffolds, together with fluorescence detection of cell 
body and nucleus allow to establish a quantitative map of constitutive tissue tracks 
before and during cell invasion. The data suggest that the leader cells of collective tumor 
invasion preferentially exploit pre-existing tissue tracks and adapt their shape to the 
space available; thereby perimuscular tracks receive minor and other tracks no widening, 
without evidence for large-scale de-novo track generation or tissue destruction.  
  
Figure 3. THG/SHG 3D reconstruction of tissue interfaces in native dermis. Backward THG/SHG were 
acquired at 1180nm excitation and 100-130mW laser intensity under the objective. THG was generated by 
cellular interfaces of fat cells (A-B, E); flowing erythrocytes labeling perfused blood vessels (A-B; arrowheads); 
cell bodies interspersed in loose connective tissue (C; arrowheads); matrix interfaces including collagen fiber 
bundles (C-D); peripheral nerves (A, D); striated muscles (F) and outer membranes of myofibers (F; 
arrowhead). SHG was confined to collagen bundles (A-B, D) and striated muscle fibers (A, F). Combined 
THG/SHG revealed tissue tracks and spaces available for tumor cell invasion (examples highlighted in C-F as 
dotted lines). Scale bars, 50µm. Abbreviations: f, fat cells; m, myofiber; n, nerve; c, collagen.    
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Conditioning of the tumor microenvironment by microparticles.  
Whereas little immediate remodeling of tissue structures was noted during invasion, 
THG revealed altered tissue composition via strongly THG-positive tumor-associated 
microvesicles or microparticles. Using THG as measure, the size of microparticles ranged 
from below 1 ʅm in diameter (corresponding to 1–2 pixels in lateral diameter) to larger 
particles of up to 8 ʅm in diameter (Fig. 6A and B). In the B16/F10 live-cell models in vitro 
and in vivo, microparticles commonly lacked cytosolic fluorescence of E2-Crimson, in 
contrast to intact cells, larger macroaggregates and cell debris (Figs. S3, S4 and Vid. S6). 
Microvesicles are shed from a variety of cells including tumor cells during invasion31 
(data not shown), and have been implicated in intercellular communication, with 
variable function depending on the cellular origin and cargo contained.32 To monitor the 
kinetics of microparticles in vivo, time-lapse microscopy was performed and the diffusion 
dynamics of THG-positive particles were compared with marker regions of the SHG-
positive collagen network (Fig. 6A). Tracking of microparticle mobility showed at last 
three distinct subsets, including non-moving, randomly moving and directionally moving 
particles (Fig. 6C). The velocity and diffusion constant distributions of mobile THG-
positive particles (filled bars) exceeded the dynamics of collagen reference points (open 
bars) reaching velocities of 9 ʅm/h, whereas a subset of particles showed overlapping 
velocity and diffusion constants consistent with immobilization (Fig. 6C and D). These 
observations suggest that the majority of THG-positive microparticles are mobile and 
independent of small tissue drifts which are intrinsic to live-tissue dynamics during 
intravital microscopy. 
Figure 4. B16F10 melanoma invasion along dermal tissue interfaces. (A) B16F10 tumor volume growth over 
time. Error bars, mean ± SD (n=8). (B) File-like collective invasion of mosaic tumors (compare Supplementary 
Fig. 2A) into the deep dermis. Invasion strands progressed on average 70 µm/day (b) and appeared as coherent 
and tightly organized cell strains of near-constant diameter, except for occasional detachment of single cells or 
small cell files at the tip of the strands (B, inset). (C) Time-lapse microscopy and single-nuclei tracking show 
high intra-strand dynamics in rearward and forward direction (a) with median velocities of 0.25 µm/min (b). 
During migration individual tumor cells remained within the 3D spaces defined by tissue interfaces (C, dotted 
lines) with leading edges strongly adapted to tissue confinement (D, E; dotted lines). Linear, aligned tracks 
along muscle fibers and nerves guiding file-like collective invasion (D), while irregular shaped spaces within fat 
tissue supported broad and diffusely organized collective invasion patterns (E). Invading tip cells preferentially 
moved along tissue interfaces such as linear perimuscular (F; dotted lines) and perineural (G; dotted lines) 
tracks, and irregular trails consisting of adipocyte interfaces (H) or collagen fiber networks (I). Cell body 
adapting to existing matrix spaces (F-I; arrowheads). Backward THG/SHG, E2-Crimson and AlexaFluor750 were 
excited with 1180nm (100-130 mW), eGFP was excited with 910nm (20-40 mW). Color scale: yellow, E2-
Crimson (tumor cytoplasm); blue, histone-2B/eGFP (tumor nuclei); green, AlexaFluor750 (blood vessels); red, 
SHG; cyan, THG. Scale bars, 50 µm. 
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structures guiding tumor-cell invasion and the kinetics of tumor-cell derived 
microparticles. Cancer invasion into interstitial tissue is thought to require proteolytic 
degeneration of tissue barriers and to ultimately cause tissue destruction, consistent 
with upregulation of MMPs and extensive tissue remodeling detected upon 
histopathological analysis of advanced lesions.33 The concept of de novo trail formation 
during invasion is strengthened by in vitro models showing proteolytic micro-and macro-
patterning of dense 3D invasion models for tumor cells or fibroblasts.8,34,35 Using 
THG/SHG/fluorescence detection of both 3D tissue anatomy and invading cells, 
comparison of tumor-free and tumor-cell invaded tissue strongly suggests that invading 
cells follow pre-existing tracks bordered by cell or ECM interfaces and, rather than 
generating neo-trails, show remarkable adaptation of cell shape and invasion mode in 
response to tissue organization. Two topographic types of track systems were identified, 
(1) discontinuous, loosely confined spaces within fibrillar collagen networks (Fig. 7A and 
B) and (2) irregular- or linear-shaped tracks confined by 2D interfaces (Fig. 7C and D). The 
trails composed of fibrillar collagen networks consist of small fibrils or thicker fiber 
bundles bordering discontinuous spaces of 5–30 ʅm in diameter in random or aligned 
order, which support the invasion of individual or loosely connected cells oriented in 
parallel to the matrix structure (Fig. 7A and B). Irregular microtracks identified by 
THG/SHG imaging in fat tissue are composed of neighboring adipocytes, with occasional 
interspersed collagen bundles, forming irregular-shaped 3D clefts of 2–10 ʅm in 
diameter and polygonal, random organization (Fig. 7C). These tracks support multiple tip 
cells leading diffuse, irregularly shaped collective invasion as broad amorphous mass. 
Conversely, regular-shaped, aligned trails between myofibers, nerves and blood vessels 
are linear in organization, uniform in width and promote directionally persistent file-like 
collective invasion led by one or two tip cells (Fig. 7D). In tumor-free tissue, such aligned 
tracks either show a constitutive diameter range of 2 to 5 ʅm, as along nerves and 
myofibers or between myofibers and blood vessels. Alternatively, linear tracks are 
detectable as singular interphase along myofibers, possibly representing collapsed but 
preexisting space, which becomes moderately expanded by invading cells without 
apparent change of tissue structure, similar to cell-imposed but non-proteolytic widening 
of experimental microtracks in 3D collagen scaffolds.36 Using mosaic-type tumors to 
visualize leading edges of invasion within a complex tumor mass, combined 
THG/SHG/fluorescence imaging allows to categorize tissue geometry and its impact on 
the mode of migration. Invasion into collagen-rich interstitial tissue occurs along fibrillar 
meshworks of collagen fibers bordering discontinuous, heterogeneous spaces, thus 
representing migration in 1D when cells move predominantly along a singular fiber,11 3D 
when three-dimensionally surrounded and touched by multiple fibers,3 and 1D/3D 
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combinations depending of alternating ECM porosity and alignment (Fig. 7A and B). By 
contrast, confined tracks consist of often simple-shaped 2D interfaces, such as the linear 
surface of myofibers or nerve strands, or the curved but nonetheless 2D surfaces of 
adipocytes. Because migrating cells engage with one interface scaffold and, with their 
apical pole, touch the counter-scaffold, here the adjacent myofiber, vessel, or collagen 
bundle, the tissue topography combines elements of 2D and 3D migration (Fig. 7C and 
D), similar to the continuous 3D environment that confines individual cells migrating 
between opposing 2D interfaces (“chimneying”).37 Myofibers, peripheral nerves and 
adipocytes are covered by a basement membrane consisting of type IV collagen, laminin, 
nidogen/entactin, and perlecan,38 and collagen fibers and bundles consist of fibrillar 
collagens, predominantly collagen type I and III; thus each invasion routes provides a 
variety of 1D fibrils, 2D surfaces of basement membrane and/ or bundled collagen, and 
complex fibrillar and multi-surface 3D geometries in close vicinity which are employed by 
cells in a versatile, adaptive and often simultaneous manner. In 2D models, surfaces 
coated with both basement membrane components and fibrillar collagens provide bona-
fide substrate for cell polarization along the surface, engagement of integrins for 
mechanosensing and -transduction for haptokinetic migration.39,40 Likewise, B16F10 cells 
during 1D, 2D and/or 3D migration show preferential orientation along the preexisting 
tissue topography, consistent with contact guidance of in vivo invasion.11 Similar ECM-
directed guidance of tumor-cell invasion occurs along radially aligned collagen fiber 
bundles surrounding breast tumors in perpendicular orientation.11,12,19 Besides tissue 
topography and spaces of least resistance, the stiffness of such 2D/3D tissue scaffolds 
may support directional cell migration by reinforcing cell protrusions, formation of focal 
adhesions, and high-traction force for elongated cell movement.41,42 The stiffness of skin 
tissue components varies between deformable collagen networks (elastic modulus 1–3 
kPa),43 more rigid muscle fibers (elastic modulus ~12 kPa)44 and fat tissue (elastic 
modulus 5–25 kPa),45 thus providing different mechanical strengths for haptotactic and 
durotactic guidance cues in conjunction with 1D, 2D and 3D topography. Collective 
invasion is a multicellular migration mode dependent on cell-cell cohesion, supracellular 
organization, and the capacity to proteolytically degrade ECM and generate tracks.34,35 
THG/SHG/fluorescence imaging further suggests that the shape, extend and speed of 
collective invasion is strongly impacted by the type and shape of encountered tissue. 
Linear microtracks, such as along muscle fibers, support fast (70 ʅm/d), directionally 
persistent and laterally confined collective invasion in B16F10 cells. Conversely, 
irregularly shaped, discontinuous tracks within fat tissues result in comparably slow, 
poorly organized multicellular mass invasion with multiple tip cells advancing slowly 
(estimated speed 10 to 15 ʅm/d; data not shown). Thus, besides cell-intrinsic features, 
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the topography and composition of connective tissue strongly impact the shape, 
distribution and efficacy of collective invasion with preference for tissue topography 
matching 2D/3D organization along flat and relatively rigid surfaces. As unexpected 
finding, THG imaging visualized (sub) micrometer sized tumor-associated particles in the 
tumor microenvironment and allowed estimations of size distribution, location and 
dynamics. Tumor microparticles are detectable using fluorescence labeling from in vitro 
or ex vivo samples,46 but have not been visualized yet in native state in vivo. THG thus 
facilitates the visualization of native microvesicles in live tissue without fluorescence 
labeling requirement or tissue processing which delivers robust microparticle signal, in 
contrast to intra-vesicle fluorescence which may be degraded or leak out through 
membrane defects. As important technical limitation, due to the diffraction limit of 
infrared excited multiphoton excitation (lateral point-spread function above 650 nm30) 
the size of very small particles is either overestimated (toward the micron range) or 
particles below 200 nm in diameter may remain undetected.47 Tumor cells produce a 
heterogeneous mixture of small vesicular structures of submicrometer size which are 
implicated in cancer progression, by a dual mechanistic function. Microparticles may 
enhance progression by mediating intercellular communication and oncogenic 
conditioning of local and systemic microenvironmental niches and thereby promote 
tumor invasion and metastasis, angiogenesis and drug resistance.32,48 Conversely, 
microparticles serve as antigen carriers and after uptake by antigen-presenting cells may 
enhance anti-tumor immune reactions.49 Time-lapse THG imaging shows distinct subsets 
of immobilized as well as randomly or directionally moving particles, likely in response to 
respective immobilization at collagen fibers or convection with interstitial fluid drifts.50 
Thus, THG may serve as supportive approach to monitor particle dynamics in vivo under 
physiological conditions and disease states.  
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Materials and Methods  
Cells and cell culture. B16F10 mouse melanoma cells were cultured in RPMI1640 
medium (GIBCO, 21875) supplemented with 10% FCS (SIGMA, F7524), 1% sodium 
pyruvate (GIBCO, 11360) and 1% penicillin and streptomycin (PA A, P11–010). Dual color 
cell lines were generated using the following constructs: pLenti6.2/V5-DEST™ Gateway® 
(Invitrogen, V36820) containing histone2B/eGFP and pCMV-E2-Crimson (Clontech, 
632556).56 Stable histone-2B/eGFP expressing cell lines were obtained by lentiviral 
transduction and blasticidin selection (10 ʅg/ml). Subsequently, stable dual color lines 
expressing histone-2B/eGFP and cytoplasmic E2-Crimson were created by 
electroporation followed by G418 selection (100 ʅg/ml) and fluorescence activated cell 
sorting of the double positive population.   
Tumor implantation and intravital monitoring. Dorsal skin-fold chambers were 
transplanted on 8 to 14-week-old male C57/Bl6 J mice (Charles River), as described.16 
The dorsal skin-fold chamber is mounted on a skin-flap to cover the deep dermis after 
surgically removing the opposite side of the skin, as described.51 One day post-surgery, 
two small tumors per chamber were implanted by injecting a cell pellet of histone-
2B/eGFP and E2-Crimson expressing B16F10 cells (5 ×104–2 × 105 cells) with a 30 G 
needle into the dermis nearby the deep dermal vascular plexus.16 Tumor growth was 
then monitored for up to 13 d by epifluorescence and multi-photon microscopy. For 
intravital microscopy, mice were anesthesized with isoflurane (1–3 % in oxygen) and the 
skin-fold chamber was stably mounted on the temperature-controlled stage (37°C). 
Blood vessels were visualized by intravenous injection of AlexaFluor®750 labeled 70kDa-
dextran (2 mg/mouse).  
All animal experiments were approved by the Ethical Committee on Animal Experiments 
and performed in the Central Animal Laboratory of the Radboud University, Nijmegen, in 
accordance with the Dutch Animal Experimentation Act and the European FELASA 
protocol (www.felasa.eu/guidelines.php). 
Two-photon system setup and image acquisition. Imaging was performed on a 
customized multiphoton microscope (TriMScope-II, LaVision BioTec), equipped with 
three tunable Ti:Sa (Coherent Ultra II Titanium:Sapphire) lasers and an Optical 
Parametric Oscillator (OPO PP Automatic equipped with a PP800 crystal; Coherent APE ; 
typical pulse width 200 fs, repetition rate 80 MHz; peak output power of 500– 650 mW 
at 1180 nm). THG imaging was performed with an Olympus XLUMPlanFl 206/0.95 W 
objective at a wavelength of 1180 nm resulting in a maximum intensity of 190 mW below 
the objective, which for imaging living tissue was commonly attenuated to 100–130 mW 
in the sample. During in vivo measurements, emission was backward detected by 4 PMTs 
in standard position (blue/THG, FF417/60 or FF01 395/8; green, ET525/50; red ET620/60, 
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FF01 593/11 or FF01 593/40 and far-red FF01 675/67, ET710/75x or ET810/90 FF filters: 
Semrock, Inc., ET filters: Chroma Technology Inc.). For high-sensitivity in vitro 
measurements, emission was also collected in the forward direction using a 1.4NA 
condensor and two detection channels (FF417/60 or FF01 395/8; and FF01 593/11 
respectively). Ultrasensitive gallium arsenide phosphide, blue and red sensitive PMTs 
(Hamamatsu, H7422-40, H6780-01 and H6780-20 respectively) were used for backward 
detection using an ultasensitive port directly adjacent to the objective. For THG forward 
detection, blue and red sensitive PMTs were used. 
Image processing, single particle tracking and analysis. Images were processed using Fiji 
(http://pacific.mpi-cbg.de/ wiki/index.php/Fiji). Mosaic images were stitched using the 
Fiji 2D/3D stitching plugin52 and drifts in time-lapse recordings were corrected using the 
StackReg plugin.53 Quantitative analysis of tumor microvesicle dynamics was performed 
by single particle tracking, as described.54 Two-dimensional trajectories in the plane of 
focus were reconstructed using IDL-based colloidal particle tracking software55 which has 
been translated to MATLAB (Daniel Blair and Eric Dufresne, 
http://physics.georgetown.edu/ matlab) and modified for tracing of heterogeneously 
distributed, low-intensity fluorescent spots. During tracking a maximum frame-to-frame 
displacement of 3 or 2 pixels (1.5 and 1 ʅm) was allowed for THG and SHG reference 
spots, respectively. The cross section of a tracked particle has been calculated by 
determination of the radius of gyration, around its local intensity maximum, in the first 
frame of the trajectory. Mean square displacement (MSD) curves were generated for 
each trajectory with a minimum length of 21 frames, and the short time lag diffusion 
coefficient D used in the histogram of Figure 6D was retrieved by linear fitting of the first 
four points of the MSD plot. To generate histograms of microvesicle velocity distribution, 
the first 1/4th of the points of the MSD plot of individual trajectories was fitted with a 
model function for directed diffusion: < r(t)2 > = 4Dt + (Vt),2 where < r(t)2 > is the mean 
square displacement for time lag t and V equals the velocity component.  
Colocalization analysis was performed using the Colocalization Highlighter plugin of 
ImageJ software (NIH, Bethesda, MD). Images were background corrected, thresholded 
using automatically settings of the threshold tool, and ratio of intensity was set at 50% . 
Two points were considered as colocalized when their respective intensities were above 
threshold and the ratio of their intensities above 0.5.  
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Abstract 
Cytotoxic T lymphocytes (CTL) mediate antigen- and cell–cell contact dependent killing 
of target cells, such as cancer cells and virus-infected cells. In vivo, this process requires 
the active migration of CTL towards and away from target cells. We here describe an 
organotypic 3D collagen matrix assay to monitor CTL migration together with CTL-
mediated killing of target cells. The assay supports both, time-lapse microscopy of 
killing dynamics as well as population analysis of killing after matrix digestion and Ňow 
cytometry. The assay was used to assess the detrimental effect of cyclosporine A (CsA) 
present during CTL activation, which caused an inhibition of CTL-target cell conjugation 
and strongly impaired CTL-mediated killing, particularly at low effector–target ratios. 
Thus, the organotypic assay is useful to monitor spatiotemporal control mechanisms of 
cytotoxic immune effector functions. 
Introduction 
Cytotoxic T lymphocytes (CTL) mediate the killing of target cells that express antigenic 
peptide in the context of the MHC complex and thereby eliminate virally infected and 
malignant cells. In the tissues, CTL-mediated cytotoxicity is a multi-step process which 
requires initial entry through the blood vasculature into the diseased tissue, migration 
towards and surface scanning of target cells followed by TCR triggering by cognate 
peptide/MHC complexes and stable conjugation. SpeciĮc TCR-induced signaling then 
mediates lytic granule release or the engagement of FasL death receptors with Fas on 
the target cell and subsequent apoptosis induction. As last step, mediated by the re-
onset of migration, the CTL dissociates from the dying or already dead target cell for 
consecutive contacts [1]. Thus a complex series of migration, adhesive cell–cell 
interaction and signaling steps is integrated in a spatiotemporal manner.  
Because of their ability to kill tumor cells effectively and speciĮcally, adoptive 
transfer of ex vivo activated, autologous or heterologous CTL are used for anti-tumor 
immunotherapy. The current criteria for selection of T cells for adoptive immunotherapy 
include a high avidity for tumor-associated antigens, the capability to produce Th1 
cytokines, and a potent tumor speciĮc lytic capacity [2]. In the clinical practice however, 
in vitro measured anti-tumor reactivity often fails to correlate with the anti-tumor 
efĮcacy after adoptive transfer into the patient [2]. Thus, yet unidentiĮed factors present 
in the tumor microenvironment counteract CTL function.  
CTL mediated cytotoxicity is typically studied in two-dimensional liquid cocultures of 
target cells and CTL [3,4]. However, this approach does not sufĮciently reŇect the in vivo 
situation in solid tumors and likely leads to an inaccurate estimation of CTL efĮciency. 
Therefore, in vitro assays that mimic the interstitial characteristics of the tumor 
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microenvironment are required to identify and routinely test additional parameters of an 
efĮcient CTL effector phase.  
In the clinic, the immunosuppressive drug cyclosporine A (CsA) is used as standard 
treatment to reduce CTL effector function to cope with autoimmune diseases and 
unwanted graft rejection. By blocking the calcium calmodulin-dependent 
serine/threonine phosphatase calcineurin, CsA interferes with TCR mediated activation 
of the transcription factor NF-AT and subsequently with the transcription of genes 
required for T cell activation and proliferation (e.g., IL-2) [6]. Calcineurin signaling 
supports T cell effector functions including degranulation and formation of the 
immunological synapse [9,10]; consequently inhibition of this pathway was shown to 
inhibit CTL effector function in classical CTL-mediated killing assays which use passive co-
sedimentation and, hence, bypass the active phase of CTL conjugation with the target 
cell [8–10]. 
We here describe an organotypic collagen matrix-based three-dimensional assay for 
measuring CTL effector function against antigenic target cells that can be used for 
monitoring single-cell dynamics and killing as well as population analysis of killing 
efĮciency. To avoid the potential bias towards forced conjugation and lytic interaction 
introduced by passive sedimentation present in other CTL function assays we here re-
assessed CsA effects on CTL functions. 
Material and methods 
Target cells.  
C57BL/6 mouse embryonic Įbroblast-like cells transfected with B7.1 and a minigene 
encoding the OVA-derived CTL epitope SIINFEKL (MEC/OVAp) or the adenovirus type 5 
E1A-derived CTL epitope SGPSNTPPEI (MEC/E1Ap) coupled to a signal-sequence which 
directs epitope expression to the endoplasmatic reticulum were used as target cells [5]. 
The cells were cultured in RPMI1640 medium (GIBCO, 21875) supplemented with 10% 
FCS (SIGMA, F7524), 10 mM HEPES (GIBCO, 15630), 500 mM 2-mercaptopethanol, 1% 
penicillin and streptomycin (PAA, P11-010), 1% sodium pyruvate (GIBCO, 11360), and 0.1 
mM non-essential amino acids (GIBCO, 11140).  
Isolation and activation of primary OT1 CD8+ T lymphocytes.  
Splenocytes from OT1 mice were isolated and erythrocytes were depleted by ammonium 
chloride (0.83% NH4Cl,  0.1%  KHCO3,  0.37%  Na2EDTA) treatment. For the expansion of 
antigen-speciĮc CTL, splenocytes were cultured at a concentration of 2.5 x 105/ml in the 
presence of 0.5 µg/ml SIINFEKL peptide in 24-well plates for 3 days. On day 3, IL-2 (100 
U/ml), either alone or in combination with cyclosporine A (Sigma) in different 
concentrations was added to the cultures. Lymphocytes were incubated for further 48 h 
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and harvested on day 5 by a Ficoll gradient (AXIS-SHIELD PoC AS, Oslo, Norway) – with a 
purity of Valpha2+CD8+CD44hi cells exceeding 96 %, determined by Ňow cytometry.  
To determine the proliferation of CTL upon addition of IL-2 and CsA, CTL were labeled 
with 5 mM CFSE and proliferation was quantiĮed as decreasing CFSE Ňuorescence 
following cell divisions.  
Collagen-matrix based cytotoxicity assay.  
A sandwich assay consisting of target cells adherent to the bottom to the culture dish 
overlaid with a polymerized 3D collagen lattice containing preactivated CTL was 
developed (Fig. 1A). SubconŇuent MEC/OVAp target or MEC/E1Ap control cells were 
washed with phosphate-buffered saline (PBS), labeled with either low (0.4 mM, CFSElow) 
or high (8 mM CFSEhigh) concentrations of CFSE (5 min, RT) to generate differentially 
labeled target/control cells. Cells were then washed twice with PBS, detached with 
trypsin/EDTA and seeded in a 1:1 ratio into 96-Ňat bottom wells (Įnal density of 2 
104/well). After 4 h of incubation and cell attachment to form a subconŇuent target cell 
layer, collagen solution (PureCol1, Inamed BioMaterials; 75 ml/well; collagen 
concentration 1.7 mg/ml;) containing the CD8+ T lymphocytes was added on top. After 
polymerization for 30 min at 37 °C, the matrix was overlaid with growth medium (75 ml) 
and incubated for 16– 20 h (37 °C, 5% CO2, humidiĮed atmosphere).  
To harvest surviving cells, the collagen was dissolved by collagenase I (40 U/well; 30 
min; Sigma C0130) and the remaining adherent cells detached with trypsin/EDTA (5 min). 
Both cell fractions were uniĮed, stained with propidium iodide (5 mg/ml, 5 min, RT) 
washed twice with PBS, Įxed in 4 % PFA (30 min, RT) and analyzed by Ňow cytometry.  
The speciĮc killing efĮciency was determined as the ratio of propidium iodide 
negative CFSElow target to CFSEhigh control cells and normalized to background cell death 
from the negative control cultured in the absence of CTL. The relative survival of CFSElow 
target  cells  compared  to  CFSEhigh control cells was calculated as follows: 1 - (ratio 
CFSElow/CFSEhigh reference sample)/(ratio CFSE
low/CFSEhigh CTL sample) = % speciĮc killing efĮciency. 
At least 10,000 CFSE+ PI events were measured from each sample.  
To compare CTL viability in different samples and treatment conditions, the ratio of 
viable CTL to surviving CFSEhigh control cells was determined. At E:T ratios below 1:2 no 
unspeciĮc bystander killing of CFSEhigh labeled control cells was observed, which allowed 
their use as internal standard for cell counting given their presence in equal numbers in 
all samples. To quantify CTL-target cell conjugate formation, CTL were labeled with 4 mM 
CellTrackerTM Orange (CMTMR; Molecular Probes) before coculture and CTL-target cell 
conjugates were determined by Ňow cytometry as propidium iodide negative, 
CFSE/CMTMR double positive events.  
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Time-lapse bright-Įeld and Ňuorescence microscopy.  
Migration  of  CTL  in  the  collagen  matrix  and  scanning  of  CFSE  labeled  target  cells  was  
recorded by Ňuorescence time-lapse microscopy in a Microscope Stage Incubator (Oko-
Lab, Italy), ensuring optimal culture conditions, using a Nikon DiaPhot equipped with a 
Hamamatsu  C8484-05G digital  camera.  Images  were  taken with  a  1  min  frame interval  
for up to 24 h using the time-lapse software (Oko-Lab, version 2.7).   
 
Figure 1. Visualization of CTL migration dynamics and target cell killing. (A) 3D  collagen  assay  setup.  
Monolayers of CFSElow target  and  CFSEhigh control cells (in 1:1 ratio), were overlaid with a collagen matrix 
containing CTL. The three-dimensional matrix prevents passive aggregation of CTL and target cells and 
instead promotes the natural migration behavior of CTL. (B) CTL mediated killing of target cells, monitored 
by  time-lapse  epiŇuorescence  and bright  Įeld  microscopy.  MEC/OVAp target  cells  (CFSElow) and MEC/E1Ap 
control cells (CFSEhigh) were cocultured with in vitro activated CTL from OT1 mice. Time-lapse movies were 
recorded for up to 24 h with a frame rate of 1/min. The combination of bright Įeld and Ňuorescence 
microscopy allowed the detection of speciĮc apoptosis induction in target cells (indicated by membrane 
blebbing) during or after CTL interactions and effector function. Areas of apoptotic target cells are indicated 
by red crosses. 
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Figure 2. QuantiĮcation of antigen-speciĮc target cell killing by Ňow cytometry. (A) Flow  cytometric  read  
out. Dot plots were gated on morphologically intact cells. The differentially CFSE labeled target and control 
cells were distinguished from CFSE negative CTL, with propidium iodide staining discriminating viable, intact 
from dead subpopulations. At E:T ratios above 1:1 unspeciĮc cell death was observed in control cells through 
bystander effects. The histograms depict the viable CFSE positive target cell populations. The relative 
percentage of surviving CFSElow target  cells  to  CFSEhigh control cells served to calculate the speciĮc killing 
efĮciency. (B) Dose–response curve. Increasing numbers of CTL were cocultured with stable numbers of 
target cells and harvested for analysis after 16 h of incubation. Data represent the means and standard 
deviation of at least 4 independent experiments. 
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Results  
Principle of migration-based cytotoxicity assay  
The  organotypic  killing  assay  consisted  of  a  3D  Įbrillar  collagen  matrix  containing  CTL  
and the interface between collagen and the culture dish containing subconŇuent target 
cells (Fig. 1A). To address whether the design supports CTL effector function together 
with active movement before and after target cell killing, the interface was monitored by 
long-term time-lapse Ňuorescence microscopy. MEC/OVAp target cells (CFSElow) and 
MEC/E1Ap control cells (CFSEhigh) were equally well contacted by CTL which immigrated 
from the above collagen scaffold towards the collagen-target cell interface (Fig. 1B; 
Movie 1). Contacts of individual CTL with MEC/OVAp eventually led to target cell 
rounding, detachment and blebbing, followed by structural disintegration, consistent 
with apoptosis induction (Fig. 1B; arrowheads) supplementary information, movie 1. 
Compared with MEC/E1Ap control cells which only occasionally showed unspeciĮc cell 
death, MEC/OVAp cells were preferentially contacted and killed within the 24 h 
observation period (Fig. 1B). Thus, the assay supports migration-dependent interaction 
of CTL with target cells followed by apoptosis induction in target cells in an antigen-
dependent manner.   
QuantiĮcation of CTL mediated speciĮc killing by Ňow cytometry  
To achieve sufĮcient throughput for pharmacological and other screenings, the 3D 
culture system was combined with a Ňow cytometry read out. At the end of the 
incubation time the collagen matrix was dissolved using collagenase and surviving 
adherent target cells were detached and combined with the supernatant containing CTL 
and dead target cells for Ňow cytometric analysis. The differential CFSEhigh/low label in 
combination with propidium iodide staining allowed to distinguish several discrete cell 
populations (Fig. 2A). Intact, viable CFSElow MEC/OVAp target and CFSEhigh MEC/ E1Ap 
control cells formed two distinct propidium iodide-negative populations which were 
separate from CFSEnegative but weakly autoŇuorescent CTL (Fig. 2A). Propidium iodide-
positive cells retained the initial CFSE intensity prior to structural disintegration (Fig. 2A, 
lower  panel).  The  relative  percentage  of  surviving  CFSElow MEC/OVAp target cells 
compared to CFSEhigh MEC/E1Ap  control  cells  was  used  to  calculate  the  speciĮc  killing  
efĮciency. Thereby, the ratio of viable CFSEhigh to CFSElow target cells at the endpoint of 
the  assay  was  compared  to  the  ratio  of  viable  CFSEhigh to CFSElow target  cells  in  a  
reference sample without CTL.  
To analyze the dose effect of CTL mediated cytotoxicity, effector and target cells 
were incubated in various ratios and harvested for analysis after 16 h of incubation.  
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Figure 3. Cyclosporine A (CsA) reduces CTL-target cell conjugation and killing in the organotypic assay. 
Activated  CTL  were  cultured  for  48  h  with  IL-2  and  CsA  at  different  concentration  and  tested  for  killing  
efĮciency in the organotypic assay. (A) Dose-dependent inhibition of speciĮc killing in the presence of CsA. CsA 
concentrations  of  0.1  mM  and  1  mM  resulted  in  signiĮcantly  reduced  CTL  killing  efĮciencies  after  16  h  of  
coculture  with  target  cells  and  in  presence  of  CsA.  For  improved sensitivity  at  low effector:target  (E:T)  ratios  
(1:32 and below) the duration of coculture was 40 h and otherwise 16 h. Data represent the means and SEM of 
at least 3 independent experiments. Asterisks, p < 0.05 (two-tailed Mann Whitney test). (B) Flow-cytometric 
detection of CTL– target cell conjugate formation in the absence (DMSO solvent) or presence of CsA. Gating of 
CMTMR labelled CTL (dashed box) either as CMTMR single-positive cells without conjugation (M1) or as 
CFSE/CMTMR double positive CTL–target cell conjugates with MEC/OVAp target cells (M2) or MEC/E1Ap 
control cells (M3). (C) Ratio of conjugated and unconjugated CTL with MEC/OVAp target or MEC/E1Ap control 
cells (3 independent experiments). (D) Correlation (r) of CTL conjugation with target cells and killing efĮciency 
(Spearman’s correlation test). (C and D) Frequency of conjugates and killing efĮciency are shown as means SD 
from 3 independent experiments. 
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SpeciĮc  killing  efĮciency  was  reliably  obtained  for  a  minimum  E:T  ratio  of  1:128  and  
above. At an ET ratio of 1:1 a plateau of killing efĮciency (85%) was reached. Higher E:T 
ratios induced substantial unspeciĮc collateral damage and thereby decreased the target 
cell number in non-cognate control cultures which served as internal reference to 
calculate the speciĮc killing efĮciency. The combination of the sensitive single cell read 
out and incubation times of up to 40 h (data not shown) allow the sensitive 
quantiĮcation of CTL effector pathways at low effector: target ratios. 
Cyclosporine A impairs  CTL  effector  function by reducing the ability  of  CTL  to  
form stable interactions with target cells  
To address the effect of CsA on in vitro activated CTL effector function, CTL during pre-
activation were cultured in the absence or presence of CsA at concentrations reached in 
patients’ blood samples [7], together with IL-2. Even at high concentrations (1 mM), CsA 
did not affect CTL proliferation or the expression levels of CD25 during pOVA-induced 
CTL priming (data not shown). However, in the organotypic effector function assay, CsA 
impaired CTL mediated target cell lysis signiĮcantly at concentrations of 0.1 mM and 
above (Fig. 3) which led to near-complete abrogation of killing even at intermediate and 
low E:T ratio. CsA had no effect on CTL viability (data not shown) but strongly inhibited 
adhesive interaction of CTL with target cells. Using CTL labeled with red-Ňuorescent 
CMTMR confronted with green-Ňuorescent CFSE-labeled target cells, a strong reduction 
of CFSE/CMTMR double positive CTL-target cell conjugates was obtained by Ňow 
cytometry (Fig. 3B, dashed lines). The conjugation defect was dose-dependent and near-
complete at high CsA concentration for both, pOVA expressing target cells and non-
cognate control cells (Fig. 3C). Using time-lapse microscopy in parallel, no difference in 
basic migration in the collagen lattice and towards target cells was detected for CsA 
treated and control CTL, excluding that CsA causes a migration deĮcit (supplementary 
information, Movie 2). Consequently, impaired killing efĮciency was a linear function of 
impaired CTL adhesion to target cells in the presence of CsA (Fig. 3D).   
Discussion  
The 3D matrix environment of the organotypic killing assay mimics the tumor matrix 
interface and depends upon an active migration phase of CTL to reach and interact with 
target cells. Consequently, passive aggregation of CTL with target cells, which is integral 
to established cell-suspension based killing assays, is avoided. Further, the dense 
accumulation of CTL in conventional killing assays may promote unspeciĮc killing through 
high local concentrations of effector molecules. In addition, the absence of Įbrillar 
extracellular matrix structures or stable cellular networks hinders active migration and 
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scanning of cell surfaces by CTL. In contrast, the novel migration-based system promotes 
the natural dynamic behavior of CTL thereby providing improved biologically relevant 
information on CTL effector function. In contrast to a recently developed 3D matrix-
based spheroid model to monitor CTL function which does not support microscopic 
monitoring of live-cell interactions and target cell apoptosis [11], the organotypic assay 
allows to monitor all substeps of CTL mediated killing, including migration through the 
interstitial matrix, active conjugation with target cells including a stop-signal, and 
detachment from the target cell.  
The assay was validated using CsA present during the activation of effector CTL, 
which mimics CsA effects under steady-state conditions in patients [7]. The used doses 
match  CsA plasma levels  reached under  clinical  conditions  with  an  average  of  0.2  mM 
and peak concentrations up to 1.8 mM [7]. In the 51Cr release assay subtotal (80%) 
inhibition of target cell lysis was described after CsA exposure for a dose-range up to 1 
mM  [8],  which  was  fully  reproduced  here  using  the  3D  organotypic  assay.  As  main  
difference, in contrast to the passive aggregation used in conventional CTL-mediated 
killing assays which preclude meaningful assessment of CTL-target cell conjugation, the 
3D collagen environment requires CTL to migrate towards and actively approach, and 
detach from, target cells. Thus the natural conjugation phases are recapitulated and an 
overestimation of killing efĮciency caused by artiĮcial aggregation is avoided. Further, 
unlike the conventional 51Cr release assay which is limited to 4–8 h, the organotypic 
assay supports observation periods of up to 40 h which facilitates the sensitive detection 
of weak or delayed effector mechanisms at low effector-to-target ratios and thereby 
better reŇects the sequence of conjugation steps during CTL effector function. This new 
topographic element allows the meaningful combination of measuring killing efĮciency 
with associated functions, including conjugation measured by Ňow cytometry and CTL 
migration monitored by time-lapse microscopy. This combined approach provides 
mechanistic insight into CTL effector function beyond the capabilities of cell-suspension 
based  killing  assays.  Treatment  of  CTL  with  CsA  in  the  presence  of  IL-2  leaves  CTL  
proliferation and migration capabilities intact, however near-completely ablates stable 
conjugation with target cells and, consequently cytotoxic outcome. This Įnding 
complements previous observations of a CsA mediated reduction of CD3/TCR 
relocalization to the T cell– target cell interface [9] and is consistent with an impaired 
timely formation of the cytolytic effector synapse [12].  
Because of its tissue-based organization, this assay will be amenable to further 
mechanistic studies on effector CTL functions, including the detection of cell surface 
markers to characterize surviving target cell subpopulations; intracellular staining of 
cytokine expression proĮles of the immune effector cells; and to determine the cell cycle 
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stage of surviving target cells based on propidium iodide labeling. If combined with 
Įxation and antibody staining in parallel cultures, additional information of  cell–cell 
conjugation and the immunological synapse can be retrieved (own unpublished 
observations) providing additional information on effector–target cell conjugation and 
the mechanisms of CTL mediated apoptosis induction. This will allow screening for 
factors modulating CTL efĮciency, including factors that affect dynamic CTL migration 
and antigen- and costimulation dependent cell–cell adhesion with adequate throughput. 
Thus, the organotypic CTL function assay will be useful to establish and monitor 
optimized tumor-reactive CTL for adoptive immunotherapy as well as for 
pharmacological screenings in the development of efĮcient and selective 
immunosuppressive or –activating drugs.  
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Abstract 
Immunological control of cancer lesions requires local uptake of tumor-speciĮc antigen 
followed by the activation and expansion of tumor speciĮc cytotoxic T-lymphocytes 
(CTL). An efĮcient effector phase further depends upon the entry of activated CTL into 
the tumor microenvironment and scanning of tumor tissue, which leads to direct 
interaction of the CTL with target cells followed by apoptosis induction and shrinkage 
of the tumor lesion [1,2]. Whereas the antigens and pathways that lead to efĮcient 
activation of tumor-speciĮc CTL are well established, the local mechanisms that enable 
efĮcient – or deĮcient – CTL function in the tumor tissue are poorly understood. Firstly, 
effector T lymphocytes need to be mobile to reach the tumor lesion. Next, they must 
physically interact with and scan tumor cells for antigenic MHC/peptide complexes. 
Lastly, CTLs must undergo activation and functional conjugation with target cells to 
induce apoptosis either by the release of perforins or the engagement of Fas/FasL [3]. 
All these steps of effector function are interdependent and require the amoeboid 
migration of CTL through tissue to reach, engage with and leave encountered cells [4].  
Amoeboid migration and tissue surveillance by cytotoxic T lymphocytes  
With the onset of amoeboid migration, leukocytes adopt a typical ‘hand-mirror’ shape, 
consisting of a leading edge where short-lived pseudopods form and engage with the 
tissue substrate, a more rigid mid-region including the nucleus, and a posterior tail, 
termed uropod, that contains actin Įlaments, microtubules and organelles [5]. The force 
that drives amoeboid locomotion is generated by the actin-mediated forward Ňow of the 
leading edge, including pseudopods and lamellipods, followed by actomyosin-mediated 
contraction of the mid region and uropod [6]. In contrast to other migration modes, 
amoeboid cell locomotion does not depend on integrin mediated adhesion [6,7]. Due to 
the low adhesion coupled to rapid turn-over of cell–matrix interaction amoeboid moving 
cells are the fastest mammalian cells in tissues (up to 30  µm/min) with the ability to 
rapidly change directions, enter and pass through tissues, and engage with other cells 
[4]. Consistent with short-lived, poorly adhesive cell–substrate interactions, migrating 
lymphocytes deform tissue structures only temporarily and do not degrade or reorganize 
the extracellular matrix but rather slip through and along existing tissue gaps and trails 
[8], thereby preserving tissue integrity despite locally high lymphocyte inĮltration [9].  
Besides its function in T cell trafĮcking, the amoeboid polarization contributes to T 
cell functions by enhancing the cells’ capability to sense and respond to signals received 
from the extracellular environment. Leading edge and uropod are both required for cell 
and tissue scanning during the effector phase. The dynamic leading edge shows an 
increased sensitivity to TCR triggering by peptide/MHC complexes and chemokine signals 
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[10]. Conversely, the trailing uropod contains increased levels of adhesion receptors, 
including intercellular adhesion molecule (ICAM)-1, integrins and the highly glycosylated 
surface receptors CD43 and CD44 [11]; which likely regulate attachment to cell surfaces 
and extracellular matrix (ECM) during migration [12]. The uropod is important in 
maintaining polarity during migration. Interfering with a cytoplasmic domain of CD44 in 
CTL affects polarity and migration as well as scanning of target cells needed for an 
efĮcient anti-tumor immune reaction in vivo [13].  
Contact acquisition and killing of target cells  
During scanning of encountered cells, CTL engage the TCR to probe counterpart 
peptide/MHC complexes. Initial scanning of tumor cells occurs randomly along the 
tumor-stroma border until cognate peptide–MHC (pMHC) complexes on target cells 
result in TCR triggering and delivery of a “stop-signal” [14]. Initial adhesion with B cell 
target cells results from integrin engagement, such as LFA-1/ICAM-1 and/or CD2/CD58 so 
that T cell motility slows down and a stable immunological synapse is being formed [15]. 
Consistently, when monitored by intravital microscopy in vivo, CTL tend to slow down 
migration in tumors expressing cognate antigen, engage with individual tumor cells for at 
least half an hour, and are able to induce cytotoxic killing and eradication of the lesion 
[16,17].  
The induction of apoptosis in target cells is a sensitive and fast process (Fig. 1). CTLs 
detect single pMHC complexes on the cell surface and interaction with only few pMHC 
complexes can induce a cytolytic response [18]. If B cells are the target, few minutes of 
contact can lead to apoptotic cell death [15]. Yet, in vivo, CTL contacts to target cells in 
solid tumors occur in the range of several hours until killing is achieved [17].  
Two often synergistic pathways lead to target cell killing, the ligation of death 
receptors (Fas–FasL) and the release of lytic granules. The Fas pathway is important in 
eliminating activated immune cells in the termination of immune responses and further 
contributes to anti-tumor responses in Fas expressing tumors [19]. A different route to 
target cell death induction is degranulation of lytic granules that contain the pore-
forming protein perforin and a set of proteases, including Granzyme A and B, which 
enter the target cell, activate intracellular caspases, and thereby induce apoptosis. 
During binding to target cells, granules move via microtubules towards the cell–cell 
contact, and release their content towards the target cell [15]. Whereas stop signal, MHC 
density and contact times in vitro occur under usually optimized conditions, their 
contribution to in vivo killing in the tumor microenvironment likely differs in both 
mechanism and efĮciency [17].   
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Determinants of killing efĮciency  
The mechanisms that modulate CTL-target cell interactions in vivo are incompletely 
understood; they comprise the molecular plasticity of tumor cells to evade CTL-induced 
killing and cytokines and chemokines released by the tumor microenvironment. 
Consequently, immunologic evasion of tumor cells occurs via downregulation of 
peptide/MHC, Fas and/or accessory adhesion receptors at the cell surface.  
The strength of TCR signaling depends on the duration of the interaction and the 
avidity of the TCR for its peptide/MHC ligand. Consequently, higher peptide avidity or 
higher peptide density both support exocytosis of granule content and target cell killing 
[20]. The presence of cognate antigen further induces CTL migration deeply into the 
tumor. In model tumors, CTL initially accumulate in the periphery of the tumor by an 
Figure 1. Dynamics of cytotoxic T cell induced apoptosis in a target cell. Murine B16F10 melanoma cells 
endogenously expressing ovalbumin (OVA) peptide (SIINFEKL) and histone 2B–eGFP were cocultured with in vitro 
activated CTL from OT1 mice. Time-lapse movies were recorded for up to 24 h with a frame rate of 1/min. The 
combination of bright Įeld and Ňuorescence microscopy allowed the detection of apoptosis induction (indicated 
by membrane blebbing and change of nuclear histone 2B–eGFP pattern) during CTL binding and effector function. 
The phases of nuclear condensation, fragmentation and terminal aggregation are indicated. Notably, membrane 
blebbing occurred near-simultaneously to nuclear condensation. Time (min) after contact initiation is indicated 
(right lower corner). 
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antigen-independent process, however their inĮltration towards the center is only 
observed in antigen expressing tumors [16,17].  
Likewise altered availability of accessory molecules modulates effector function. LFA-1 
and CD2 initiate and stabilize cell–cell binding which, together with costimulating CD28 
signaling, enhances effector function [21]. On the other hand, compromising contact 
duration and/or polarization are thought to lower killing efĮciency by interfering with the 
focusing or the release of lytic granules towards the target cell. Accordingly, interference 
with contact stability by blocking LFA-1 receptors reduces CTL mediated killing [22].  
Besides their established promigratory function, chemokines (e.g. CXCL12) in high 
concentration can induce a paradox negative chemotactic signal in CTLs and thereby 
prevent sufĮcient inĮltration into the tumor [23]. By a different mechanism chemokines 
(e.g. CXCL10) may further impair CTL effector function by overruling the antigen-driven 
stop signal [24]. Conversely, IL-12 appears to promote immunological synapse formation 
and enhance CTL efĮciency [25]. Thus, the balance of both positive and negative 
regulators in a given microenvironment determines local CTL efĮciency.  
Conclusions  
In vitro assays for CTL function poorly mimic the tumor microenvironment and may 
provide an over-optimistic view on when and how efĮcient target cell killing occurs in 
vivo. Therefore they likely fail to recapitulate thus far unknown factors and rules present 
in the tumor microenvironment that support or inhibit target cell killing. As key 
denominators, the balance of CTL migration towards and less mobile positioning within 
the tumor lesion to generate precise- and long-enough antigen-dependent polarization 
towards the target cell are regulated by diverse factors of the tumor microenvironment. 
The positive or negative outcome may be greatly context dependent. Therefore, not only 
achieving sufĮcient CTL density and an even distribution in the tumor but also the local 
control of migration versus adhesion are critical determinants of efĮcient 
immunotherapy.  
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Abstract 
Cytotoxic T lymphocytes (CTL) eliminate tumor target cells in an antigen and cell-
contact dependent manner, both spontaneously and when activated by 
immunotherapy. Lethal hit delivery is considered to be a rapid and binary “yes/no” 
process under conditions of high immunogenicity1–3, and killing enhancement may 
result from sequential conjugation of one CTL with multiple target cells, termed “serial 
killing”4,5. Despite its potential significance in amplifying anti-tumor immune 
responses, the principles of serial killing and its contribution to effector function in 
established tumors remain unclear6,7.  Here  we  show  that  elimination  of  cancer  cells  
results from a cooperative process executed by multiple CTL engaging sequentially 
with the same target cell. Long-term time-lapse microscopy of three distinct tumor 
models supported by statistical modeling revealed that migrating CTL transit between 
target cells and cooperate to initiate apoptosis by a series of sublethal interactions 
(additive cytotoxicity), whereas individual conjugations rarely reached thresholds to 
induce apoptosis. Consequently, in invading B16F10 melanoma tumors treated with 
adoptive T cell therapy in vivo, serial engagements and tumor-cell apoptosis induction 
were confined to regions with high CTL density, which supported CTL accumulation and 
additive cytotoxicity. Highest rates of serial engagements followed by tumor 
eradication were reached in the invasive tumor front where moving tumor cells and 
CTL collided within the same pro-migratory tissue compartment, suggesting invading 
tumor cells as target for immunotherapy. Thus, additive cytotoxicity requires CTL 
cooperation and serial engagements with target cells to deliver cumulative sublethal 
events and successfully eradicate solid tumor cells. The need for additive “hits” has 
implications for topographic mechanisms of immune evasion of tumor cells as well as 
immune intervention to enhance CTL accumulation and cooperation.  
CTL can bind to and attack more than one target cell simultaneously8 and retain 
detectable levels of granzyme, an effector molecule required for apoptosis induction, 
after killing target cells9. Consistently, mathematical modeling suggests that CTL are 
capable of eliminating multiple target cells expressing viral antigen in vitro and in vivo 
(ranging  from  1  up  to  20  kills  per  CTL  and  day  in  bulk  killing  assays)10,11. Quantitative 
time-lapse analysis of target cell killing by NK cells identifies sequential or simultaneous 
kills of up to 14 adjacent tumor cells within 6 hours, with target cell elimination occurring 
in spatio-temporally confined clusters (burst-kinetics)12. Whereas the concept of multiple 
kills per effector cell is emerging, the underlying kinetics and efficacy thresholds of serial 
killing at the single-cell level, and how these interactions impact immune control of 
subregions within solid tumors, remains unclear. 
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To quantitatively establish serial killing of target cells by single CTL in solid tumor models, 
we used a 3D collagen-matrix based, organotypic assay to enable CTL movements along 
a tumor-stroma interface monitored by long-term time-lapse microscopy (Fig. 1a). In 
vitro activated OVA-specific OT1 CTLs were confronted with transformed mouse 
embryonic fibroblasts expressing the OVA peptide (MEC-1/OVA) and the co-stimulatory 
molecule B7.113 (Extended Data Fig. 1a-c). In contrast to in vivo generated tumor cell 
lines, this engineered model lacks natural immune escape modifications (e.g. down 
regulation of MHC-I or apoptosis resistance) and, thus, represents an idealized model for 
maximized CTL efficacy at a single cell level. After 24 h of co-culture, killing efficacy was 
near 100% at high effector-target (ET) ratios and reached background level below ET 
ratios of 1:128 (Fig.  1b).  At moderate ET ratio (1:32),  the daily killing efficiency per CTL 
amounted to 17 killed target cells (Fig. 1b), consolidating that individual CTL can kill 
multiple target cells in a serial or simultaneous manner. At the end-point, Lamp-1, a 
cytotoxic vesicle-associated transmembrane protein which appears on the CTL surface 
after lytic vesicle exocytosis, is upregulated in 85% of CTL (Fig. 1c), indicating cytolytic 
engagement of nearly the complete CTL population.  
To assess the killing efficacy at single CTL level, we analyzed singular CTL-target cell 
interactions and outcome by excluding conjugations of multiple other CTL with the same 
target cell. After contact initiation, the duration of individual CTL-target cell interactions 
was variable until detachment, lasting few minutes for non-specific interactions (median 
7.8 ±1.9) and several minutes to hours in antigen-specific interactions (Extended Data 
Fig. 1d; median 19.2 ±6.5 min). With the onset of apoptosis, target cells underwent cell 
rounding and membrane blebbing simultaneously with condensation and fragmentation 
of the nucleus, both markers of irreversible apoptotic cell death (Extended Data Fig. 1e). 
The median lag phase from contact initiation to target cell blebbing was 1.8 ± 1.5 h with 
a range of, again, minutes to hours (Extended Data Fig. 1f), often followed by ongoing 
CTL engagement with the dead cell body (Fig. 1d; “necrophilic phase”).  
This extended lag phase until apoptosis differs from those obtained for CTL-
mediated killing of target cells from leukocyte lineages, including P815 mastocytoma (<5 
min)1, B cell lymphoma (<15 min)3 and peptide-pulsed B cells (<25 min)2. As control, 
excluding compromised CTL movement or cytotoxic conjugation ability caused by the 
interface assay (Fig. 1a), the lag phase to apoptosis of target cells distributed in interface-
free 3D collagen matrices yielded equal variability ranging from few minutes to hours 
after initial contact (median 90 min) (Extended Data Fig. 2; Movie 1). Thus, the induction 
time to apoptosis was highly variable, ranging from several minutes to hours. 
When monitored in regions of low local CTL density, the repetition of contact 
acquisition, death induction and detachment resulted in the serial killing of multiple  
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Figure 1. Serial killing. a, 3D collagen-target cell interface assay to monitor serial cytotoxicity. b, Killing of 
MEC-1/OVA targets by OT1 CTL at different ET ratios, determined by flow cytometry after 24 h of co-culture. 
Error bars, means ± SD (3 independent experiments). c, Lamp-1 expression at the surface of OT1 CTL after 24h 
coculture with MEC-1/OVA cells. d, Duration of CTL-target cell contacts before and after the onset of target 
cell apoptosis. Red bars, median. e, Time-lapse  sequence  and migration  track  of  one  OT1 CTL  killing  7  MEC-
1/OVA target cells sequentially within 11 h. Circles, CTL; cross, apoptotic target cell. f, Frequency of serial kills 
and (g)  lag-phase  until  apoptosis  of  consecutive  kills  by  the  same  CTL  (43  CTL  from  8  independent  
experiments). Red bars, median. h, Population survival of 4 distinct antigen-dependent target cell and 3 
control models. Quantifications stem from ш3 independent experiments. 
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neighboring  target  cells  by  a  single  CTL  (Fig.  1e;  Movie  2).  Population-wise,  50% of  the  
CTL acted as serial  killers (maximum of 11 killed target cells/24 h),  whereas a small  CTL 
subset (15%), repeatedly contacted target cells but failed to induce apoptosis (Fig. 1f) 
despite a largely homogeneous activation status of the CTL population (Material and 
methods section). The lag phase to apoptosis was neither compromised nor accelerated 
over consecutive killing events (Fig. 1g), which resulted in a median eradication 
frequency  of  1  kill  every  2  hours  (Extended  Data  Fig.  1g).  Thus,  for  eliminating  highly  
immunogenic target cells, serial killing is a non-exhaustive process. 
To validate serial killing for solid tumor cells which typically retain resistance to CTL 
mediated  killing,  OT1  CTL  were  confronted  with  mouse  melanoma  B16F10  cells  
expressing the OVA peptide (B16F10/OVA) (Extended Data Fig. 3a). As second model, IL-
2 activated human SMCY.A2 CTL14, which recognize an HLA-A2 restricted antigen 
encoded on the y chromosome, were confronted with male human melanoma cell lines 
BLM and MV3 (Extended Data Fig. 4a, b). Compared to the MEC-1/OVA cells, these three 
melanoma models show moderately delayed, but ultimately equally complete, target cell 
elimination at the end-point after 24 hours (Fig. 1h), whereas OVA-negative B16F10 and 
female MCF-7 cells survived. Thus, both murine and human models for probing CTL 
effector function in 3D culture show similar overall kinetics and efficacy to target cell 
elimination. 
CTL killing efficiency depends on multiple parameters, such as the CTL killing 
mechanism (perforin/granzyme exocytosis or engagement of death receptors Fas-FasL), 
pMHC-I expression levels on the target cell surface and the engagement of costimulatory 
molecules (e.g. molecules from the B7 family)15. The mild difference in killing kinetics 
between MEC-1 and B16/F10-OVA cells could not be explained by differential Fas or B7.1 
expression  and  function  (Extended  Data  Fig.  1b,  3e,  f),  nor  the  surface  levels  of  pOVA  
(Extended Data Fig. 3g), indicating additional cell-intrinsic mechanisms for divergent half-
maximum survival rates (Fig. 1h). Consequently, consistent with pronounced surface 
induction of Lamp-1 on OT1 cells (Fig. 1c), these findings suggest a perforin-mediated 
elimination program in both models. 
Comparing contact kinetics at single-cell level, all melanoma models confirmed the 
serial interaction concept, including extended lag phases until target cell apoptosis with 
broad variance from min to hours (Extended Data Fig. 3c, d and 4c-e, Movie 3,4) and an 
extended necrophilic phase (Extended Data Fig. 1d; 3d, 4e). Thus, dynamic serial 
conjugations with multiple target cells characterize CTL effector function across target 
cell types and species.  
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Figure 2. Additive cytotoxicity. a, Inefficiency of individual CTL contacts in OT-1 and SMCY.A2 CTL models. 
Error bars, mean ± SD (ш100 contacts from ш3 independent experiments per model). b, Time-lapse sequence 
of CTL-associated intracellular Ca2+ event in B16F10/OVA cell and subsequent target cell survival. Ca2+ intensity 
was measured in the target cell  cytosol and plotted over time. Green, OT1 CTL (GFP); Fire LUT, Ca2+ intensity 
(GCaMP6s). c, Percentage  of  CTL  contacts  that  induce  Ca2+ events. Error bars, mean ± SD (n=3 independent 
experiments). d, Time-lapse sequence of multiple CTL sequentially engaging with 1 target cell followed by 
apoptosis. Circles, CTL; crosses, apoptotic target cells. e, Frequency of multiple contacts preceding apoptosis. 
f, Time-lapse sequence and intensity plot of multiple Ca2+ events followed by target cell apoptosis. Green 
fluorescence,  OT1  CTL  (dsRed);  Fire  LUT,  Ca2+ intensity (GCaMP6s). Cross, target cell death. g, Survival 
probability of B16F10/OVA cells having received increasing numbers of Ca2+ events prior to the last event 
preceding apoptosis. P value, log rank test comparing all groups.  
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We next tested whether apoptosis induction is a stochastic event of individual contacts 
or caused by cooperation of multiple CTL. Consistent across models, only a minority of 
individual CTL-target cell contacts induced apoptosis at first encounter (Fig. 2a). 
Conversely,  60-70%  (MEC-1/OVA,  BLM)  or  >90%  (B16F10/OVA,  MV3)  of  individual  
conjugations were unsuccessful, followed by target cell survival (Fig. 2a; Extended Data 
Fig. 1d, Movie 5). CTL degranulation mediates transient, reversible perforin-mediated 
pores in the target cell membrane, which elicits diffusion of extracellular factors into the 
target cell cytosol, including CTL-derived granzymes and extracellular calcium16. To 
discriminate sublethal cytotoxic hits from functionally inert interactions, MEC-1/OVA and 
B16F10/OVA cells were engineered to express the calcium sensor GCamP6s17, to 
measure transient Ca2+ influx through perforin pores during CTL engagement. OT1 CTL 
contacts were associated with single or repetitive Ca2+ events occurring after a variable 
lag phase of few minutes to several hours after contact acquisition (Fig. 2b; Extended 
Data Fig. 5a-g, Movie 6). A substantial fraction of antigen-specific but non-lethal CTL-
target cell contacts showed CTL associated intracellular Ca2+ events in B16F10/OVA (40%) 
and MEC-1/OVA (60%), whereas target cell death without prior Ca2+ events  was  rare  
(Extended Data Fig. 5i) and OVA-negative control cells lacked such Ca2+ events (Fig. 2c). 
Single CTL contacts predominantly induced singular and less frequently repetitive Ca2+ 
events at intervals of several minutes, with higher number and frequency for contacts 
with MEC-1/OVA fibroblasts compared to B16F10/OVA melanoma cells (Extended Data 
Fig. 5e, f). Surviving B16F10 melanoma cells could tolerate multiple serial Ca2+ events, 
triggered by one or multiple, serially or simultaneously engaging CTL (Extended Data Fig. 
5i, 6a). Thus, despite effective high-affinity peptide/MHC conditions single OT1 CTL 
conjugations with tumor cells often remain sublethal, consistent with serial but sub-
threshold cytotoxicity. 
By gating on successful kills together with Ca2+ events, two kinetic apoptosis 
induction mechanisms were identified. The longer uninterrupted single contacts 
persisted, the more likely apoptosis was achieved in the absence of conjugation by 
additional CTL (Extended Data Fig. 1d, 3b, 4c). Alternatively, sequential or simultaneous 
contacts by the same or multiple CTL with the same target cell resulted in multiple 
sequential calcium events and lethal outcome (Fig. 2d, Extended Data Fig. 1d, 3b, 4c). On 
average, successful kills were preceded by conjugations of 2-9 independent CTL (Fig. 2d, 
e; Movie 7, 8), and the probability for apoptosis induction increased with the number of 
Ca2+ events (Extended Data Fig. 5i). Thus, apoptosis induction by CTL may occur through 
a sequence of sublethal cytotoxic hits which accumulate over time. 
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Figure 3. CTL cooperation in live tumors. a, Time-dependent impact of adoptive CTL transfer on B16F10 tumor 
volume. Error bars, mean ± SD (5 independent tumors). b, Multi-photon 3D reconstruction of B16F10/OVA 
lesion 3 days after transfer of OT1 CTL. c, Subregional ET ratios over time (8 independent tumors). d, Intravital 
time-lapse  detection  (left)  and  frequency  (right)  of  CTL-mediated tumor cell apoptosis using H2B/mCherry. 
Arrow heads, nuclear condensation/fragmentation. Data represent 32 apoptotic events from ~150 h of time-
lapse imaging. e, Contact duration and outcome of single or multiple CTL contacting B16F10/OVA cells. Fire LUT, 
CTL dwell time. f, Repetitive intracellular Ca2+ events (GCaMP6s) in B16F10/OVA cell during CTL engagement. 
Green, OT1 CTL; Cyan, GCaMP6s in B16F10/OVA; Lower panel: Fire LUT, Ca2+ intensity (GCaMP6s). g, Frequency 
of CTL-target cell contacts which induced one or more Ca2+ events (45 contacts from 4 independent tumors). h,
Correlation of CTL density and apoptotic frequency in tumor subregions (8 independent tumors). 
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To discriminate whether apoptosis induction occurred stochastically from individual hits 
within a series of Ca2+ events, or as an additive process from a consecutive series of hits 
we probed the stochastic killing hypothesis using time-lapse monitoring over 18-24h and 
survival analysis (Supporting Methods). The survival probability of B16F10/OVA target 
cells after the last received Ca2+ event was plotted, classifying cells according to the total 
number of preceding Ca2+ events received prior to the last event before apoptosis (Fig. 
2g). Both the lag time to apoptosis after the last Ca2+ event and the survival probability 
significantly depended on the number of preceding Ca2+ events, with 80% survival 
probability after none or a single Ca2+ event and strongly increased death rate after 2 and 
more prior Ca2+ events (Fig. 2g). This contradicts apoptosis induction as stochastic 
process. Simulations assuming stochastic apoptosis induction by single hits resulted in 
the loss of the correlation between the number of prior Ca2+ events and the probability 
to survive (Extended Data Fig. 6c), which fails to replicate the actual survival data (Fig. 2g, 
Extended Data Fig. 6a, b). Hence, apoptosis induction results from additive CTL-mediated 
cytotoxic events which individually remain sublethal but, when occurring as series over 
time, achieve target cell damage. 
The significance of apoptosis induction by sequential versus individual interactions 
by CTL was further tested by varying CTL density. At high CTL density (ET 1:2) target cell 
death was frequent and predominantly resulted from contacts by multiple CTL, whereas 
at low CTL density (ET 1:16) apoptosis was rare and followed near-exclusively single-
contact engagements (Extended data Fig. 5j). Thus, both the predominant CTL 
conjugation type and killing efficiency are functions of CTL density. Serial conjugation 
and efficient apoptosis induction require high CTL density (“swarming”, “crowding”), 
whereas killing at low CTL density must rely on single encounters with low overall 
efficacy.  
To address whether and in which tumor subregions CTL-mediated serial killing 
occurs in vivo, activated OT1 CTL were adoptively transferred into C57BL/6 J mice 
bearing intradermally invading B16F10 melanoma lesions and monitored longitudinally 
by intravital microscopy through a skin window (Extended Data Fig. 7a, b). A single 
application of OT1 CTL caused a dose-dependent growth delay of the OVA antigen-
expressing but not of control tumors (Fig. 3a, Extended Data Fig. 7c), indicating efficient 
but transient anti-tumor activity. Topographic volume analysis of entire tumors (Fig. 3b) 
showed that intra-tumor CTL density varied time-dependently and locally with peak 
numbers at days 3-6 after transfer (Extended Data Fig. 7c). Peak densities along the 
tumor-stroma interface reached local ET ratios of 1:1 contrasting poor CTL infiltration in 
the  tumor  core  with  ET  ratios  below 1:250  (Fig.  3b,  h)  between day  3  and 6  after  CTL  
transfer (Fig. 3c). Individual CTL-tumor cell interactions were mapped by time-lapse  
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Figure 4. Preferential elimination of invading tumor cells. a, b, Time-dependent CTL accumulation along the 
tumor-stroma  interface.  Red,  nuclei  B16F10/OVA  cells;  green:  OT1  CTL.  c, CTL migration speed within tumor 
main mass and invasion zones. d, Distribution (top), migration tracks (middle) and dwell-time (bottom) after 4 h 
time-lapse recording (bottom) of CTL (yellow) between tumor cells (red) along channel-like invasion niche 
confined by collagen bundles (cyan) and blood vessels (blue). e, f, Time-lapse sequence (e) and plot (f) of serial 
engagements of multiple CTL with B16F10/OVA cells and outcome. g, Apoptosis of B16F10/OVA cells after one 
single or multiple contacts by CTL (30 apoptotic events from 150 h of movies, 20 independent tumors). 
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microscopy over 4–8h at non-toxic imaging conditions (Extended Data Fig. 7 f-h). 
Apoptosis induction in B16F10/OVA cells was registered by the histone-2B/mCherry 
(H2B/mCherry) signal which reliably discriminates intact from condensed or fragmented 
nuclei (Fig. 3d) and detects apoptosis with similar temporal precision as phosphatidyl-
serine staining (Extended Data Fig. 8a-c). OT1 CTL efficiently migrated between tumor 
cells with intermittently reduced migration speed and migration arrest during interaction 
with B16F10/OVA cells (Extended Data Fig. 8d), but maintained non-confined high-speed 
migration in OVA-negative tumors (Extended Data Fig. 8d, e). This indicates decreased 
CTL mobility upon OVA-mediated recognition and effector function18.  
Whereas most contacts were transient in duration (median 15 min) and non-lethal 
(Fig. 3e), rare individual CTL-target cell interactions were sustained enough to induce 
apoptosis followed by sequential conjugation of adjacent tumor cells (Fig 3e, Movie 9). 
Individual productive but sublethal interactions in vivo were confirmed by Ca2+ imaging in 
target cells during CTL engagement, with kinetics and efficacy rates similar to those 
obtained in vitro (Fig 3f,g, Movie 10). In regions of low CTL density and consistent with 
their short duration (median 15 min), individual CTL-target cell contacts typically lacked 
repeated Ca2+ events during 3-4 h observation periods, with target cell survival as 
consequence (Fig. 3e). Conversely, regions with high CTL density reached higher 
cumulative contact times per target cell by several CTL (Fig. 3e, median 1.5 h) and high 
frequency of apoptosis (Fig. 3h). Thus, high CTL density favors serial interactions and 
apoptosis induction whereas individual short-lived contacts typically lack efficacy.  
As key progression event of established melanoma, B16F10 cells invade the skin as 
coherent multi-cellular strands19. Concomitantly, CTL first accumulated in the tumor 
periphery from where they redistributed preferentially towards the invasive tumor front 
(Fig. 4a, b). As consequence, quantified by high-resolution 3D mapping of tumor 
subregions, high apoptosis rates occurred in this invasion niche, while central tumor 
regions with overall low CTL density harbored negligible apoptosis rates (Fig. 3h). To 
identify how preferential eradication of invading tumor cells was achieved, we co-
registered CTL kinetics and apoptosis induction over time. In the invasion niche, median 
CTL speed was nearly doubled compared to the main tumor mass (Fig. 4c), with 
consistent orientation of CTL migration tracks along the invasion zone and its 
microanatomy, particularly myofibers, blood vessels and collagen bundles (Extended 
Data Fig. 8f, Movie 11). Whereas most individual CTL-target cell contacts were, again, 
dynamic and short-lived (median 15 min), local CTL accumulation combined with 
confined migration along the tissue structures supported consecutive engagements with 
tumor cells and high cumulative contact duration (Fig. 4d-f; median 2.2 h). Despite 
generally short-lived and non-productive individual engagements, this niche supported 
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serial additive conjugation and eradication of invading melanoma cells (Fig. 4e, Movie 12, 
4g). Thus, in vivo eradication  of  tumor  regions  by  CTL  is  a  primary  function  of  CTL  
migration and cumulative contact duration in the context of particular tissue niches.  
  
Compared with the deterministic and reliable elimination of B cells1–3,  CTL  effector  
function against solid tumor cells is an inefficient process with a high failure rate which is 
rarely completed by a single CTL interaction, but requires a sequence of sublethal hits. 
Apoptosis induction is, thus, not a binary event but instead implies the accumulation of a 
death signal within the target cell over time (“additive cytotoxicity”), not unlike the 
accumulation of activation signal in naïve T cells by successive encounters with APCs in 
vitro and in vivo20–23. Because additive cytotoxicity is rarely delivered by repetitive 
contacts from the same CTL (Extended Data Fig. 5e) but typically requires cooperation of 
multiple  CTL  (compare  Movies  7,  12),  CTL  density  control  may  provide  a  filter  limiting  
accidental cell damage by single, miss-targeted CTL. Conversely, high CTL density 
provides effector redundancy as fail-safe mechanism to maintain effector function under 
adverse conditions, such as in immunosuppressive environments. Lethal hit delivery by 
serial CTL engagements, as gradual, tunable process, may further respond to 
microenvironmental and therapeutic immunomodulation, including stabilization of CTL-
target cell contacts24,25, activation of immunostimulatory pathways26 and/or blockade of 
immune checkpoints27. In conclusion, serial interaction of CTL with target cells and 
additive induction of death signal define the efficacy of CTL effector function which can 
be exploited by targeted therapy to increase both single contact efficacy and CTL 
cooperativity.  
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Methods summary  
Organotypic three-dimensional cytotoxicity assay and time lapse microscopy.  
Sub-confluent target cell monolayers were overlaid with 3D fibrillar collagen (PureCol, 
concentration: 1.7 mg/ml) containing in vitro activated  OT1  CTL  (cell  models  and  
activation protocols described in the Methods section). CTL migration, interactions with 
target cells and apoptosis induction was monitored by time-lapse bright-field microscopy 
frame intervals of 30 sec for 12 h followed by cell manual tracking and quantitative 
population analysis. 
CTL induced calcium events in target cells.  
Target cells were lentivirally transduced to stably express the calcium sensor GCaMP6 17. 
DsRed OT1 CTL-target cell conjugation and consecutive intracellular Ca2+ events were 
coregistered by confocal 3D time-lapse microscopy (Leica SP8 SMD) at 488 nm and 561 
nm excitation (both 0.05 mW) at frame intervals of 8-12 sec for up to 12 h. CTL position 
and Ca2+ intensity analysis were obtained by manual image segmentation and 
quantification. 
Intravital multiphoton microscopy.  
Histone-2B/mCherry expressing B16F10/OVA melanoma cells (1x105) were injected into 
the  deep dermis  of  C57/B16 J  mice  (Charles  River)  carrying  a  dorsal  skin-fold  chamber  
and were repeatedly monitored for up to 15 days28. With the onset of tumor invasion 
and angiogenesis at day 3 after implantation, in vitro activated eGFP or dsRed OT1 CTLs 
(0.5–1 x106) were injected intravenously. Multi-parameter intravital multiphoton 
microscopy was performed on anesthesized mice (1-3 % isoflurane in oxygen) on a 
temperature-controlled stage (37°C) recording up to 5 channels simultaneously to 
visualize blood vasculature (70kD dextran/ AlexaFluor750) and peri-tumor stroma (SHG).  
Statistical modeling.  
Survival curves of target cells receiving serial Ca2+ events were computed in GNU R using 
the 'survival' and ‘rms’ packages. 
Statistical analysis.  
Unpaired student’s t-tests or Mann-Whitney U-tests, as appropriate, were applied using 
GraphPad Prism 5. 
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Methods section 
Cell lines and primary cell culture.  
C57BL/6 mouse embryonic fibroblast-like cells (MEC-1) expressed B7.1 and the OVA-
derived CTL epitope SIINFEKL (MEC-1/OVA) or the adenovirus type 5 E1A-derived CTL 
epitope SGPSNTPPEI (MEC-1/E1A) coupled to a signal-sequence which directs epitope 
expression to the endoplasmatic reticulum1. The cells were cultured in RPMI 1640 
medium (GIBCO, 21875-034) supplemented with 10% FCS (SIGMA, F7524), 10 mM HEPES 
(GIBCO, 15630-056), 500 mM 2-mercaptopethanol, 1% penicillin and streptomycin (PAA, 
P11-010), 1% sodium pyruvate (GIBCO, 11360-039), and 0.1 mM non-essential amino 
acids (GIBCO, 11140-035). 
B16F10 mouse melanoma cells expressing the OVA-derived CTL epitope SIINFEKL 
(B16F10/OVA) were transduced to express histone-2B/mCherry as described2.  A  low-
pigmented subline was derived by sequential passaging and validated for unchanged 
growth, invasion ability, antigenicity and apoptosis resistance in vitro and in vivo. The 
cells were cultured in RPMI 1640 medium (GIBCO, 21875-034) supplemented with 10% 
FCS (SIGMA, F7524), 1% sodium pyruvate (GIBCO, 13360-039) and 1% penicillin and 
streptomycin (PAA, P11-010). Prior to experiments, cells were stimulated with 200 U/ml 
murine IFNJ (PEPROTECH, 315-05) for 48h. 
MV3  and  BLM  male  HLA-A2  expressing  human  melanoma  cells  were  cultured  in  
DMEM medium (GIBCO, 10938-025) supplemented with 10% FCS (SIGMA, F7524), 
glutamine (LONZA, BE17-605), 1% sodium pyruvate (GIBCO, 13360-039) and 1% penicillin 
and streptomycin (PAA, P11-010). Prior to experiments, cells were stimulated with 200 
U/ml human IFNJ (SIGMA, I3265) for 48h. 
Mice.  
C57BL/6  J  mice  (4-6  weeks  of  age)  were  purchased  at  Charles  River  Laboratories.  
Transgenic mice expressing eGFP under the human ubiquitin C promoter (Jackson 
Laboratories, stock number: 004353) and transgenic mice expressing dsRed under the 
chicken beta-actin promoter (Jackson Laboratories, stock number: 006051) were crossed 
to OT-I TCR transgenic mice (Jackson Laboratories, stock number: 003831). Double 
transgenic eGFP/OT-1 and dsRed/OT-1 were bred in the Central Animal Laboratory of the 
Radboud University Nijmegen, The Netherlands. 
Isolation and activation of primary CD8+ OT1 CTL.  
OT1  CTL  were  activated  as  described3. In short, splenocytes from OT1 or double-
transgenic eGFP/OT1 or dsRed/OT1 mice were isolated and erythrocytes were depleted 
by ammonium chloride (0.83% NH4Cl,  0.1% KHCO3, 0.37% Na2 EDTA). For the expansion 
of antigen-specific CTL, splenocytes were cultured at a concentration of 2.5 x105 /ml in 
the presence of 0.5 µg/ml SIINFEKL peptide in 24-well  plates for 3 days. On day 3, IL-2 
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(100 U/ml) (ABD SEROTEC, PMP-38) was added to the cultures. Lymphocytes were 
incubated for further 24-48 h and harvested on days 4-5 by a Ficoll gradient (AXIS-SHIELD 
PoC AS, Oslo, Norway). Purity was determined by flow cytometry and typically exceeded 
96% of VD2+CD8+CD62LlowCD44hi cells.  
To determine the surface expression of Lamp-1 after 24h of coculture with target 
cells in the 3D cytotoxicity assay, CTL and surviving target cells were harvested by 
dissolving  the  collagen  with  collagenase  I  (40  U  /  96-well;  30  min;  SIGMA  C0130)  and  
detaching the remaining adherent cells with trypsin/EDTA (5 min). Both cell fractions 
were combined, washed in PBS, stained with AlexaFluor488-conjugated anti-Lamp-1 rat-
IgG (BIOLEGEND, 121608) and detected after signal enhancement by donkey anti-
rat/Alexa488 (LIFE TECHNOLOGIES, A21208). CTL were gated on intact morphology, 
viability by propidium iodide exclusion and dsRed expression using De Novo FCS Express 
4. Percentages of positive events were calculated using the build-in FCS Express function 
for histogram subtraction. 
Activation and culture of primary human SMCY.A2 CTL.  
The CD8+ SMCY CTL line was isolated and cultured as described previously4. In short, 
CD8+ CTL were isolated from PBMC obtained from a renal cell carcinoma patient who 
received allogeneic stem cell transplantation (SCT) and donor lymphocyte infusions (DLI). 
This patient has given informed consent to the prospective collection of peripheral blood 
samples for investigational use, which was approved by the Radboud University Medical 
Centre (RUMC) Institutional Review Board. CD8+ T  cells  were  expanded  by  weekly  
stimulation with PBMC obtained before SCT in Iscove’s modified Dulbecco’s medium 
(IMDM; INVITROGEN, Carlsbad, CA) supplemented with 10% human serum (HS; Sanquin 
blood bank, Nijmegen, the Netherlands). After initial stimulation, CTL (0.5 x 106) were 
cultured in IMDM/10% HS containing irradiated (80 Gy) recipient EBV-LCL (0.5 x 106) and 
irradiated (60 Gy) allogeneic PBMC (0.5 x 106) from two donors, together with IL-2 (100 
IU/ml;  Chiron,  Emeryville,  CA)  and  PHA-M  (1  mg/ml;  Boehringer,  Alkmaar,  the  
Netherlands). A greater than 95% pure population of SMCY.A2 specific CTL was isolated 
by FACS sorting (tetramer staining of HLA-A2-restricted SMCY.A2 epitope FIDSYICQV). 
Specificity of SMCY.A2 CTL was further confirmed by lack of cytotoxicity against female 
HLA-A2 expressing breast carcinoma cell (MCF-7) as target cells (Fig. 1h). 
Three-dimensional cytotoxicity assay and time-lapse microscopy.  
A sub-confluent monolayer of target cells was overlaid with a 3D collagen gel (PureCol, 
concentration: 1.7 mg/ml) containing pre-activated CTL in a customized imaging 
chamber, allowed to polymerize (30 min, 37°C) and filled with undiluted CTL growth 
medium.  CTL  dynamics  were  recorded  by  time-lapse  bright-field  microscopy  with  a  30  
sec frame interval for 24-48 h. 
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CTL-target cell interactions were quantified by manual analysis. CTLs in contact with 
target cells slowed migration speed and spread on the target cell surface, which was 
used as morphological marker to distinguish irrelevant passenger CTL. For quantification 
of  the  frequency  of  serial  killing  events,  only  CTLs  which  could  be  followed  for  >12  h  
were included in the statistical analysis. CTL-target cell interactions were classified as 
non-lethal after survival of the target cell for > 3 h after CTL detachment. The > 3 h 
follow-up period is based on statistics of the lag time between last CTL induced Ca2+ 
event and target cell death which predominantly remained below 1 h in MEC-1/OVA and 
1-2 h in B16F10/OVA (Extended Data Fig. 5h).  
Monitoring CTL induced calcium events in target cells.  
Target cells were lentivirally transduced to stably express the calcium sensor GCaMP6s5 
by selection with blasticidin (10 µg/ml: Life Technologies, R210-01) and FACS sorting on 
GCaMP6s background expression. CTL-target cell conjugation and associated intracellular 
Ca2+ events were obtained by coregistering GCaMP6 and dsRed OT1 CTL as single scans 
at frame intervals of 8-12 sec for up to 12 h on a Leica SP8 SMD confocal scanner using 
0.05 mW for each excitation line (488, 561 nm). Viability of CTL and target cells during 
long-term imaging was controlled by verifying constant CTL migration speed and viability 
over time as well as lack of laser induced cell death and unperturbed proliferation 
compared to bright-field imaging in target cell cultures without CTL. CTL-associated Ca2+ 
events were identified by manual image segmentation and intensity analysis and 
displayed for cell populations of multiple independent experiments. 
Intravital multiphoton microscopy.  
All intravital imaging experiments were approved by the Ethical Committee on Animal 
Experiments and performed in the Central Animal Laboratory of the Radboud University, 
Nijmegen (RU-DEC 2009-174, 2011-298), in accordance with the Dutch Animal 
Experimentation Act and the European FELASA protocol (www.felasa.eu/guidelines.php).  
Histone-2B/mCherry expressing tumor cells (1x105) were injected into the deep 
dermis  of  C57/B16 J  mice  (Charles  River)  carrying  a  dorsal  skin-fold  chamber  and were  
repeatedly monitored for up to 15 days6. Three days after tumor implantation, in vitro 
activated  eGFP  or  dsRed  OT1  CTLs  (0.5–1x106) were injected intravenously. Multi-
parameter intravital multiphoton microscopy was performed on anesthesized mice (1-3 
% isoflurane in oxygen) on a temperature-controlled stage (37°C). Blood vessels were 
contrasted by intravenous injection of AlexaFluor750-labeled 70kD dextran (2 
mg/mouse; Invitrogen).  
Tumor volume was reconstructed from epifluorescence overview images recorded at 
sequential time points. Tumor volume (V) was calculated as (tumor width)² x (tumor 
length) x ʋ/6. 
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Imaging was performed on a customized near-infrared/infrared multiphoton 
microscope (TriMScope-II, LaVision BioTec, Bielefeld, Germany), equipped with three 
tunable Ti:Sa (Coherent Ultra II Titanium:Sapphire) lasers and an Optical Parametric 
Oscillator (OPO). 4D time-lapse recordings were acquired by sequential scanning with 
910 nm (eGFP and Alexa750, 20-30 mW) and 1090 nm (mCherry and SHG, 30-60 mW) 
with  a  sampling  rate  of  1  frame  /  2min  over  periods  of  4-8  h  or  for  visualization  of  
intracellular Ca2+ dynamics with a sampling rate of 1 frame / 10-15 sec over periods of 1-
2 h. 
Image processing and quantification.  
Images were processed using Fiji/ImageJ (http://pacific.mpi-cbg.de/wiki/index.php /Fiji). 
Mosaic images were stitched using the Stitch Grid/Collection plugin7 and drifts in time-
lapse recordings were corrected using the StackReg plugin8 and  the  Correct  3D  Drift  
plugin. For presentation of time-lapse recordings, 4D stacks were adjusted for bleaching 
using the Bleach Correction plugin (Histogram normalization). If necessary background 
noise was filtered using the Remove Outliners plugin and images were scaled and 
adjusted for brightness and contrast to enhance visualization. For image quantifications 
the raw, unmodified images were used. 
Intact vs. apoptotic states of tumor nuclei and CTL ratios were quantified from 
individual slices of multiple 3D stacks of 350 x 350 µm, acquired with 7 µm z-resolution 
until imaging depths of up to 300 µm. To avoid repeated counting of the same cell, every 
3rd slice per stack was analyzed. Nuclei and CTL were segmented by applying a Gaussian 
Blur filtering followed by automated thresholding (Li algorithm) and separation of 
touching objects using Watershed. Using the Analyze Particles command of FIJI, 
segmented objects were filtered for size (Nuclei: ш 60 µm2; CTL: ш 50 µm2) and counted 
per slice. To determine subregional apoptosis and mitosis rates, apoptotic and mitotic 
nuclei were counted manually and calculated as percentage of total nuclei per slice. 
Statistical modeling.  
The  analysis  of  target  cell  survival,  Ca2+ events and the resulting survival probability 
curves were computed in GNU R using the 'survival' and 'rms' packages. In a subset of 
analyses, redundant Ca2+-positive “hits” which may bias the analysis by concealing the 
already occurred lethal hit and being misleadingly interpreted as prior, additive hits were 
removed, based on the following considerations. The "stochastic killing" hypothesis 
predicts that each Ca2+ event has the same likelihood to induce apoptosis and, 
consequently, the number of Ca2+ events received prior to the last event preceding 
apoptosis should not impact target cell survival. However, redundant Ca2+ events 
induced by the same or other CTL, which are dispensable for apoptosis, may occur after 
target cells received the lethal hit, and result on an overestimation of required hits. We 
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used the following approach to identify and remove such redundant events. Waiting 
times to apoptosis following the last lethal event were assumed to be exponentially 
distributed, and the mean waiting time best describing the data was fitted using the 
maximum likelihood method. For each target cell, the Ca2+ event whose likelihood of 
being the terminal event was largest, given the fitted distribution, was determined. This 
event was defined as the terminal event for the given cell, and all subsequent Ca2+ events 
were considered redundant (Extended Data Fig. 6a). Despite the removal of redundant 
contacts, survival probability and lag times to apoptosis remained significantly 
dependent on prior Ca2+ events (p=0.00032 with removal, p=0.00003 without), in 
agreement with additive cytotoxicity of serial Ca2+ events (Extended Data Fig. 6b). 
To simulate purely stochastic killing, the time between serial Ca2+ events and the lag 
time between Ca2+ events to apoptosis were randomly permuted. Assuming stochastic 
killing, these permutations should not affect target cell survival probability after the last 
contact. However, the permuted data revealed significantly enhanced killing efficiency 
compared to the actual killing efficiency derived from live-cell measurements whereby 
the amount of prior Ca2+ events lacked impact on survival probability after the last Ca2+ 
event (Extended Data Fig. 6c). Thus, stochastic apoptosis induction by individual hits is 
incompatible with the experimentally observed killing kinetics. 
Statistical analysis.  
Unpaired student’s t-tests or Mann-Whitney U-tests, as appropriate, were applied using 
GraphPad Prism 5. 
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Supplementary Figures 
 
Extended data figure 1. CTL contact phases, types and duration in MEC-1/OVA model. a, Expression level of 
B7.1 on MEC-1/OVA target cells. b, Efficiency of killing by OT1 CTL after blocking B7.1 with D-B7.1 Ab (15 µg/ml) 
in 3D cytotoxicity assay. c, Contact phases and speed of individual OT1 CTL during contact. d, CTL-target cell 
contact durations and contact outcome. e, Live detection of apoptosis by target cell morphology (blebbing) and 
nuclear condensation/fragmentation, using H2B/eGFP as label. Image sequence shows two MEC-1/OVA target 
cells  (TC)  killed  by  two  OT1  CTL.  Circles:  OT1  CTL;  Cross:  target  cell  apoptosis;  Arrow  heads:  nuclear  
condensation and fragmentation. f, Lag phase until apoptosis of targets induced by single or multiple CTL. g,
Time  between  serial  killing  events  mediated  by  the  same  CTL.  ***  p  <  0.001;  n.s.,  not  significant  (two-tailed 
Mann-Whitney U-test). Red bars, median. Pooled data (d,f,g) from 9 independent experiments. 
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Extended data figure 2. Validation of CTL contacts by interphase-free 3D invasion assay. a, 3D collagen-based 
invasion assay. b, Early and late CTL immigration into 3D collagen matrix containing individually dispersed MEC-
1/OVA target cells. Dotted white line, medium-collagen matrix interface overlaid with CTLs. Colored circles and 
colored lines denote CTLs and migration paths. Dotted red circles, target cells. Insets, CTL-target cell 
conjugates. c, Phases of OT1 CTL engaging with target cell in 3D collagen (time-lapse sequence). d, CTL-target
cell contact durations and outcome. e, Lag phase until apoptosis induced by single CTL-target cell contact. f, CTL 
contact durations with the same target cell before and after target cell blebbing. Individual CTL contacts and 
target  cell  fate  were  manually  tracked and quantified.  ***  p  <  0.001  (two-tailed  Mann-Whitney  U-test). Red 
bars, median. Pooled data from 3 independent experiments. 
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Extended data figure 3. Validation of CTL effector function against mouse B16F10 melanoma cells. a, Overview 
image of sub-confluent  monolayer  of  B16F10/OVA  with  CTL  in  the  3D  collagen  matrix  interface  assay  at  
consecutive  time  points.  Green  circles,  CTL;  Red  cross,  apoptotic  target  cell.  b, Duration of contacts between 
individual and multiple CTL with B16F10/OVA target cells until apoptosis induction. c, Lag phase until apoptosis 
induced by contacts from single or multiple, sequentially engaged CTL. d, Duration of contact phases between 
individual CTL with target cell before and after target cell blebbing, obtained by manual tracking. Red lines, 
median. e, Fas expression levels on MEC-1/OVA and B16F10/OVA target cells. Histograms representative for 2 
independent experiments. f, CTL killing efficiency upon blocking FasL by D-FasL Ab (MFL4) (10µg/ml). Error bars, 
mean ± SD (n=3). n.s., non-significant (two-tailed Mann-Whitney U-test). g, MHC/OVA expression levels on MEC-
1/OVA and B16F10/OVA. Histograms representative for 3 independent experiments. 
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Extended data figure 4. Validation of CTL effector phases in human SMCY.A2 model. a, SMCY.A2 tetramer  /  
CD8 double staining confirming CTL specificity and purity of > 95%. b, Time-lapse  sequence  of  two  
simultaneously engaging CTL with human BLM melanoma target cell followed by target-cell apoptosis. c,
SMCY.A2 CTL contact durations with BLM and MV3 melanoma targets and contact outcome. N.a., not applicable. 
d, Lag phase until apoptosis induced by single or multiple CTL. e, CTL contact duration with the same target cell 
before and after target cell blebbing. Red  bars,  median.  Pooled  data  from  3  (MV3)  and  4  (BLM)  independent  
experiments. 
 
 
Extended data figure 5. (see next page) CTL induced intracellular Ca2+ events in target cells. a, Time-lapse 
sequence of OT1 CTL (green) associated Ca2+ event (Fire LUT) in MEC-1/OVA target cell. Frame rate: 1 sec. b, Ca2+
influx originating at the CTL-target cell contact plane and propagating through the target cell cytoplasm at 20 
µm/sec velocity. c, Amplitude and duration of CTL-associated calcium events compared with spontaneous 
intracellular calcium fluctuations in the absence of CTL. d, Lag phase until first Ca2+ event after contact initiation. 
e, Number  of  Ca2+ events  associated  with  the  same  CTL  in  MEC-1/OVA  and  B16F10/OVA  cells.  f, Intervals 
between repetitive Ca2+ events induced by the same CTL during one contact, ranging from seconds to hours with 
medians of 4 min (MEC-1/OVA) and 18 min (B16F10/OVA). g, Time-lapse sequence and intensity plot of 
simultaneous Ca2+ events (Fire LUT, GCaMP6s) in 2 neighboring target cells contacted by the same CTL (green). 
TC, target cell. h, Lag phase between last Ca2+ event and target cell apoptosis. *** p < 0.0001 (two-tailed Mann-
Whitney U-test). Red line, median. Pooled data from 2 (MEC-1/OVA) and 3 (B16F10/OVA) independent 
experiments. i, Survival probability as percentage of target cells that survived increasing numbers of CTL-
associated Ca2+ events. j, Absolute killing efficacy of B16F10/OVA cells and frequency of apoptosis induction by 
single or multiple CTL in dependence of ET ratio. Killing efficiency, n=3 cytotoxicity assays. Contact frequency, 
110 contacts from 4 independent movies per ET ratio. 
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Extended data figure 5. See previous page. 
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Extended data figure 6. Statistical 
analysis. a, Time-points  of  Ca2+-
positive events (black arrows) in 
individual B16F10/OVA cells 
contacted by OT-1  CTL  and  lethal  or  
non-lethal  outcome.  Red  arrow  
indicates  the  terminal  Ca2+ event 
(determined by data fitting using the 
maximum likelihood method)
resulting in irreversible apoptosis 
induction. Red crosses, apoptosis of 
target cell. Ca2+ events subsequent to 
the  terminal  Ca2+ event were 
considered redundant. Gray lines, 
observation time. b, Survival 
probability of B16F10/OVA cells 
having received increasing numbers 
of Ca2+ events prior to the terminal 
event after filtering redundant Ca2+
events. c, Simulation of stochastic 
apoptosis induction by permutation 
of  waiting  times  between  Ca2+
events, survival and lag times until 
apoptosis. p-values, log rank test 
comparing all groups. 
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Extended data figure 7. See next page. 
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Extended data figure 8 (see next page). Visualization of target cell apoptosis, CTL dwell time and migration 
dynamics along guiding tissue structures. a, Time-lapse detection of apoptosis in B16F10/OVA cell by nuclear 
condensation (red: nuclei, histone-2B/mCherry) and phosphatidyl serine exposure (green: pSIVA-IANBD) on the 
cell surface upon CTL contact (red: dsRed CTL). Arrowhead, onset of nuclear condensation. b, Intensity increase 
of H2B/mCherry coincides with nuclear condensation during apoptosis and is followed by an increase of pSIVA-
IANBD signal. Representative example for >15 cells from 3 independent experiments. The time difference ( t) 
between the onset of detected nuclear condensation or fragmentation and cell blebbing and subsequent onset 
of  phosphatidyl  serine  signal  was  23.3  ±  6.1  min  ( t until maximum PS signal: 36.6 ± 12.6 min). c, Duration of 
increased fluorescence intensity in nuclei during/after apoptosis induction . Arrow, duration of signal increase 
(average 2-3 h). d, CTL migration speed and confinement ratio over time. e, Image processing routine to display 
3D and 2D CTL  dwell  time heat  maps.  f, CTL  migration  tracks  in  tumor-free deep dermis (perimuscular niche). 
CTL tracks align with guiding structures of the tissue. Zoom: CTL shape change and alignment along perimuscular 
space. Arrowheads, collagen fibrils. Bar, 20  m. g, CTL migration speed (left) and directionality during 
intradermal migration. Red bars: median. 
Extended data figure 7. (see previous page) Intravital microscopy of target cell killing: experimental model and 
data analysis. Established B16F10/OVA melanoma tumors received adoptive OT1 CTL therapy (day 3) followed 
by CTL arrival in the lesion (day5-6). a, Dorsal skin-fold chamber setup and tumor model. b, Setup and time line, 
including cell application, intravital monitoring and parameter extraction. c, Time-dependent tumor morphology 
and distribution of CTL monitored by epifluorescence detection through the skin window. Red fluorescence, 
B16F10 nuclei (histone-2B/mCherry); strong green, OT1 CTL (eGFP); weak green, background autofluorescence. 
d, 3D multi-photon microscopy image stacks obtained from multiple positions in the same tumor. Image 
dimensions:  350  x  350  µm with  5-7  µm z-resolution  and total  depth  of  ~350 µm.  Red,  tumor  nuclei  (histone-
2B/mCherry); green, OT1 CTL (eGFP); cyan, collagen fibers (SHG); blue, blood vessels (70kDa-dextran/Alexa750). 
Images were acquired as sequential scans of 910nm (GFP, Al750) and 1090nm (mCherry, SHG) with a linear laser 
power increase in z ranging from 20-75 mW (910nm) and 30-100 mW (1090nm). e, Loss of fluorescence intensity 
as function of imaging depth. As consequence, the detection limit for CTL expressing GFP was ~150 µm and ~280 
µm for dsRed. f-h, Lack of phototoxicity in long-term time-lapse recordings. Imaging conditions: z resolution, 5 
µm; frame rate, 2 min; imaging duration, 8h; laser power, 25 mW (910nm) and ~40 mW (1090nm). f, Bleaching 
of GFP (CTL) and mCherry (tumor nuclei). g, Unperturbed mitosis or apoptosis rates in CTL and tumor cells. h,
Unperturbed average migration speed of CTLs. Error bars: mean ± SD.  
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Abstract 
Cancer immunotherapy is undergoing significant progress due to recent clinical success 
of refined adoptive T-cell transfer and immunostimulatory monoclonal Ab (mAbs). 
B16F10-derived OVA-expressing mouse melanomas resist curative immunotherapy 
with either adoptive transfer of activated anti-OVA OT1 CTLs or agonist anti-CD137 (4-
1BB) mAb. However, when acting in synergistic combination, these treatments 
consistently achieve tumor eradication. Tumor-infiltrating lymphocytes that 
accomplish tumor rejection exhibit enhanced effector functions in both transferred OT-
1 and endogenous cytotoxic T lymphocytes (CTLs). This is consistent with higher levels 
of expression of eomesodermin in transferred and endogenous CTLs and with intravital 
live-cell two-photon microscopy evidence for more efficacious CTL-mediated tumor cell 
killing. Anti-CD137 mAb treatment resulted in prolonged intratumor persistence of the 
OT1 CTL-effector cells and improved function with focused and confined interaction 
kinetics of OT-1 CTL with target cells and increased apoptosis induction lasting up to six 
days post-adoptive transfer. The synergy of adoptive T-cell therapy and agonist anti-
CD137 mAb thus results from in vivo enhancement and sustainment of effector 
functions.  
Adoptive T-cell therapy is being developed following different approaches including 
infusion of expanded tumor infiltrating lymphocytes to preconditioned lympho-depleted 
hosts (1) and adoptive transfer of T cells genetically engineered to express tumor-specific 
T-cell receptors or chimeric antigen receptors (CARs) (2). The dazzling clinical success of 
CARs against leukemias (3, 4) is related to the fact that these chimeric receptors 
intracellularly include both signaling elements of the CD3-TCR (CD3ɺ) and of 
costimulatory molecules (3). The intracellular costimulatory signaling domain with best 
reported  effects  so  far  is  that  of  CD137  (4-1BB)  (5).  CD137  (4-1BB)  is  a  TNFR  family  
costimulatory receptor (TNFRSF9) that is expressed on activated T (6) and NK cells (7) 
and mediates costimulation of both types of lymphocytes (8). On CD8+ T cells ex vivo, 
CD137 ligation with the agonist antibodies determines increased proliferation, survival, 
memory formation and stronger effector functions in terms of both cytotoxicity and 
cytokine production (9). In vivo, anti-CD137 mAb protects adoptively transferred CTLs 
from activation-induced cell death resulting in better antitumor efficacy in a mouse 
myeloma model (10). Significant therapeutic effects against transplanted tumor models 
(11) have provided the rationale for currently ongoing phase I and II clinical trials 
(NCT01471210; NCT01775631; NCT01307267) (8). NK cells up-regulate CD137 and 
ligation by anti-CD137 mAb enhances NK-mediated antibody-dependent cellular 
cytotoxicity functions resulting in synergistic effects with anti-CD20 (12), anti-HER2 (13) 
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and anti-EGFR (14) mAb. CD137 expression can also be induced on dendritic cells (15), 
tumor endothelial cells (16), B cells (17), and myeloid leukocytes (18) upon activation.  
Although positive  effects  of  CD137 ligation  for  CD8+ T-cell memory generation are well 
explored (9, 19), its relevance for enhancing effector function in solid tumor lesions in 
vivo has not been established. In this study we show a synergy of adoptively transferred 
and endogenous CD8+ T cells against B16F10 melanoma that depends on the ability of 
both CTL populations to receive costimulation via CD137. Flow-cytometry of tumor-
rejecting lymphocyte infiltrates and intravital microscopy of tumors provide evidence 
that anti-CD137 mAb therapy sustained the efficacy of more focused anti-tumor CTLs.  
Results  
B16F10-OVA tumors are amenable to eradication by combined adoptive 
transfer of OT-1 CTLs and CD137 costimulation.  
The B16F10-OVA cell line is a stable transfectant derived from B16F10 melanoma that 
expresses chicken ovalbumin (20). In our hands, it is a difficult-to-treat transplantable 
tumor model, at least by means of immunotherapy (21). Adoptive transfer of 2 × 106 
cognate peptide-activated OT-1 cells to mice s.c. inoculated with 5 × 105 tumor cells and 
given no antibody or control antibody showed rapid exponential tumor growth (Fig. 1A). 
Treatment on day 3 with 100 ʅg of the agonist anti-CD137 mAb 1D8 (22) showed no 
therapeutic impact in this model (Fig. 1B). Likewise, infusion of polyclonal activated CD8+ 
T cells showed no efficacy, indicating that OVA-specificity was an absolute requirement 
(Fig. 1B). In striking contrast, combined treatment with activated OT1 CTL and anti-
CD137 mAb accomplished complete regression of all tumors when treatment was 
instigated 3 days following tumor cell inoculation (Fig. 1C). However, if combination 
immuno-therapy was delayed until day +7, no therapeutic effects were retained, and 
mice developed lethal tumors that progressed consistently, albeit with a slight delay (Fig. 
1D) compared with controls (Fig. 1A). A single dose of 1D8 anti-CD137 did not alter 
hepatic function parameters but increased the content of liver CD8+ T, NKT and NK cells 
(Fig. S1). CD4+ T-cell depletion experiments with a monoclonal antibody ruled out a role 
for CD4+ T cells in this therapeutic setting, because tumors in mice depleted of CD4+ T 
cells were rejected as in nondepleted controls (Fig. 1E). NK1.1+ NK lymphocytes were 
also dispensable because complete depletion did not hinder the therapeutic outcome of 
treatment with 1D8 and 2A, two different anti-CD137 mAb (Fig. S2). Mice cured with the 
combined therapy of anti-CD137 mAB 1D8 and adoptive OT1 transfer were able to reject 
an inoculum of B16F10-OVA given at day 90 posttreatment (Fig. S3, Left), showing 
effective memory state. OVA-negative B16F10 tumors progressed in all mice, irrespective  
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Figure 1. Synergistic combination of adoptive T-cell therapy and anti-CD137 mAb requires CD137 expression 
on both transferred OT-1 and endogenous CD8+ T lymphocytes. Mice  were  s.c.  inoculated  with  5  ×  105 
B16F10-OVA melanoma cells on day 0. Graphs represent individual follow-up of tumor size and the fraction of 
tumor-free mice at the end of the experiment. (A) Mice were left untreated or treated on day +3 with rat IgG 
or cognate peptide-activated OT-1 lymphocytes. (B) Mice were adoptively transferred with 2 × 106 polyclonally 
activated T cells from non–TCR-transgenic CD45.1 congenic mice and anti-CD137 mAb (1D8) on day +3. (C  ) 
Mice were adoptively transferred with activated OT-1 CD8+ T lymphocytes and 100 ʅg of anti-CD137 mAb on 
day +3. (D) Mice were treated as in C but treatment was postponed to day +7 following tumor cell inoculation. 
(E ) Mice were treated as in C but starting one day before treatment (day +2) mice received a depleting course 
of anti-CD4 mAb that was dosed every 5 d for up to four doses. (F ) Mice were treated as in C, but OT-1 cells 
were harvested from OT-1 CD137- deficient mice. (G) B16F10-OVA–bearing CD137оͬо mice were treated as in C 
with CD137-sufficient OT-1 lymphocytes. (H) Tumor-bearing recipient mice were RAG1оͬо and were treated as 
in  C.  Experiments  were  repeated  at  least  twice  rendering  comparable  results  with  at  least  six  animals  per  
group. 
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of prior treatments, even though mice that had undergone CD4+ T-cell depletion 
experienced faster tumor progression (Fig. S3, Right).  
Combined adoptive T-Cell therapy and anti-CD137 mAb requires CD137 
expression on transferred and endogenous T cells.  
To study which lymphocyte subsets needed to express CD137 for efficacy, we performed 
experiments using CD137оͬо syngenic mice as tumor recipients and CD8+ T  cells  from  
double transgenic OT-1 CD137оͬо mice. Mice treated with peptide-activated CD137оͬо OT-
 
Figure 2. Combination with CD137 mAb does not result in increased numbers of transferred OT-1 
lymphocytes in the tumor but enhances recruitment of endogenous T cells in a CD137-dependent 
manner. Absolute numbers of CD8+ T lymphocytes were counted in cell suspensions obtained from tumors 
(n = 6 per group) excised 7 d following treatment with OT-1 T lymphocytes and anti-CD137 on day 3 after 
tumor cell inoculation. Transferred CD45.1+ (A) and endogenous CD45.2+CD8+ T (B) cells were differentially 
counted using perfect count beads as internal standards. Recipient mice and OT-1 lymphocytes were WT or 
CD137оͬо as indicated in the figure. Treatment with antibodies (Ab): 1D8 or control rat antibody (Ab) as 
indicated. Two similar independent experiments were performed rendering similar results. Statistical 
differences were assessed by Student’s t tests. (C) Representative  dot  plots  are  shown  to  indicate  the  
relative abundance of endogenous (CD45.2) and transferrect (CD45.1) CD8+ T  lymphocyte  in  the  tumor  
infiltrates. *P ч 0.01.  
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1 lymphocytes did not show activity upon combined treatment with anti-CD137 mAb, 
exhibiting only a transient delay in progression (Fig. 1F). Surprisingly, if recipient mice 
were CD137оͬо and treated with CD137-sufficient OT-1 cells, tumors also progressed in 
every case after a brief period of transient tumor control (Fig.  1G).  To address whether 
endogenous T cells were indispensable, we performed similar experiments in RAG1оͬо 
deficient mice that lack T and B lymphocytes. Results in Fig. 1H indicate that dual-
treatment with OT-1 cells and anti-CD137 mAb transiently controlled tumor growth even 
though all tumor lesions progressed after week three. Collectively, our results indicate 
that expression CD137 both on adoptively transferred T cells and on endogenous CD8+ T 
cells is mandatory to achieve complete tumor eradication upon combined 
immunotherapy.  
Combined therapy results in tumor infiltrating CTLs with an enhanced effector 
phenotype.  
To understand the mechanisms behind the therapeutic synergistic effects, we studied 
the CD8+ T lymphocytes present in the tumors on day 10 when the lesions start to shrink 
in size. Our first hypothesis was that a higher number of adoptively transferred T 
lymphocytes infiltrated the tumor lesion thus numerically explaining the synergistic 
effects. We performed quantitative experiments using WT or CD137оͬо mice as recipients 
and either CD137-sufficient or CD137оͬо OT1  cells.  Adoptively  transferred  OT-1  T  cells  
were CD45.1 in these experiments, which allowed their tracing and discrimination from 
the endogenous CD45.2 CD8+ T  cells.  Surprisingly,  we  observed  that  anti-CD137  mAb  
treatment did not increase the number of OT-1 T cells within the tumors in both wild-
type and CD137оͬо recipient  mice  (Fig.  2  A  and B).  However,  when CD137оͬо OT-1 were 
used, virtually none of these cells were present in the infiltrate (Fig. 2A). Dot plots in Fig. 
2C provide a reference at a glance of the relative abundance of transferred (CD45.1+) and 
endogenous (CD45.2+) CD8+ T lymphocytes in the different experimental groups. When 
treatment was given on day +7, absolute OT1 CTL numbers in the tumor increased but 
normalization by tumor weight was consistent with decreased OT-1 CTL density (Fig. S4 A 
and B). Increased expression of VCAM on tumor endothelial cells induced by 1D8 
treatment of B16F10-OVA tumors growing in RAGоͬо T-cell–deficient mice indicated an 
inflammatory phenotype induced by direct effects on endothelial cells (16). However, 
combined treatment did not alter transcription of CTL-attracting chemokines in WT mice 
compared with mice treated with OT-1 and control antibody (Fig. S5). Thus, rather than a 
mere numeric increase, these data implicate altered CTL function as the basis for 
improved therapeutic outcome. CD107a (Lamp-1) is a cytotoxic granule protein that 
reaches the plasma membrane when CTLs degranulate  
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Figure 3. Combined treatment enhances the effector phenotype in both transferred and endogenous 
CD8+ TILs. Results from FACS analyses of cell suspensions retrieved on day 10 from tumors as those in Fig. 
2 treated with OT-1 cells and anti-CD137 mAb (1D8). When indicated, recipient mice or transferred OT-1 
lymphocytes were CD137оͬо. Transferred and endogenous lymphocytes were differentially gated as 
CD45.1+ or CD45.1о CD8+ lymphocytes and analyzed for surface CD107a (A), KLRG1 (B), and intracellular 
IFNɶ (C).  Results  are  presented  as  the  mean  intensity  of  fluorescence  for  the  indicated  marker  from  
individual mice including three pooled experiments. p represents Student’s t test P values. Lines 
represent the median values. n.s., not significant; *P ч 0.01; **P ч 0.001; ***P ч 0.0001. CD137KO, 
CD137оͬо; WT, wild type.  
            Chapter 7 134
on target cells. Surface CD107a was increased after treatment with OT-1 and anti-CD137, 
compared with treatment with OT-1 and control antibody (Fig. 3A) in both transferred 
OT-1 CTL and, importantly, endogenous CD8+ T cells of unknown antigen specificity. 
Levels of surface CD107a on transferred cells were reduced when the recipient mouse 
was CD137оͬо but undiminished on transferred CD137оͬо OT-1 lymphocytes in WT mice. A 
similar picture emerged when surface KLRG1 was used as effector T-cell marker (Fig. 3B) 
and when immunostaining for intracellular IFNɶ was carried out (Fig. 3C). Similarly, 
intracellular IFNɶ expression in transferred OT1 and endogenous CTL tended to decrease 
when  either  transferred  OT-1  cells  or  the  recipient  mouse  were  CD137оͬо, suggesting 
cooperation between exogenous and endogenous lymphocyte subsets. When CTLs were 
restimulated in vitro with SIINKFEL IFNɶ levels were increased in OT-1 TILs treated with 
1D8 compared with control antibody, whereas endogenous TILs did not respond to the 
immunodominant OVA epitope (Fig. S6). Tumor draining lymph nodes showed similar 
but  less  obvious  changes  of  CTL  effector  markers  (Fig.  S7).  Moreover,  transferred  OT-1  
CTLs expressed PD-1 and TIM-3 but anti-CD137 treatment did not modify their level of 
expression, whereas anti-CD137 enhanced the expression on endogenous CD8+ CTLs (Fig. 
S8). Of note, tumors treated by the OT-1 + 1D8 combination tended to contain more 
CD4+ Foxp-3+ Treg cells. An interplay of transcription factors is involved in regulating the 
lymphocyte effector phenotype (23). Previous studies revealed a relation of 
eomesodermin and CD137 costimulation (24, 25). Eomes is involved in both favoring the 
expression of effector molecules (26) and favoring differentiation to memory T 
lymphocytes (27, 28). We stained for intracellular expression of EOMES in tumor 
infiltrating CD8+ T cells. Combined treatment induced higher levels of intracellular 
EOMES (Fig. 4A). This was much more evident among endogenous TILs than transferred 
OT-1 CTLs (Fig. 4A). More importantly, the induction of EOMES critically required the 
ability to express CD137 in the recipient mouse but not in the transferred OT-1 cells. 
Thus, transcriptional regulation of eomesodermin satisfactorily explains a more robust 
effector phenotype. Further evidence for a more pronounced effector phenotype was 
attained by detecting multiple CTL effector markers by quantitative RT-PCR on whole 
tumor mRNA comparing the effect of OT-1 + 1D8 over OT-1 + control antibody 
treatments, including increased expression of EOMES, Granzyme B, perforin, FAS-L, 
BLIMP-1, and CXCR3 (Fig. S5). Conversely, the homologous and functionally interrelated 
T-bet transcription factor was not induced by anti-CD137 mAb treatment, although the 
CD137 sufficiency of the receptor mouse favored higher T-bet expression in adoptively 
transferred and endogenous CD8+ T cells (Fig. 4B and Fig. S5). Despite a similar induction 
of effector markers (including TIM-3 and PD-1), tumors surpassed immune control when 
treatment start was delayed until day +7 after tumor inoculation (Fig. S4B). 
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Figure 4. EOMES is induced in transferred and endogenous intratumor CTLs by anti-CD137 mAb 
treatment. FACS analyses experiments as in Fig. 3 with intracellular staining for the transcription factors 
EOMES (A) and T-bet (B) in  CD8+ TILS from the indicated experimental groups. In each graph, the 
adoptively transferred cells, the recipient mouse, and the antibody treatment are provided in the 
horizontal  axis  [WT:  wild  type;  CD137KO:  CD137оͬо]. Results in A are from two pooled experiments 
performed identically. Statistical differences were assessed with Mann–Whitney u test. n.s., not 
significant, *P ч 0.01.  
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Evidence for more effective CTL activity in the microenvironment of B16F10-
OVA tumors upon combined immunotherapy.  
To address whether anti-CD137 mAb therapy enhances local antitumor CTL efficacy, 
frozen tumor sections were stained for CD8 and cleaved Caspase-3 to identify apoptotic 
cells. Tumors undergoing combined treatment revealed an increase of apoptotic tumor 
cells (Fig. S9) together with an increased total number and relative ratio of CTLs in direct 
contact with caspase-3–positive, dead, or dying tumor cells (Fig. S9 A–C). Thus, combined 
treatment increases tumoricidal events between CTL and tumor cells. Both CTL-tumor 
cell conjugates and cytotoxic efficacy observed upon combined treatment were partially 
reduced when recipient mice were CD137оͬо deficient (Fig. S9 C and D). Analysis of OT-1 
CD137оͬо lymphocytes did not permit relevant observations due to the paucity of such T 
cells in the tumors. 
Anti-CD137 mAb therapy prolongs in vivo efficacy of CTL effector function.  
To dissect how anti-CD137 therapy improves CTL effector function and tumor growth 
control or regression, the intratumor migration, interactions, and viability of adoptively 
transferred dsRed2, OT1 CTL were directly monitored by intravital multiphoton 
microscopy in B16F10-OVA tumors expressing histone-2B/mCherry as readout for 
mitosis, apoptosis, or necrosis (Fig. S10A). In control mice, adoptively transferred OT1 
CTL induced a transient growth delay with exponential regrowth of the tumor thereafter, 
whereas combined therapy of OT1 transfer + anti-CD137 mAb resulted in a significantly 
increased suppression of tumor growth (Fig. S10 A and B). To directly address whether 
individual CTL show enhanced effector function, we quantified CTL effector dynamics by 
long-term 4D time-lapse microscopy. Migrating OT1 CTL efficiently infiltrated the tumor 
margin with decreasing CTL densities towards the tumor core and with reduced 
migration speed of 2 ± 1.7 ʅm/min in OVA expressing tumors compared with B16F10 
parental tumors (4 ± 2.8 ʅm/min) and increased confinement of migration (Fig. 5 A and 
B). This interaction pattern explains cognate antigen recognition and active effector 
function (29). 
When combined with anti-CD137 mAb, tumor infiltrating CTL showed an even more 
focused effector phenotype, defined by further reduced migration speed (1.5 ± 1.2 
ʅm/min) during interactions with tumor cells resulting in prolonged dwell time per focus 
(Fig. 5 A–D and Movie S1). Quantification of OT1 CTL– tumor cell interactions and 
outcome showed that 75 % of tumor cell apoptosis were directly preceded by an OT1 
contact, indicating cell-contact dependent cytotoxicity as major mechanism of apoptosis 
induction (Fig. 6A and Movies S2 and S3). Combined treatment of OT1 transfer and anti-
CD137 mAb resulted in mildly enhanced frequency but substantially prolonged effector 
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Figure. 5. Intravital microscopy shows focused effector dynamics of adoptively transferred OT1 CTL. (A) 
OT1 CTL migration dynamics and pattern. Heat map of CTL dwell time shows confined CTL migration tracks 
(arrow heads) in CD137 cotreated tumors. (B) OT1 CTL migration speed in parental, OVA expressing and anti-
CD137 mAb treated tumors. (C) The mean square displacement relates to the area covered by the migrating 
cells at increasing time intervals. For each time interval ȴt, the mean squared displacement is plotted for 
tracks  of  OT1  CTL  with  and  without  anti-CD137  treatment.  Significance  test,  two-way  ANOVA.  (D) 
Cumulative OT1 CTL–tumor cell interactions. Quantifications are based on at least three independent 
experiments  with  at  least  180  CTL  tracks  of  75  min  length  analyzed  per  condition.  Black  lines  indicate  the  
median. Statistical differences were assessed using the Mann–Whitney u test; ***P ч 0.0001. (Scale bars, 50 
ʅm.)  
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window of apoptosis induction by OT1 CTL (Fig. 6B). Concurrently, tumor cell 
proliferation was impaired (Fig. 6B), but OT1 CTL proliferation increased and apoptosis 
rates decreased, consistent with transiently increased CTL densities in the tumor under 
combined anti-CD137 mAb treatment (Fig. 6D). Thus, combining adoptive CD8+ T-cell 
therapy with anti-CD137 mAb induces a local effector phenotype with prolonged and 
more focused cytotoxic activity against tumor cells.  
 
 
Figure 6. Intravital microscopy shows improved CTL viability and sustained effector function of adoptively 
transferred OT-1 T cells. (A) Percentage of tumor cell apoptosis events preceded by OT1 CTL contacts. Error 
bars, SD. (B) Image  sequence  of  B16F10/OVA  apoptosis  and  mitosis  visualized  by  H2B-mCherry.  Ar-  
rowheads point to nuclear fragmentation and mitotic nuclei, respectively. Dot plots: Quantification of tumor 
cell  apoptosis  and  mitosis  rates  per  hour.  (C  ) OT1  CTL  numbers  in  the  tumor.  Error  bars,  SD.  (D) Image 
sequence  of  CTL  mitosis  and  apoptosis  in  the  tumor.  Arrowheads  indicate  apoptotic  fragmentation.  Dot  
plots: Quantification of OT1 CTL apoptosis and mitosis rates per hour. Data were obtained from time lapse 
recordings  of  350  ×  350  ×  100  ʅm  stacks  scanned  at  2-min  frame  rate  and  recorded  at  ш3  independent  
positions per tumor. n = 3 independent tumors with total observation times of ш 20 h per condition and 
time point. Statistical differences were assessed using the Mann–Whitney u test; n.s., not significant, *P ч 
0.01, **P ч 0.001, ***P ч 0.0001.  
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Discussion  
In this study we observed effective synergism of CTL infusion combined with anti-CD137 
mAb treatment, resulting in complete regression of s.c. and efficient growth control of 
intradermal B16F10-OVA melanoma tumors in a CD4 and NK cell independent fashion. 
However, when treatment is postponed to day +7, the therapy loses efficacy probably as 
a result of immunosuppressive mechanisms deployed by the larger tumor (30) and 
because the rapidly increasing tumor cell burden overwhelms the immunotherapeutic 
regimen despite transient increases in CTL tumor infiltration. The synergistic effects 
between adoptive CTL transfer and antibody-induced enhanced CD137 signaling could 
operate and be exploited at multiple levels: (i) CD137 ligation is known to promote 
proliferation (6) and prevent activation induced cell death (31) in T cells. (ii) CD137 is 
expressed on the endothelial cells of tumor vessels which, when stimulated in this 
location, enhances T-cell trafficking into tumors (16). In our case this mechanism appears 
dispensable for recruiting adoptively transferred T cells into tumors, but we observe 
higher numbers of endogenous CD8+ T  cells,  that  are  lost  if  the  recipient  mouse  is  
CD137оͬо, indicating an effect of anti-CD137 therapy on endothelial cells and/or on the 
tumor homing capability of endogenous CD8+ T lymphocytes. Of note, endogenous CD8+ 
T cells outnumbered by about 8- to 10-fold those adoptively transferred and their 
function is crucial to sustain the complete response over time, as found in experiments 
with recipient RAG1оͬо mice deficient in T cells. Rather than increasing the peak activity in 
the lesion, here we show that exposure to the CD137 agonist results in prolonged CTL-
mediated cytotoxicity as the basis for higher efficacy at killing tumor cells. These 
phenotypic changes were dependent on the ability of CD137 to be expressed both on 
endogenous cells of the recipient mouse and on adoptively transferred OT1 cells. This 
finding is consistent with the in vivo treatment efficacy that required the expression of 
CD137 on both endogenous and adoptively transferred cells. Our results are compatible 
with those on targeting hematologic malignancy using bone marrow chimeras (32) which 
showed that endogenous T cells were required for the efficacy of transferred memory-
like CD8+ T cells and anti-CD137 mAb combined treatment against experimental 
immunogenic EG7 lymphomas. In this case of high CTL efficacy, the ability to express 
CD137 on endogenous or adoptively transferred cells was mutually dispensable, being 
required only in one of the subsets. The apparent discrepancy with our results indicates 
the different degree of immunogenicity of EG7-OVA lymphomas compared with the 
B16F10-OVA melanomas and, possibly, different efficacy of reactivated memory-like OT-
1 lymphocytes (32) versus the recently activated OT-1 used here. Our observations using 
the very aggressive B16F10-OVA melanoma which shows poor immunogenicity toward 
endogenous effector cells strongly advocate for translational research of this 
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immunotherapy combination. Indeed, we have recently reported synergy against 
spontaneous liver cancer expressing transgenic OVA of a combination of anti-OVA OT-1 + 
OT-2 T cells in conjunction with a combination of immunostimulatory mAb (33). Our 
work is also consistent with previous reports on the critical role of EOMES as a 
transcription factor in the effects of CD137 costimulation (24, 25). EOMES up-regulates 
transcription of molecules that CTLs use for killing (26), and likely supports the overall 
enhanced performance of transferred and endogenous CTLs. However, the 
transcriptional and epigenetic control networks that would mediate the effects of CD137 
costimulation are likely more complex (34) involving an interplay of transcription factors 
regulating CTL differentiation. Live-cell imaging of tumors undergoing rejection clearly 
showed that CTLs were associated with more tumor cell death that was correlated with 
more frequent and prolonged interaction of CTLs with target cells. The perforin-
granzyme machinery represents the predominant tumor-killer effector mechanism upon 
anti-CD137 mAb treatment (35), which is consistent with more focused behavior of the 
OT-1 lymphocytes inside the tumor and strongly suggests enhanced stringency of CTL 
engagement with target cells, degranulation, and apoptosis induction. Previous intravital 
imaging studies indicated that long-lasting CTL-tumor cell interactions support tumor cell 
killing (36) and tumor immunotherapy models show that CTLs initiate relevant tumor 
regression few days after adoptive transfer. Besides initial activation, CTL are required to 
maintain a sustained effector phenotype within the tumor microenvironment (37) for 
prolonged time periods to efficiently eradicate tumors. Our data indicate that CD137 
mAb therapy, besides directly stimulating cytotoxic function, prolongs the CTL effector 
phase and viability in the local tumor microenvironment, which sustains local 
cytotoxicity. The combination of adoptive T-cell therapy and anti-CD137 mAb is likely to 
involve various application possibilities. First, CD137 expression can be used for 
immunomagnetic selection of tumor reactive TILs (38), and subsequent culture of T cells 
in the presence of CD137 renders more efficacious phenotypic features (39, 40). Second, 
the effector performance (11), survival (10), and memory differentiation (41) can be 
enhanced by coadministration of the agonist antibody in vivo. Lastly, as shown here, 
anti-CD137 infusion may enhance adoptive immunotherapy by CTL by a dual mechanism, 
enhancing endogenous effector functions as well as focusing and prolonging the efficacy 
of therapeutically transferred lymphocytes.  
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Materials and Methods  
See SI Materials and Methods. In brief, experimental designs were based on adoptive 
transfer of OT-1 TCR transgenic T cells. As needed, OT-1 donor mice were crossed to 
become CD137оͬо or double transgenic for green or red fluorescent proteins. Adoptively 
T-cell transferred mice were dosed anti-CD137 agonist antibodies (1D8 or 2A) or control 
antibodies to subsequently follow up tumor size, retrieve intratumoral lymphocytes for 
flow cytometry evaluation or to perform imaging experiments by intravital microscopy of 
tumors implanted in dorsal skin-fold chambers, using a customized multiphoton 
microscope (TriMScope-II, LaVision BioTec). 
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Supporting Information  
SI Materials and Methods  
Mice.  
C57BL/6  J  WT  mice  (5–6  wk  old)  were  purchased  from  Harlan  Laboratories.  CD137оͬо 
[B6.Cg-Tnfrsf9tm1Byk] (1), OT-I/ CD45.1 [C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-1) crossing 
with B6.SJL-PtprcaPep3b/BoyJ (CD45.1)], CD137оͬо/OT-1/CD45.1 [C.129 × 1(B6)-Ptprc < 
tmlWeis > Tg(TcraTcrb) 1100 Mjb/J crossing with B6.Cg-Tnfrsf9tm1Byk] TCR transgenic 
mice  harboring  OVA-specific  CD8+  T  cells  and  Rag1оͬо[B6.129S7-Rag1tm1Mom/J], were 
bred in our animal facility under specific pathogen-free conditions (breeding protocol 
numbers 064/10, 026/09, 118/12, and 068/10). All animal procedures were conducted 
under institutional guidelines that comply with national laws and policies (study number 
066/ 10).  
Transgenic mice expressing dsRed under the chicken beta actin promoter (Jackson 
Laboratories, stock number: 006051) were crossed to OT-I TCR transgenic mice (Jackson 
Laboratories, stock number: 003831). Double transgenic dsRed/OT-1 were bred in the 
central animal facility (CDL) of the Radboud University Nijmegen, The Netherlands.  
B16F10 OVA Tumors and Treatment.  
5 × 105 B16F10-OVA (2) cells (mycoplasma free, tested by MycoAlert Mycoplasma 
Detection Kit from Lonza) were injected s.c. into the right flank of C57BL/6 syngenic mice 
(3). B16F10-OVA melanoma-derived cells are B16F10 cells transfected to express chicken 
ovalbumin (OVA) (2). On day 3 or 7 after tumor inoculation, mice were treated i.v. with 2 
× 106 OT-1 lymphocytes, obtained from OT1-TCR transgenic mice spleens and activated 
for 48 h with 0.1 ʅg/mL of SIINFEKL cognate peptide, and 100 ʅg of anti-CD137 (4) (clone 
1D8) or Rat IgG (Sigma-Aldrich) given intraperitoneally. At the indicating time point, 
tumors were excised and digested in collagenase (400 mandl)/DNase I (50 ʅg/mL) at 37 
°C. After 15 min of incubation, collagenase/DNase were inactivated with 12 ʅL of EDTA 
per mL. Then tumors were mechanically disaggregated and passed by a 0.7-ʅm cell 
strainer. Cell suspensions were then immunostained and/or mixed with perfect-count 
beads (Cytognox) for cell counting according to manufacturer’s instructions. For CD4+ T-
cell depletion, tumor-bearing mice were injected with depleting anti-CD4 mAb (clone 
GK1.5) before anti-CD137 treatment. A total of 200 ʅg per dose of the depleting mAb 
were administered intraperitoneally every 5th day beginning 1 d before treatment onset. 
For  NK  depletion,  NK1.1-specific  mAb  (200  ʅg  per  dose)  was  administered  i.v.  for  5  
consecutive days, beginning 3 d before anti-CD137 treatment, and thereafter 
administration continued in 3-d intervals.  
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Flow Cytometry.  
A single cell suspension was obtained from excised tumors and lymph nodes to be 
stained with the following fluorochrome-conjugated antibodies: anti–CD8-APC (clone 
53– 6.7 from Pharmingen), anti–CD8-BV510 (clone 53–6.7 from Pharmingen), anti–CD8ɴ-
APC (clone YTS156.7.7 from Biolegend), anti–CD4-BV421 (clone RM4-5 from 
Pharmingen), anti–CD4-PE (clone GK1.5 from e-Bioscience), anti–CD45.1-PrcPC5 (clone 
A20 from Pharmingen), anti–CD3-FITC (clone 145–2C11 from Pharmingen), anti–NK1.1-
PrCPC5 (clone PK-136 from Pharmingen), anti–CD107a-FITC (clone 1D4B), anti–IFNɶ-FITC 
(clone XMG1.2 from Biolegend), anti–EOMES-PE (clone 21Mags8 from eBioscience), 
anti–KLRG1-FITC (clone 2F1 from Santa Cruz), anti– T-bet-BV421(clone eBio4B10 from 
eBioscience), anti–PD1-FITC (clone 29F.1A12 from Biolegend), anti–Tim3-PE (clone 
RMT3-28 from life Technologies), Zombie NIR (from Biolegend). Perfect-count 
microspheres were purchased from Cytognos. For intracellular staining of IFNɶ cells, 
suspensions were stimulated in 5 h cultures in the presence of GolgiPlug (Becton-
Dickinson). Cells were acquired using a BD Biosciences FACSCanto II flow cytometer. Data 
were  analyzed  using  FlowJo  software  (Tree  Star).  For  intracellular  stainings  cells  were  
permeabilized with Cytofix/cytoperm according to manufacturer instructions (BD-
Biosciences).  
Quantitative RT-PCR.  
B16F10-OVA bearing mice treated on day 3 with 2 × 106 OT1 and 1D8 or control antibody 
were killed on day 10 and their tumors excised and disaggregated. RNA from cell 
suspensions was extracted by trizol-phenol-chlorophorm and was subjected 
retrotranscription (Invitrogen).  
Quantitative PCR was made using CFX96 Real-Time PCR Detection System. Specific 
primer pairs for each gene were:  
T-bet  (5഻AGCAAGG-ACGGCGAATGTT3഻; 5഻GGGTGGACATATAAGCGGTTC3഻),  
Eomes  (5഻GGCCCCTATGGCTCAAATTCC3഻; 5഻GAACCAC-TTCCACGAAAACATTG3഻),  
Granzime B  (5഻CCACTCTCGA-CCCTACATGG3഻; 5഻GGCCCCCAAAGTGACATTTATT3഻),  
Perforin  (5഻ TGCAGCTGAGAAGACCTATCA3഻; 5഻AGTC-AAGGTGGAGTGGAGGT3഻),  
FasL  (5഻TCCGTGAGTTCACC-AACCAAA3഻; 5഻GGGGGTTCCCTGTTAAATGGG3഻),  
BIM1  (5഻CCCGGAGATACGGATTGCAC3഻; 5഻GCCTCGCGGTAA-TCATTTGC3഻),  
Bcl-xL  (5഻GACAAGGAGATGCAGGTATT-GG3഻; 5഻TCCCGTAGAGATCCACAAAAGT3഻),  
FOXO3  (5഻CT-GGGGGAACCTGTCCTATG3഻; 5഻TCATTCTGAACGCGCAT-GAAG3഻),  
Blimp1 (5഻TTCTCTTGGAAAAACGTGTGGG3഻; 5഻GGAGCCGGAGCTAGACTTG3഻),  
CXCR3  (5഻TACCTTGAGG-TTAGTGAACGTCA3഻; 5഻CGCTCTCGTTTTCCCCATAATC3഻),  
CXCL9  (5഻GGAGTTCGAGGAACCCTAGTG3഻; 5഻GCACGA-TCCACTACAAATCCC3഻),  
CXCL10  (5഻CCAAGTGCTGCCG-TCATTTTC3഻; 5഻GGCTCGCAGGGATGATTTCAA3഻),  
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RPLO  (5഻AACATCTCCCCCTTCTCCT3഻; 5഻GAAGGCTTGACCTTT-TCAG3഻).  
Results were normalized to RPLO and fold change of each gene was calculated by 2(ȴȴCt 
1D8-ȴȴCtRatIgG).  
Confocal Microscopy.  
B16 tumor-bearing mice were killed at day 10 post tumor engraftment and tumors were 
excised, embedded in OCT, and frozen. Cryosections (10–12 ʅm) were treated for 20 min 
with 0.01 % Triton X-100 in 3 % BSA/PBS and treated with anti-CD8 (clone 53-6.7, 
Pharmingen) and anti-cleaved Caspase-3 (clone C92-605, Pharmingen) at 4 °C in BSA 3 
%/PBS overnight. Cryosections were then incubated with anti-rat AlexaFluor488 antibody 
(Life technologies,). Ten micrometer confocal z-stack acquisitions were taken on a LSM-
510 confocal microscope (Zeiss, Jena, Germany) with a 40× objective (N.A., 1.3). 10 CD8+ 
T-cell containing fields were imaged per condition. Data were obtained from three 
experiments. Maximum z-stack projections, linear contrast, and 3D reconstruction of 
images were performed with Imaris software (Bitplane). The number of cells positive for 
both markers and the contact between them was quantified manually.  
Intravital Multiphoton Microscopy.  
Dorsal skin-fold chambers were transplanted onto 8- to 14-wk-old male C57/Bl6 J mice 
(Charles River), as described (5). After one epidermal side of the skin flap was surgically 
removed, the chamber was mounted and a cover glass was added to shield the imaging 
field. One day post surgery, one or two small tumors per chamber were implanted into 
the deep dermis near the deep dermal vascular plexus by injecting a cell pellet of 
histone-2B/mCherry expressing B16F10/OVA (6) cells (5 × 104 to 2 × 105 cells) with a 30 G 
needle. Tumor growth was monitored for up to 15 d by epifluorescence and multiphoton 
microscopy. For intravital microscopy, mice were anesthetized with isoflurane (1–3 % in 
oxygen) and the skin-fold chamber was stably mounted on a temperature-controlled 
stage (37 °C). Blood vessels were visualized by i.v. injection of AlexaFluor750-labeled 70-
kDa dextran (2 mg per mouse). Three days after tumor implantation, 0.5–1 × 106 in vitro 
activated eGFP OT1 CTL were i.v. administered.  
All intravital imaging experiments were approved by the Ethical Committee on Animal 
Experiments and performed in the Central Animal Laboratory of the Radboud University, 
Nijmegen (protocol no. RU-DEC 2010–259), in accordance with the Dutch Animal 
Experimentation Act and the European FELASA protocol  
(www.felasa.eu/recommendations).  
Multiphoton Microscopy and Image Processing.  
Imaging was performed on a customized multiphoton microscope (TriMScope-II, LaVision 
BioTec), equipped with three tunable Ti:Sa (Coherent Ultra II Titanium:Sapphire) lasers 
and an Optical Parametric  Oscillator (OPO) (PP Automatic equipped with a PP800 
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crystal; Coherent APE; typical pulse width, 200 fs; repetition rate, 80 MHz; peak output 
power  of  500–650  mW  at  1,180  nm).  Three-dimensional  time-lapse  recordings  were  
acquired by sequential scanning with 1,090 nm (mCherry and SHG) using 60 mW under 
the objective, and with 910 nm (eGFP and Alexa750) using 20 mW under the objective 
with  a  sampling  rate  of  1  frame/2  min  over  a  maximum  period  of  4  h.  Images  were  
processed using Fiji (pacific.mpi-cbg.de/wiki/index.php/Fiji). Drifts in time-lapse 
recordings were corrected using the StackReg plugin (7), and CTL tracking was performed 
manually using the Manual Tracking plugin.  
Statistics.  
Prism software (Graph Pad Software V4.0) was used for statistical analysis by applying 
unpaired Student’s t test or Mann-Whitney U tests, as appropriate. P values of < 0.05 
were considered significant.   
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Supplementary figures 
  
 
Figure S1. Liver safety of a single dose of 1D8 anti-CD137 mAb. C57BL/6 mice were treated with a single dose of 
100 ʅg of 1D8 or control antibody and killed 1 wk later after bleeding when livers were excised. (A) Liver function 
tests in treated mice (n = 5 per group) measuring transaminases, total serum protein and bilirubin as indicated. 
(B) Absolute lymphocyte numbers in the liver parenchyma of treated mice assessed by multicolor 
immunostaining with anti CD3, CD4, CD8, and NK1.1 monoclonal antibodies using flow cytometry and true-count 
beads. Results are from a single experiment with five mice per group. 
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Figure S2. Therapeutic efficacy is elicited by anti-CD137 mAb binding different epitopes and is not dependent 
on NK cells. Experiments  as  in  Fig.  1  in  which  B16F10-OVA bearing  mice  (for  3  d),  were  treated  with  adoptive  
transfer of OT-1 and the indicated anti-CD137 mAb or control antibody as in Fig. 1. Mice represented in the last 
panel were given NK and NKT depleting doses of anti-NK.1.1 mAb (dot plots representing the extent of depletion 
in peripheral blood on day 10 are included as Inset). Individual tumor size follow-ups of a single experiment are 
provided in each graph with the fraction of mice completely Fig. S2. Therapeutic efficacy is elicited by anti-CD137 
mAb binding different epitopes and is not dependent on NK cells. Experiments as in Fig. 1 in which B16F10-OVA 
bearing mice (for 3 d), were treated with adoptive transfer of OT-1 and the indicated anti-CD137 mAb or control 
antibody as in Fig. 1. Mice represented in the last panel were given NK and NKT depleting doses of anti-NK.1.1 
mAb (dot plots representing the extent of depletion in peripheral blood on day 10 are included as Inset). 
Individual tumor size follow-ups of a single experiment are provided in each graph with the fraction of mice 
completely rejecting their tumors. 1D8 and 2A mAbs bind to different noncompeting CD137 epitopes and 2A 
blocks CD137L binding, whereas 1D8 does not. 
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Figure S3. Mice cured by combined adoptive OT-1 lymphocytes + CD137 mAb treatment were rechallenged 
with B16F10-OVA (right flank) or B16F10 (left flank). When indicated mice had been depleted of CD4+ T cells 
during the primary tumor inoculation and combined therapy. Although B16F10-OVA rechallenges were rejected 
in every case, B16F10 grafted in all mice. However, engraftment took place with faster kinetics in mice that had 
been depleted of CD4+ cells during combined immunotherapy. Of note, these mice, which had been depleted of 
CD4+ lymphocytes, grafted the B16F10-derived tumors with the kinetics of tumor-naïve mice. 
            Chapter 7 152
  
 
Figure S4. Comparison of tumor infiltrates of mice treated on day 3 or day 7 with the combination of activated 
OT-1 cells and anti-CD137 mAb. Mice treated as in Fig. 1 on day 3 or day 7, as indicated, were killed on day 10, 
and their tumors were excised. (A) Number of adoptively transferred and endogenous CD8+ T lymphocytes 
normalized by mg of tumor tissue and assessed with perfect-count beads. (B) Expression of the indicated 
markers as in Figs. 3 and 4. Results are from a single experiment with five mice per group. 
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Figure S5. Comparative changes in mRNA expression in B16F10-OVA tumors from mice transferred with 
activated OT-1 lymphocytes that are dependent on cotreatment with anti-CD137 mAb or control antibody.
Total mRNA extracted from excised tumors on day +7 following adoptive transfer and antibody treatment was 
subjected to quatitative RT-PCR analyses for the indicated genes using specific primers. Data are represented as 
the  fold  change  in  CD137  mAb-treated cases over the mean expression of mice treated with the control 
antibody  that  was  normalized  to  one.  Data  were  attained with  the  analyses  of  three  independent  tumors  per  
treatment condition with less than 10% coefficient of variation. 
 
 
 
Figure S6. TIL restimulation with cognate peptide. TILs in tumor cell  suspensions retrieved as in Figs. 3 and 4 
were cultured in the presence of SIINKFEL or control peptide for 5 h, and gated transferred endogenous CD8+ T 
lymphocytes were stained for intracellular IFNɶ. Data are represented as the MFI subtracting isotype-matched 
control staining. Results are from a single experiment with three mice per group. 
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Figure S7. Lymph node CD8+ T cells from animals in Figs. 3 and 4 were analyzed by multicolor FACS analyses for 
the  indicated  markers.  Data  are  presented  as  in  Fig.  3  and  4  indicating  the  CD137  wt  or  CD137оͬо status of 
recipient mice or transferred OT-1 T cells. (A) shows CD107A surface staining, (B) shows surface KLRG1 staining, 
and (C) shows intracellular IFN-gamma  staining.  Results  show  a  similar  tendency  for  a  stronger  effector  
phenotype upon CD137 mAb treatment, although less marked than in TILs. ns, not significant, *P ч 0.01, **P ч 
0.001. 
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Figure S8. Experiment as those in Figs. 3 and 4 in which TILs were immunostained for surface expression of PD-1 
and TIM-3. Results are presented as the MFI subtracting immunostaining by isotype-matched controls. Results 
are from a single experiment with five mice per group. *P ч 0.01, **P ч 0.001. 
 
Figure S9. Combined treatment gives rise to more effective OT-1 CTLs in the tumor tissue microenvironment. 
B16F10-OVA–bearing  mice  were  treated  as  in  Fig.  1C  with  adoptive  transfer  of  OT-1  T  cells  along  with  anti-
CD137 or control antibody. Tumors excised on day 10 were analyzed by immunofluorescence and confocal 
microscopy for CD8 and cleaved caspase 3 as a marker of apoptosis in morphologically identified tumor cells. (A) 
Z-stack  maximum  projection  of  a  representative  field  showing  more  apoptotic  cells  in  contact  to  CD8+ T cells 
upon combined treatment. (B) A 3D reconstruction of a representative case XY (up) and XZ (down) maximum 
projection of Z-Stack. C and D represent the indicated ratios of events of 30 microscopy fields of images as in A 
from six tumors treated with OT-1 with or without CD137 mAb. CD137KO indicates when recipient mice were 
CD137оͬо. (C and D) The ratio of CD8+ T cells engaged with a dead or dying caspase 3+ B16F10-OVA cell (C ) and 
the ratio of apoptotic B16F10-OVA cells that are in contact with a CD8 CTL (D). n.s., not significant, **P ч 0.001. 
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Figure S10. (A) Experimental setup for intravital imaging of CTL dynamics in the dorsal skin-fold chamber model 
to monitor tumor growth and regression. (B) Growth control by adoptively transferred CTL. A single dose of 1 × 
106 OT1 CTL and anti-CD137 mAb was given either day 3 or 7 after tumor implantation and tumor volume was 
monitored over time. Significance test, two-Way ANOVA. n.s., not significant, **P ч 0.001. (C ) Overview image 
of vessel structures and CTL infiltration. On day 3 after OT1 CTL transfer and anti-CD137 mAb injection, a tissue 
volume of 1,000 × 1,000 × 160 ʅm was recorded with 7-ʅm z-steps. Maximum projections of the image volumes 
were analyzed for area covered by vessels and vessel density using the MATLAB based program RAVE. Anti-
CD137 therapy decreased blood vessel diameter and density matching neovessel normalization phenotypes. (D)
OT1 CTL numbers in the tumor (day 3 after CTL transfer) were increased with anti-CD137 therapy in late tumors 
(therapy start day  7  after  tumor  injection)  while  no  effect  on  CTL  numbers  was  detected  in  young  tumors  
(therapy start day 3 after tumor injection). Data represent 3–5 independent mice. (Scale bars, 200 ʅm.) (E–G)
CTL migration speed (E ), migration pattern (Mean Square Displacement) (F), and cumulative contact duration 
with tumor cells (G) were not affected by anti-CD137 mAb therapy in late tumors. 
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4D imaging of the tumor stroma to understand cancer progression and 
(immuno) therapy response 
As central aspect of this thesis, novel approaches to visualize connective tissues, the 
extracellular matrix (ECM) and stromal cells, and their impact on tumor biology were 
developed (Chapter 3) and applied to identify mechanisms of invasion and the 
interaction of immune effector cells with the tumor (Chapters 3, 6). In vivo, both, moving 
tumor and immune cells face complex and structurally heterogeneous 3D tissue 
architecture consisting of molecular and physical interfaces of different composition, 
length scale and stiffness, which provide space and guidance or act as a physical barrier 
and restrict cell motility. Thereby, multiple cell and ECM parameters are integrated by 
migrating cells to determine type, direction and efficiency of migration. Thus, to 
understand cellular function it is mandatory to visualize cell behavior within tissue 
context. When assessed with multiphoton excitation, most tissue structures generate 
intrinsic signals (higher harmonic generation) which can be exploited for label-free 
visualization of 3D tissue topography. In interstitial tissues, SHG (frequency doubling of 
photons) is elicited by collagen fibers and striated muscle myosin, detecting tumor-
associated remodeling of collagen-rich ECM1,2. As novel imaging modality in cancer 
research, THG (frequency tripling of photons) was introduced (Chapter 3) to detect 
water-lipid or water-protein scaffold interfaces, including cellular membranes, tissue 
discontinuities and interfaces along blood vessels, myofibers, nerves, and adipocytes. 
While fluorescence provides information about specifically labeled molecules, higher 
harmonic generation microscopy provides structural information and serves as a 
framework within which the fluorescence signals can be interpreted. Thus, when 
combined, SHG, THG, and fluorescence detection enable multispectral analysis of cell-
tissue interactions and reveal connective tissue as remarkably heterogeneous in density 
and organization, which impacts guidance of moving cells (Fig. 1). The data show the 
efficacy and tolerability of backward THG compared with SHG and fluorescence 
detection in tumor-free and B16F10 melanoma-bearing tissue in live mice3 and thus 
establish THG as important complement to SHG and fluorescence imaging for the 
longitudinal monitoring of cancer biology in the context of tissue organization, blood 
flow and the dissemination of microparticles.   
Principles of melanoma cell migration in complex environments 
By establishing THG to detect migration-enhancing and –impeding tissue structures in 
live tumors, this thesis provided a first microanatomic classification for plasticity of 
tumor cell invasion strategies in response to tissue organization, with relevance for 
therapy design (Chapter 3).  
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Invading melanoma cell guidance is provided by cleft-like tracks along collagen bundles, 
myofibers, nerves, and vessels, or complex-shaped space within loose collagen networks 
or adipocytes (Fig. 1b). The underlying geometries of guidance tracks thus comprise 1D 
fibrillar strings of individual collagen fibers, porous 3D meshwork of ECM fibrils, and 
cleft-like 3D tracks between 2D ‘inner surfaces’ along and between collagen bundles, 
myofibers, nerve tracks, and vessels (Fig. 1b, c). The heterogeneity of tissue geometry is 
reflected and respected by invading tumor cells (Chapter 3) and further, these tissue 
tracks overlap with trafficking routes of leukocytes, likely representing constitutive 
‘highways’ exploited by adaptive tumor cells3. The data suggest that the plasticity of cell 
migration modes, ranging from single-cell and multicellular streaming to collective 
invasion is determined by tissue topography, consistent with physical principles of cell 
migration such as haptotaxis and contact guidance. In vivo tumor cell invasion thus 
occurs preferentially via tissue tracks of least resistance without apparent signs of 
structural destruction. The concept of tissue-guided invasion provides new rationales for 
designing molecular targeting of cancer invasion and could explain why therapeutic 
inhibition of matrix degrading MMPs in clinical trials was not sufficient to prevent 
metastasis formation in patients5,6. Thus, multi-modal microscopy reinforces the long-
established pathological concept of tissue-guided interstitial tumor migration by 
providing direct evidence through intravital imaging. 
Impact of the tumor stroma on immune cell positioning and function 
Besides shaping tumor cell invasion patterns, the stroma determines infiltration routes 
and positioning of tumor-infiltrating immune cells. For apoptosis induction, cytotoxic T 
lymphocytes (CTL) depend upon efficient infiltration of the tumor lesion to form direct 
cell-cell contacts with tumor cells. To ensure that rare antigen-specific target cells are 
not overlooked, CTL employ a scanning behavior which is best described as random walk 
(Brownian motion) and generalized Lévy walk migration7,8 but appears independent of 
large-range chemokine gradients which were shown to guide neutrophil swarming 
towards sites of acute tissue damage9. Intravital microscopy further suggests that 
migrating  effector  CTL  are  guided  by  ECM  fibers  and  blood  vessels10, similar to the 
‘guided random walks’ used by naive T cells in lymph nodes11,12. Following adoptive 
transfer, CTLs efficiently infiltrate solid tumors but their distribution is heterogeneous 
and often limited to the tumor periphery13, suggesting that the tumor core escapes 
immune surveillance. In Chapter 6, CTL infiltration of solid tumors was reconstructed 
until 300 µm depth and revealed a wide heterogeneity of variable ET ratios ranging from 
ET 1:1 in the tumor margins to complete lack of CTL infiltration in deep tumor regions.  
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The concerted impact of mechanisms mediating exclusion of tumor-infiltrating CTL from 
central tumor regions remains unclear. Dysfunctional endothelium of core neo-vessels 
which prevents CTL adhesion and extravasation14 as well as lack of nutrients and oxygen 
are possible factors that limit deep tumor infiltration. In addition, aligned ECM fibers 
which encapsulate human lung cancer lesions were shown to misdirect and trap 
migrating CTL in peripheral tumor areas15. Compromised infiltration may further result 
from dendritic cell networks within solid tumors which attract and immobilize CTLs in 
non-productive engagements and thereby deviate or exhaust effector activity in 
irrelevant interactions16,17. Consequently, limited tumor infiltration restricts therapeutic 
efficacy18 and thus, represents a relevant target with the potential to improve 
immunotherapy. 
Principles of cytotoxic T cell cooperation and additive cytotoxicity  
By using dynamic imaging, Chapter 6 of this thesis discovered the cooperation of 
multiple CTL as mandatory to overcome melanoma cell resistance to CTL-mediated killing 
and thus, further emphasizes the relevance of CTL migration concomitant to sufficient 
local CTL densities for reaching tumor regression. In contrast to immunogenic B cell 
targets19–21, CTL effector function against melanoma cells is an inefficient process with a 
high failure rate which is rarely completed by a single CTL interaction, but requires a 
sequence of sublethal hits (Fig. 2). Apoptosis induction is, thus, not a binary event but 
instead implies the accumulation of a death signal within the target cell over time 
(“additive cytotoxicity”).  
This further implies that target cells may resist CTL attack by degrading cytotoxic 
mediators and repairing received damage between serial hits. The requirement for 
synergistic effects of multiple CTL to kill a target cell may represent a safety mechanism, 
Figure 1. Multi-parameter 3D mapping of tumor invasion into interstitial stroma. (a) Diversity of the 
microanatomy of connective tissue (mouse dermis), visualized by intravital MPM. Collagen-rich loose (A) and 
dense (B) interstitial tissue. Interface-dependent tissue discontinuities along (C) myofibers and accompanying 
blood vessels and (D) between nerves and collagen-rich stroma. (E) Fat tissue showing interfaces along 
adipocytes (asterisk) and interstitial collagen fibers, resulting in complex geometries. (F) Detection of 
microparticles drifting through spaces between collagen fibers. (b) Plasticity of tumor cell invasion into the 
mouse dermis, in dependence of encountered tissue structures. 3D tissue reconstruction displaying two 
invasion zones (‘niches’) at different depth with either diffuse or compact collective invasion. Zoomed images 
show  tip  cells  (10)  and  the  multicellular  core  (20)  of  the  invasion  zone.  Scale  bars:  50  mm.  (c) Concepts of 
tissue-guided invasion modes derived from IVM. Interstitial collagen-rich connective tissue supports 
predominantly individual-cell dissemination, whereas movement along complex interfaces enables linear-
ordered or diffuse collective invasion. Abbreviations: BM, basement membrane; ECM, extracellular matrix; 
SHG, second harmonic generation; THG, third harmonic generation. Reproduced from Ref. 4. 
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by creating a local threshold to autoimmunity in absence of significant or sustained 
antigen-specific CTL tissue infiltration. Concomitantly, CTL cooperation may strengthen 
the killing efficacy of CTL populations in immunosuppressive environments by 
compensating for compromised hits of individual CTL with multiple additive hits at high 
local CTL densities. The concept of additive cytotoxicity further opens the possibility that 
distinct subthreshold cytotoxic mechanisms may converge in the target cell, e.g. 
cytotoxic hits of NK cells and CTL or distinct apoptosis pathways such as Fas-FasL and 
perforin-mediated cytotoxicity. Likewise, however, interactions with or factors released 
by suppressive cells of the immune system may modulate CTL effector function by 
weakening the impact of CTL hits similar to immune suppressive mechanisms during CTL 
activation21–23, thereby increasing, locally, the threshold to apoptosis. In addition, the 
microenvironment may promote target cell recovery between serial hits, e.g. by 
anchorage-mediated survival signaling or presence of growth factors. Thus, CTL effector 
function is not a binary process but instead integrates multiple synergizing or interfering 
parameters which tune the damage versus recovery in the target cell. 
Tumor niches susceptible for immunological targeting 
The concept of additive cytotoxicity predicts CTL-mediated killing in vivo to critically 
depend on local CTL density and migration capability which jointly mediate sufficient CTL 
contact frequencies for killing. In Chapter 6 and 7, intravital microscopy was used to 
monitor CTL migration, interactions with and apoptosis of tumor cells in the context of 
the 3D tissue microenvironment to identify regions permissive or ablative for CTL 
 
Figure 2. CTL cooperation and additive cytotoxicity. (a) CTL-target cell contact types and outcome. (b) 
Predicted  accumulation  of  cytotoxic  but  often  sublethal  hits  and recovery  over  time.  Black  cross,  target  cell  
apoptosis. 
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effector function. After adoptive CTL therapy of invading B16F10 melanoma, adequate 
CTL densities for killing were only reached in the tumor margin and invasion zones. 
Dynamic multiphoton microscopy combined with higher harmonic generation (SHG/THG) 
revealed tissue guidance tracks that support both, CTL migration and density, thereby 
enhancing serial CTL conjugations and consequently, increasing target cell killing. This 
validates the concept of additive cytotoxicity and provides additional relevance of the 
invasion niches identified in Chapter 3, as it shows the shared use of tissue tracks by 
tumor and immune cells with detrimental outcome for tumor cell survival. Thus, dynamic 
imaging in vitro and intravital multiphoton microscopy in vivo reveals novel 
microenvironmental niches that control success or failure of anti-tumor immune effector 
mechanisms. 
Therapeutic routes to focus and enhance cancer immunotherapy 
Additive cytotoxicity describes CTL lethal hit delivery as gradual and thus, tunable 
process, which is amenable for therapeutic targeting by increasing either the impact of 
single hits or their frequency (Fig. 2). To enhance the frequency of serial CTL-tumor cell 
engagements, it will be mandatory to increase and sustain CTL infiltration of solid 
tumors. In addition, homogeneous CTL distribution including targeting of CTL to tumor 
regions which exclude CTL invasion will be required for complete response and to 
prevent tumor regrowth from resistance niches. Combinations of immunotherapy and 
anti-angiogenic therapy may improve CTL access to poorly infiltrated regions24–27 by 
normalizing dysfunctional vessel endothelium and enhancing expression of adhesion 
molecules which facilitate CTL extravasation28. The long lag-times between initial CTL 
contact and tumor cell apoptosis emphasize strategies to either shorten the lag phase or 
to prolong CTL survival and to sustain CTL function over sufficient time periods to 
increase the probability of apoptosis induction. This may be achieved by repetitive 
adoptive CTL transfer or by combined IL-2 or immunmodulatory antibody therapy29. 
Another route to increase CTL efficiency is to enhance the impact of individual cytotoxic 
hits. This can be achieved by either increasing the amount of cytotoxic mediators 
delivered per hit, by stabilizing CTL-target cell contacts to facilitate repetitive hits 
delivered by the same CTL, or by reducing the threshold to apoptosis induction in target 
cells (Fig. 2). Several approaches were developed to increase the efficacy of cytotoxic hit 
delivery. Immunmodulatory antibodies which activate costimulatory pathways during 
CTL activation and effector phase increase the expression of genes associated with 
enhanced effector function (Chapter 7). CTL-tumor cell contacts may be stabilized by 
using bispecific antibodies30–32 that connect CTL and target cell or by blocking contact 
destabilizing inhibitory molecules expressed by tumor cells33.  However,  balancing  CTL  
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motility between swarming to promote serial CTL contacts and tumor infiltration, and 
arrest to promote stable contact formation with target cells, will be required for 
optimized serial CTL conjugation and killing efficacy. Lastly, chemotherapy34,35, 
irradiation36,37, or molecular targeted therapy to reduce stroma-derived anti-apoptotic 
signals38,39 may synergize with CTL-mediated cytotoxicity by lowering the target cell 
threshold to apoptosis. Thus, the concept of additive cytotoxicity provides a mechanistic 
explanation of immunotherapy failure in solid tumors and a rationale for improving 
combinatorial treatment schemes. 
Conclusions and outlook 
In the past decades, great advances have been made in our understanding of immune 
responses against cancer. A variety of in vitro and ex vivo methods has been applied to 
understand signaling pathways for immune cell activation and the molecular processes 
underlying immune effector function. However, much of our knowledge derived from 
these studies is static, or is obtained from reductionistic in vitro models, and does not 
fully reflect the natural dynamics of immune processes. To combine both, dynamic 
imaging and tissue complexity, intravital microscopy (IVM) of live tumors has evolved as 
powerful technique that allows capturing cell dynamics and function simultaneously and 
over time, at sub-cellular resolution and within the natural environment of living tissues. 
Visualizing immune cells in their physiological environment is particularly crucial because 
cellular function is controlled by many parameters including local cytokine 
concentrations, interactions with other cells, metabolic factors and nutrient availability 
as well as anatomical compartmentalization. Thus, combining molecular cell analysis in 
vitro and intravital microscopy of immune effector function will resolve important 
remaining questions, such as: How do immune cells navigate and interact inside complex 
tumor tissues and during the evolution of a tumor lesion? How do specific tumor 
subregions evade immune control? How does the microenvironment influence immune 
effector phase and how can we address such niche-dependent evasion by molecular 
targeting? The work in this thesis thus re-emphasized the importance of studying 
immune effector function in the context of 3D structural environments and cell 
navigation as integrating process. In addition, this thesis establishes the physiological 
relevance for principles of cell migration in confined spaces, which was rapidly applied 
for inspired biotechnical tissue engineering to model plasticity of cell migration in 
tunable defined environments40,41. Further, kinetic imaging of adoptively transferred CTL 
in melanoma lesions revealed how 3D tissue topography determines immune effector 
function success or failure. Thus, to better predict the efficacy of adoptively transferred 
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CTL, the use of organotypic in vitro assays is required which integrate CTL migration 
capability and contact stability with tumor cells in their readout.   
With the continuing development of new fluorescent mouse models, improved 
optical reporters and enhanced detection systems, IVM will contribute to an improved 
level of understanding complex processes of tumor biology and antitumor immune 
reactions within tissues. Implementation of multicolor tracers for simultaneous detection 
of multiple immune cell subsets will deliver mechanistic insight in the reciprocal 
interactions of CTL with supportive or suppressive immune cells, such as dendritic cells, 
CD4+ T cells, Foxp3+ Treg and M1/M2 macrophages. By monitoring distribution and ratios 
of distinct immune cell subsets and the enrichment of external factors such as cytokines 
or metabolic parameters42 in relation to local CTL function, tumor resistance niches can 
be identified and characterized. Advanced molecular sensors will further allow 
simultaneous recording of CTL interactions and their consequences on CTL activation, 
e.g. by visualizing Ca2+ signaling or NFAT translocation43. Likewise, consequences of CTL 
hits on target cells and their effect on cell viability may be monitored using fluorescent 
reporters for Ca2+ levels,  cell  cycle  stage,  caspase  activation  or  DNA  damage44–47. By 
combining functional readouts with high spatiotemporal resolution, IVM will provide the 
foundation for an integrating, systems-level understanding of CTL function in the tumor 
microenvironment. Thus, multimodal IVM will reach the maturity to visualize tumor 
resistance niches, define their molecular, structural and cellular components and thereby 
deliver novel mechanistic insight into tumor immune escape strategies to provide new 
rationales for targeted immunotherapy design. 
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Summary 
Cancer growth and invasion as well as therapy response are complex processes which 
depend upon both, cell intrinsic mechanisms and the tumor microenvironment. Besides 
conventional anti-cancer therapy, immunotherapy is a promising approach for a range of 
cancer types with the potential to raise a specific, adaptive and long-lasting anti-cancer 
protection. For immunological control of tumor progression, the activation and 
expansion of tumor-specific cytotoxic T-lymphocytes (CTL) is required followed by 
efficient infiltration of the tumor lesion, direct CTL-tumor cell contact formation and 
successful apoptosis induction. In this thesis, organotypic in vitro models and intravital 
microscopy were applied to visualize both, tumor and immune effector cells in the 
context of the tumor microenvironment to address central aspects of melanoma 
progression, including dynamic interactions of invading tumor cells with the tumor 
stroma and the local regulation of tumor infiltrating CTL.  
CTL effector function in tumors depends on both, “immunological” mechanisms, 
such as TCR-mediated recognition and signaling, and coordinated CTL positioning and 
migration within the tumor tissue. Chapter 2 summarizes the molecular and biophysical 
parameters that govern CTL migration in interstitial and tumor tissue. In the three-
dimensional tumor microenvironment, tissue topography can form barriers or provide 
guidance for CTL infiltration of solid tumors and may locally determine tumor resistance 
niches by misrouting or excluding CTL from tumor regions. Thus, visualizing tissue 
topography simultaneous to CTL dynamics is required to understand the mechanisms of 
successful or failed CTL effector function in tissues.  
In Chapter 3 multimodal intravital MPM was established which combines infrared-
excited two-photon fluorescence, second harmonic generation and, as novel modality in 
cancer research, third harmonic generation (THG) microscopy for label-free visualization 
of the structural microenvironment of melanoma growing in the mouse dermis. The data 
provide a framework for tissue cues guiding melanoma cell invasion. Melanoma cells 
invade connective tissue along constitutive interfaces which form routes of least 
resistance, including tissue tracks and spaces along blood vessels, myofibers, nerves, 
between adipocytes and collagen bundles, without immediate anatomic tissue 
remodeling or destruction. By using a novel imaging approach, this thesis provides a first 
microanatomic classification for plasticity of tumor cell invasion strategies in response to 
1D, 2D and 3D tissue organization, with relevance for therapy design for targeting 
invading tumor cells.  
In Chapter 4, a 3D collagen-based in vitro assay was established which simulates the 
connective tissue environment and allows real-time imaging of CTL function, including 
the observation of active migration, interaction, dissociation and serial engagements of 
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CTL with single target cells over extended time periods. This novel migration-based assay 
promotes the natural dynamic CTL behavior and thus provides improved physiologically 
relevant information on CTL killing kinetics. In Chapter 5 the mechanisms of CTL effector 
function are reviewed and fluorescent histone-2B labeling is established as readout for 
CTL-mediated apoptosis induction in tumor cells.  
In Chapter 6 dynamic  imaging  of  organotypic  3D  assays  of  tumor  cells  confronted  
with migratory CTL and intravital multiphoton microscopy identified a cooperation 
mechanism dependent on sequential CTL-tumor cell interactions and the accumulation 
of sub-lethal hits to overcome melanoma cell resistance to CTL-mediated apoptosis 
(‘additive cytotoxicity’). Consistently, in orthotopic melanoma in vivo, tumor regions with 
high CTL density supported additive cytotoxicity and correlated with high local apoptosis 
rates. Highest CTL densities and apoptosis induction occurred at the invasive tumor 
front, where invading tumor cells and CTL both move and accumulate along the same 
anatomic trails of least resistance, suggesting invading tumor cells as target for 
immunotherapy.  
In Chapter 7 the immune-augmenting impact of agonistic anti-CD137 antibodies on 
CTL effector phase was addressed by immunological and intravital imaging approaches. 
Prolonged CTL contacts with tumor cells and sustained effector function of adoptively 
transferred CTL over extended time periods enhanced tumor remission, providing direct 
evidence of synergistic effects of ɲ-CD137 mAb and adoptive CTL transfer.  
Thus, in summary, in this thesis kinetic imaging and intravital microscopy were 
applied to deepen the mechanistic understanding of immune cell function within 
complex tissues which provides a basis for novel, rationale design of immunotherapies. 
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Samenvatting 
De groei, het invasief gedrag en de respons van kankercellen op antikanker therapie zijn 
complex gereguleerde processen die afhankelijk zijn van zowel celintrinsieke factoren als 
de extracellulaire tumoromgeving. Naast traditionele antikanker therapieën, is 
immuuntherapie een veelbelovende nieuwe behandeling met de potentie om specifieke, 
adaptieve en langdurige bescherming te bieden tegen diverse soorten kanker. De 
immunologische remming van tumorprogressie begint met een activering en een 
toename van tumorspecifieke cytotoxische T-lymfocyten (CTL’s). Deze CTL’s doden 
tumorcellen door aan deze cellen te binden, wat vervolgens celdood door apoptose 
veroorzaakt. Een succesvolle eliminatie van de tumor wordt daarom niet alleen bepaald 
door een expansie van de tumorspecifieke CTL populatie, maar ook in de mate waarin de 
CTL’s in de tumor kunnen infiltreren en in hoeverre zij een stabiele interactie met de 
tumorcellen kunnen aangaan. In dit proefschrift worden nieuwe organotypische in vitro 
modellen en intravitale microscopische technieken beschreven die CTL’s en tumoren en 
hun onderlinge interactie in de context van tumorweefsel in beeld brengen. Hiermee 
konden belangrijke aspecten van de tumorprogressie van melanoom, waaronder de 
dynamische interacties van invasieve tumorcellen met het tumorstroma, en de lokale 
regulering van tumorinfiltrerende CTL’s worden bestudeerd. 
De effector functie van CTL’s wordt niet alleen gereguleerd door 
“immunologische”mechanismen, waaronder signaalherkenning en signaaloverdracht via 
de TCR, maar ook door de gecoördineerde positionering en migratie van CTL’s binnen het 
tumorweefsel. Hoofdstuk 2 beschrijft de moleculaire en biologische parameters die de 
migratie van CTL’s binnen het tumorweefsel bepalen. In de 3-dimensionale tumor 
omgeving kan de topografie van het tumorweefsel enerzijds een barrière vormen, maar 
anderzijds ook als routemarkering voor CTL’s in de tumor fungeren. Als gevolg hiervan is 
het mogelijk dat CTL’s sommige delen van de tumor niet kunnen bereiken waardoor er 
locale tumorresistentie niches ontstaan. Door de dynamiek van CTL’s en 
weefseltopografie tegelijkertijd in beeld te brengen, wordt het mogelijk om factoren die 
van belang zijn voor een effectieve CTL functie in weefsels in kaart te brengen.  
In Hoofdstuk 3 is de ontwikkeling beschreven van multimodale intravitale multifoton 
microscopie (MPM), waarbij infrarood-geëxciteerde tweefoton microscopie, tweede 
harmonische generatie, en derde harmonische generatie (TGH) werd gecombineerd. De 
toepassing van THG microscopie is een nieuwe microscopie modaliteit in 
kankeronderzoek, en is hier gebruikt om op een labelvrije manier de structurele micro-
omgeving  van  een melanoom in  de  dermis  van  de  muis  in  beeld  te  brengen.  De  in  dit  
hoofdstuk beschreven resultaten scheppen een kader voor hoe bepaalde “markeringen” 
 Samenvatting 177 
die in het weefsel aanwezig zijn een rol kunnen spelen bij de invasie van melanoom 
cellen.  
De invasie van melanoomcellen in het omliggende bindweefsel verloopt vaak via “de 
weg van de minste weerstand”, waarbij gebruik wordt gemaakt van al aanwezige 
anatomische “routes”. Voorbeelden hiervan zijn: de oppervlakte van bloedvaten, 
spierweefsel of zenuwen, of de ruimtes tussen collageen bundels of tussen vetcellen. 
Door gebruik te maken van deze ruimtes blijft de anatomie van het bestaande weefsel 
grotendeels behouden. Met behulp van de nieuwe microscopische technieken die in dit 
proefschrift worden beschreven, kan nu, voor de eerste keer, de plasticiteit van tumorcel 
invasie gedrag als gevolg van specifieke weefselstructuren worden geclassificeerd. Deze 
kennis kan toegepast worden om specifieke therapieën tegen tumorcel invasie te 
ontwikkelen.  
Hoofdstuk 4 beschrijft de ontwikkeling van een 3D in vitro toetsmodel waarin de 
structuur van bindweefsel wordt nagebootst en waarin de functie, migratiegedrag, en de 
(seriële) interacties en dissociaties van CTL’s met individuele tumorcellen gedurende 
langere tijd gevolgd kan worden. Dit model is in het bijzonder fysiologisch relevant om de 
kinetiek van CTL-geïnduceerde celdood te bestuderen, omdat het CTL migratie en CTL-
tumor cel interacties in een relevante weefselcontext nabootst. Hoofdstuk 5 geeft een 
overzicht van de mechanismen die betrokken zijn bij CTL-gemedieerde apoptose in 
tumorcellen, en laat zien hoe apoptose met behulp van fluorescent gelabeld histon-2B 
kan worden geanalyseerd.  
In Hoofdstuk 6 wordt met behulp van intravitale MPM en organotypische 3D in vitro 
assays (zie Hoofdstuk 3 en 4) gedemonstreerd dat een combinatie van opeenvolgende, 
subletale interacties van CTL’s met apoptosis-resistente melanoomcellen, in staat zijn om 
deze resistentie op te heffen in het in vitro model (“additieve cytotoxiciteit”). Consistent 
met deze bevindingen zijn de resultaten verkregen in een in vivo model van een 
orthotoop melanoom, waarin een positieve correlatie werd gevonden tussen 
tumorgebieden met een hoge concentratie CTL’s en de mate van apoptose. De hoogste 
concentratie CTL’s werd met name waargenomen aan het invasieve tumorfront, waar 
zowel  de  invasieve  tumor  cellen  als  de  CTL’s  de  locale  weefselanatomie  gebruikten  als  
“weg van de minste weerstand”, zoals beschreven in Hoofdstuk 3. Deze bevindingen zijn 
een aanwijzing dat invasieve tumorcellen specifiek gevoelig kunnen zijn voor 
immuuntherapie.  
In Hoofdstuk 7 werd het immunostimulerend effect van agonistische anti-CD137 
antilichamen op de CTL effector fase onderzocht met behulp van immunologische 
methoden en intravitale microscopie. De behandeling van CTL’s met anti-CD137 
antilichamen voorafgaande aan adoptieve CTL transfer verlengde het contact van CTL’s 
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met tumorcellen, verhoogde de effector functie van CTL’s en stimuleerde langdurige 
tumorremissie. Deze resultaten demonstreren daarom een synergistisch effect van 
adoptieve CTL transfer en anti-CD137 behandeling.  
Samenvattend kan worden gesteld dat in dit proefschrift kinetische- en intravitale 
microscopische methoden worden toegepast, welke diepgaand inzicht verschaffen in de 
werkingsmechanismen van immuuncellen in een complex weefselmilieu. Deze kennis 
kan leiden tot verbeteringen in de rationele ontwikkeling van nieuwe 
immuuntherapieën.  
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